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Abstract 
Apicomplexan parasites are responsible for causing a number of diseases in humans and 
animals. Toxoplasma gondii is known to cause toxoplasmosis in humans, Eimeria tenella is 
known to cause coccidiosis in chickens and Plasmodium falciparum is known to cause 
malaria in humans. These parasites place a huge burden on global health and on the global 
economy. Current methods of treatment are losing effectiveness, raising the need for new 
ways to combat these diseases. Identifying vaccine candidates against apicomplexan parasites 
has been the focus of recent research. Immune Mapped Protein 1 (IMP1) is a novel antigenic 
protein which was first identified in Eimeria maxima. Recent research has shown that 
immunisation with IMP1 raises immunity against the parasite in a species specific manner. 
However, the structure and function of IMP1 is not known. 
Here we report the structure of the IMP homologue from Plasmodium falciparum 
(PfIMP2) solved using solution state Nuclear Magnetic Resonance (NMR). The structure of 
PfIMP2 has revealed that IMP homologues have a conserved C-terminal IMP domain. Recent 
research has also revealed that the IMP domain is the immune-dominant region in the IMP 
homologues. We also report that there are two classes of IMP homologues within 
apicomplexans. This redundancy of the protein within the parasites suggests that IMP 
homologues play an important role within the parasite. In vitro experiments performed to gain 
some insight on the functional role played by IMP proteins within the parasites are also 
reported. Although the function of the IMP homologues is yet to be deduced, the 
immunogenic nature of these homologues makes them interesting candidates to study. 
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Chapter 1  
Apicomplexan Biology  
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Figure 1.1: Figure showing the structure of a T. gondii tachyzoite as a model apicomplexan. The 
important organelles found across most apicomplexans are labelled in the figure. 
1.1 Apicomplexans 
Apicomplexa is a phylum of intracellular parasites that cause a number of human and animal 
diseases. Apicomplexan parasites include Plasmodium species which cause 
malaria, Toxoplasma gondii which causes toxoplasmosis in immunocompromised 
individuals, Eimeria species which cause diseases in most vertebrates in a species-specific 
manner, Theileria species which cause diseases in cattle and Cryptosporidium species which 
cause diseases in animals and humans (Morrissette & Sibley, 2002). These parasites are polar 
cells and are characterised by the presence of a cytoplasmic complex at the apical end of the 
cell. This apical complex is known to be crucial for parasite replication and for invasion and 
consists of a microtubule organising centre called conoids and secretory organelles involved 
in invasion as shown in figure 1.1 (Morrissette & Sibley, 2002). As T. gondii is considered 
the model apicomplexan, most of the apicomplexan proteins and mechanisms have been 
widely studied in this parasite (Roos et al, 1999).  
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1.1.1 Clinical Significance of Apicomplexans 
The three apicomplexan parasites studied in this project are Toxoplasma gondii, Eimeria 
tenella and Plasmodium falciparum. T. gondii is responsible for causing toxoplasmosis in 
immunocompromised individuals, like AIDS patients, and congenital infections (Dzierszinski 
et al, 1999; Luft & Remington, 1992). The time from infection to the development of 
symptoms may take from 1-2 weeks. The disease can affect the brain, heart, lungs, eyes or 
liver (Liesenfeld, 2007). Toxoplasmosis can have a wide range of symptoms which are more 
severe in immunocompromised individuals than healthy individuals. It may also be 
responsible for causing toxoplasma encephalitis in AIDS patients (Luft & Remington, 1992). 
Toxoplasmosis is currently treated with chemotherapy but these drugs have toxic effects and 
reinfection occurs rapidly (Buxton & Innes, 1995). 
Coccidiosis in chickens is caused by seven different species belonging to the Eimeria 
genus. Eimeria tenella is an intracellular parasite that causes cecal coccidiosis in young 
chickens (Yin et al, 2014). The symptoms of cecal coccidiosis are ruffled feathers, 
inappetance, weight loss, closed eyes, diarrhoea and blood in the faeces of infected chickens. 
E. tenella infections have a high morbidity and mortality rate, thus having a detrimental effect 
on the poultry industry. Parasite oocysts are shed in the faeces of infected chickens which 
undergo sporulation and are then transmitted to healthy chickens orally during feeding. One 
of the current methods of treatment is using coccidiostats (anti-protozoan agents). Resistance 
against currently used coccidiostats are on the rise raising the need for alternative drugs 
(Blake et al, 2011). 
P. falciparum is the deadliest of the five human infecting malaria species - P. 
falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. P. falciparum is responsible for 
the majority of malaria related deaths. The parasite is spread from person to person by the 
female Anopheles mosquito, which is the vector for this parasite. Initial symptoms following 
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infection include fever, chills, nausea and headache (Ménard, 2013). If not treated 
immediately, P. falciparum infections can lead to severe illness and death. P. falciparum 
species have developed resistance against drugs that were used against malaria in the past 
which include chloroquine and sulfadoxione-pyrimethamine. The current method of treatment 
against uncomplicated P. falciparum infection is using artemisinin–based combination 
therapy (ACT). Resistance against ACT is also on the rise, raising the need for new drugs to 
treat malaria (Crutcher & Hoffman, 1996). Recent statistics from WHO have shown that there 
were 438000 malaria-related deaths worldwide in 2015 (WHO, 2015). This shows that P. 
falciparum causes a huge global health burden. 
 All three apicomplexan parasites have a huge impact on the global economy and cause 
a huge health burden. The current methods of treatment of these three diseases are losing 
effectiveness worldwide raising the need for alternative methods of treatment. A number of 
recent studies are focussed on the development of vaccines against these parasites. The recent 
developments in this area are discussed in detail in Section 1.11. 
1.2 Toxoplasma gondii  
1.2.1 Life Cycle 
The definitive host of T. gondii is the cat which is where the sexual stages of the parasite take 
place. The parasites are released from the cat in the form of oocysts. The oocysts are ingested 
by intermediate hosts including humans. Oocysts can also be ingested by humans through 
consumption of uncooked or raw infected meat. Once the oocysts enter humans, they mature 
into tachyzoites which replicate rapidly. Within humans, the parasites can become encysted 
and stored in the muscles and the brain in another form called bradyzoites (Louis & Kami, 
2007). An overview of the life cycle of T. gondii is shown in figure 1.2. 
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1.2.2 Pathogenesis  
T. gondii is an obligate intracellular parasite and hence, it survives within the host cell 
evading the host immune system. Toxoplasma exists within humans in two life forms – 
tachyzoites and bradyzoites (Louis & Kami, 2007). Tachyzoites are the rapidly dividing, 
intracellular life form. They are crescent-shaped cells and are coated with three unit 
membranes forming a pellicle (Ferguson & Hutchison, 1987). The anterior end of the 
tachyzoite contains cytoskeletal elements, a possible microtubule complex called conoids and 
secretory organelles called rhoptries and micronemes. A third type of secretory organelle 
called dense granules are distributed everywhere in the cytoplasm (Woodison & Smith, 
1990). These secretory organelles contain proteins required for the survival and invasion of 
the pathogen (Louis & Kami, 2007; Meissner et al, 2002). 
Tachyzoites are responsible for causing acute infection and when this is controlled by the host 
immune response through the induction of IFN-γ (Suzuki et al, 1988), they become encysted 
Figure 1.2: Figure showing the various stages in the life cycle of T. gondii and the various hosts 
involved. The stages of the parasite are labelled in the figure. 
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and remain within the muscles and the brain in a dormant form called the bradyzoite. The 
cysts can contain varying number of bradyzoites which are retained within the host for years 
and they are responsible for reinfection within immunocompromised hosts. This persistence 
of the pathogen within the host in a dormant form is one of the major reasons for difficulty in 
vaccine development against toxoplasmosis (Jackson & Hutchison, 1989). The invasive form 
of the pathogen is the tachyzoite and understanding its invasion process will demonstrate 
ways of controlling the infection. 
1.3 The Glideosome 
Toxoplasma adapts a substrate dependent locomotion called gliding motility and this is used 
for tissue migration and cell invasion. This locomotion is facilitated by the glideosome which 
is a multiprotein complex situated in the parasite pellicle, between the inner membrane 
complex (IMC) and the plasma membrane as shown in figure 1.3 (Williams et al, 2015). The 
glideosome consists of three components – the motor-receptor bridging proteins, motor 
complex proteins and the IMC proteins (Boucher & Bosch, 2015). Two motor-receptor 
bridging proteins have been identified so far – aldolase and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). Aldolase was reported to bind actin on one face and the C terminal 
end of microneme proteins via the active site (Buscaglia et al, 2003). However, recent studies 
have shown that mutants lacking aldolase exhibit normal gliding motility and invasion in a 
glucose-free medium. These results suggest that aldolase is necessary for energy metabolism 
and not for interacting with microneme proteins (Shen & Sibley, 2014). The interactions of 
GAPDH are yet to be characterised. The actin-myosin motor produces the force that is 
necessary for the gliding of the parasite. F-Actin polymerises to form unstable filaments, 
which are 100 nm in length, that act as the track for the glideosome motor. Myo A (Type XIV 
Myosin) pulls back on the short actin polymers causing the parasite to move forward. MyoA 
contains a neck and head region. The head region has a nucleotide binding pocket and the 
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Figure 1.3: Figure showing a cartoon representation of the glideosome in T. gondii. The proteins 
forming this multi protein complex are labelled in the figure.   
neck region interacts with two essential light chains (ELC) – ELC1 and ELC2. ELC1 and 
ELC2 have been found to be involved in regulating and stabilising MyoA. ELC1 has also 
been reported to interact with Ca
2+
 and Myosin Light Chain 1 (MLC1) (Williams et al, 2015). 
Glideosome associated proteins (GAP) are involved in bridging the IMC to the actin myosin 
motor system. GAP45 acts as a tether between the IMC and the plasma membrane. The actin-
myosin motor system is anchored to the IMC by transmembrane proteins – GAP40, GAP50 
and GAPM family of proteins (Bullen et al, 2009). Gliding motility of the parasite relies on 
the interaction of the parasite with the host cell surface. Upon secretion of microneme 
proteins and their interaction with the host cell, the actin-myosin motor system pushes the 
parasite forward, whilst pushing the protein complex rearward. 
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Figure 1.4: Figure showing the various stages of the invasion process of T. gondii. The organelles 
secreting proteins at different stages are labelled in the figure. The colour coding of the various 
organelles are also shown in the schematic of T. gondii in the bottom left of the figure. 
1.4 Invasion Mechanism 
The invasion mechanism of T. gondii in humans has been widely studied giving insight into 
the roles of various proteins and the mechanisms that they are involved in. Invasion itself 
occurs in seven steps once the pathogen has located a host cell after gliding along the 
substrate as shown in figure 1.4 (Carruthers & Boothroyd, 2007). The parasite exists within 
the host cell within a structure called the parasitophorous vacuole (PV) and this structure 
protects the parasite within the host cell from degradation by lysosome fusion (Louis & Kami, 
2007). 
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1.4.1 Initial attachment 
The surface of tachyzoites contains a number of proteins that belong to a family of GPI-
anchored surface antigens (SAGs). These SAG proteins are almost evenly distributed along 
the surface of the pathogen and they form low-affinity, lateral interactions with the host 
surface. It is thought that these proteins may allow the pathogen to analyse the host cell 
surface for an optimal invasion site. This interaction is reversible and the pathogen can 
disengage from the host cell surface when conditions are not ideal for invasion (Carruthers & 
Boothroyd, 2007).  
1.4.2 Apical attachment 
The invasion process is highly polarised and is initiated at the apical end of the parasite. This 
step requires the proteins present within the microneme, called micronemal (MIC) proteins. 
Studies have shown that these MIC proteins are secreted to the parasite’s apical surface in a 
calcium dependent manner (Lovett et al, 2002). Many MICs seem to have a conserved 
adhesin domain which aids in protein-protein or protein-carbohydrate interaction between the 
parasite and host cells (Soldati et al, 2001). Studies have also shown that a number of MIC 
proteins have adhesive domains which might allow binding to multiple receptors, and hence 
help form a robust interaction (Carruthers & Boothroyd, 2007).  
1.4.3 Commitment step 
It has been observed that the conoids extrude during invasion in a calcium dependent manner, 
possibly at the same time as MIC secretion. This extrusion brings the parasite and host 
plasma membranes into close proximity with each other. During this time, another 
micronemal protein called apical membrane antigen (AMA1) is involved in forming a third 
attachment which seems to be the commitment step for invasion (Carruthers & Boothroyd, 
2007). AMA1 has been found to form complexes with four other proteins which are secreted 
from the neck region of rhoptries (RON proteins) (Alexander et al, 2005; Lebrun et al, 2005). 
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1.4.4 Moving Junction 
The AMA1 and RON proteins form a complex as or just before they are secreted to the 
parasite’s apical surface. There they cooperatively form the moving junction (MJ). The MJ is 
a ring-like band of intimate interaction between the parasite and the host cell and is similar in 
appearance to the mammalian tight junctions. One of the functions of this structure is to act as 
a ‘sieve’ that selectively removes many host and parasite proteins from the two plasma 
membranes as it moves down the parasite (Charron & Sibley, 2004; Mordue et al, 1999). 
Rhomboid-like proteases are released by the parasite for proteolysis of these protein 
complexes (Boucher & Bosch, 2015). ROM4 is one of the most crucial proteins for adhesin 
removal from the parasite surface and is necessary for efficient host invasion. However, 
recent mutagenesis studies have shown that MIC2 is removed from the parasite surface in the 
absence of ROM4 suggesting the presence of ROM-independent mechanism for adhesin 
removal (Shen et al, 2014). This ‘stripping off’ of certain proteins may be a possible 
explanation as to why the parasitophorous vacuolar membrane (PVM) does not fuse with host 
lysosomes or any other host vesicles, thus evading the host immune system (Carruthers & 
Boothroyd, 2007). 
1.4.5 Closure 
Once the MJ ring has completed its migration down the parasitophorous vacuole, closure is 
achieved by unknown means leaving a surface residue exposed (RON4) on the outside of the 
host cell (Carruthers & Boothroyd, 2007). 
1.4.6 Separation 
The PVM is then pinched off and separated from the host plasma membrane, releasing the PV 
into the host cell. The closure and separation steps together require 2 minutes and the 
machinery required for these steps remains unknown (Carruthers & Boothroyd, 2007). Once 
the parasite is within the host, encapsulated within the PVM, the secretion of dense granules 
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is upregulated to release proteins into the lumen of the PV (Carruthers & Sibley, 1997; 
Leriche & Dubremetz, 1990). These proteins modify the PV such that it can acquire nutrients 
from the host cell (Carruthers, 2002). 
1.5 SAG proteins 
SAG1 is a surface antigen protein that is part of a superfamily of SRS (SAG1-related 
sequence) proteins. The SRS family consists of 20 homologous proteins which have 25-30%   
sequence identity. All SRS proteins seem to be (glycosylphosphatidylinositol) GPI-anchored 
to the parasite surface (Jung et al, 2004). During acute infection, SAG1 and SAG2A are the 
most immune-dominant proteins within the SRS superfamily. SAG1 is critical for producing 
a hyper-immune response at the initial stages of infection. The crystal structure of SAG1 has 
been solved to 1.7 Å resolution and is shown in figure 1.5 (He et al, 2002). 
It has also been found that SAG2A and SAG2B are the smallest SRS proteins and 
have one domain whereas a majority of the other SRS proteins are larger in size and have two 
SAG2A-like domains. The structure of SAG1 consists of two domains – DI and DII – which 
are very similar in their secondary structure composition. SAG1 has been found to form a 
homodimer which is initiated by the DI domains. Studies have also shown that SAG3 can 
bind sulphated proteoglycans (SPGs) but the exact identity of the SPG is unknown (He et al, 
2002). The homodimer interface has a positively charged groove which could possibly bind 
SPGs as shown in figure 1.5.  
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Figure 1.5: Figure showing (A) a cartoon representation of the SAG1 homodimer (alpha helices 
coloured red, beta sheets coloured yellow and loop regions coloured green) and (B) the electrostatic 
surface representation showing positively charged groove in the homodimer interface in blue 
(highlighted by the black circle)  
 
1.6 Microneme Proteins 
Micronemes are rod-shaped, secretory organelles which are the first to release proteins during 
invasion. Knockout studies have shown that MIC proteins are required for successful 
invasion. It has been found that microneme proteins form complexes such that one or more 
proteins in the complex have an adhesive function whereas the other protein contains a 
transmembrane domain that anchors the protein complex to the parasite actin-myosin motor 
system, thus forming a bridge between the parasite and host cell (Soldati et al, 2001). 
Microneme secretion is induced by a transient increase in intracellular Ca
2+
 concentration in 
the parasite (Lovett et al, 2002). 
1.6.1 MIC2 and M2AP 
The MIC2/M2AP complex has been shown to be necessary for invasion (Huynh et al, 2003). 
Knockout studies have shown that MIC2 is necessary for invasion and mutants lacking MIC2 
were deficient in host cell attachment, invasion, gliding motility and the ability to support 
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lethal infection. MIC2 has also been found to be necessary for proper trafficking of M2AP 
(Huynh & Carruthers, 2006). The NMR solution state structure of the β domain of M2AP has 
been solved and is shown in figure 1.6 (Huynh et al, 2015). MIC2 is the transmembrane 
member of the MIC2/M2AP complex, with an extracellular region composed of an integrin-
like I-domain followed by five thrombospondin like repeats (TSRs) and a degenerate sixth 
TSR near the transmembrane domain. The C-terminal cytosolic end of MIC2 is thought to 
associate with the actin-myosin motor of the parasite, but the molecular details of this 
interaction have not yet been characterised.  
M2AP is a soluble protein with an N-terminal propeptide, followed by a β domain, 
and a predicted coil domain at the C-terminus (Huynh et al, 2015). M2AP does not appear to 
be involved in adhesion but has been found to be necessary for proper trafficking and 
secretion of MIC2 (Harper et al, 2006). The degenerate sixth TSR domain has been found to 
interact with M2AP by mutation and deletion studies. The M2AP structure shows that the β 
domain of M2AP is very similar in structure to MIC1. The structure of MIC1 β domain is 
similar to the galectin fold found in carbohydrate binding proteins (Saouros et al, 2005). 
However, MIC1 does not contain a carbohydrate binding domain but a hydrophobic patch. 
Similarly, the β domain of M2AP has a protein-protein interaction surface instead of a 
canonical carbohydrate-binding surface. This hydrophobic patch present in M2AP has been 
found to be crucial for interaction with MIC2 and is shown in figure 1.6 (Huynh et al, 2015).  
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MIC2 has been found to interact with two host proteins – LAMTOR 1 (late 
endosomal/lysosomal adaptor, MARK and mTOR activator 1) and RNaseH2B (ribonuclease 
H2 subunit B). These proteins have been found to be involved in many cellular processes, 
such as lysosome maturation, signalling transduction, and RNA catabolism (Wang et al, 
2014). Although the molecular basis of this mechanism is unknown, it has been suggested 
that MIC2 is involved in altering host signal transduction, in addition to binding host cells. 
Figure 1.6: Figure showing (A) cartoon representation of the β domain of M2AP in rainbow 
colours from N to C terminus of the protein in three orientations and (B) the hydrophobic surface 
representation showing hydrophobic patches (orange) in the respective orientations. It has been 
found that the hydrophobic patch highlighted by the black circle is necessary to bind MIC2. 
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1.6.2 MIC1-MIC4-MIC6 
Another microneme protein complex which has been extensively studied is the MIC1-MIC4-
MIC6 complex. MIC1 and MIC4 are soluble adhesins whereas MIC6 does not have any 
adhesive functions. MIC6 has a transmembrane domain and acts as an escorter and 
mutagenesis studies have shown that MIC6 is necessary for proper trafficking of MIC1 and 
MIC4 (Reiss et al, 2001). MIC6 contains a transmembrane domain, followed by an acidic 
domain and three EGF-like domains. MIC4 is a soluble propeptide consisting of six 
Apple/PAN domains. It is processed extracellularly when the sixth Apple/PAN domain is 
cleaved off.  
MIC1 consists of two MAR (Microneme Adhesive Repeat) domains characterised by 
X-ray crystallography (Garnett et al, 2009), followed by a galectin-like domain at the C-
terminus which has been characterised by NMR (Saouros et al, 2005). One of the MAR 
domains is type I and the other one is type II. The C-terminal domain is a rigid β barrel 
consisting of two β sheets. This galectin-like domain does not have a carbohydrate binding 
domain but a hydrophobic patch as shown in figure 1.7 (Saouros et al, 2005). The 
hydrophobic patch from two MIC1 proteins stabilise the second and third EGF-like domains 
of MIC6 by interacting with them and is shown in figure 1.7 (Sawmynaden et al, 2008). The 
two MAR domains of MIC1 bind sialylated oligosaccharides and can differentiate between 
different linkages (Friedrich et al, 2010). The structure of MIC1 MAR domain bound to 
3'SiaLacNAc1-3 has been solved by X-ray crystallography and is shown in Figure 1.7 
(Garnett et al, 2009).  
MIC4 interacts with terminal galactose residues via the fifth Apple/PAN domain. The 
solution structure of the fifth Apple/PAN domain of MIC has been solved by NMR and is 
shown in figure 1.7 (Marchant et al, 2012). Following this, TgSUB1 is secreted and it cleaves 
MIC4 between the fourth and fifth Apple/PAN domain releasing the galectin domain (Lagal 
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et al, 2010). It has been suggested that this would aid the parasite in evading the host immune 
response activated by the galectin (Marchant et al, 2012; Marchant et al, 2008). 
 
 
Figure 1.7: Figure showing (A) cartoon representation of the complex formed by MIC1 C terminal 
domain (wheat) and the MIC6 EGF domain (rainbow colours from N to C terminus) (B) cartoon 
representation of the MIC1 MAR domain (rainbow colours from N to C terminus) bound to 
3’SiaLacNac1-3 (shown as pink spheres) and (C) cartoon representation of the fifth Apple domain 
of MIC4 (rainbow colours from N to C terminus) 
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1.6.3 Other microneme proteins 
MIC5 is another microneme protein which has been found to have a role in inhibiting 
TgSUB1 (Saouros et al, 2012). The NMR solution state structure of MIC5 has been solved 
and it has been found that the structure of MIC5 is similar to that of subtilisin prodomains as 
shown in figure 1.8. Mutation studies have also shown that MIC5 contains a C-terminal 
flexible peptide which inserts into the active site of TgSUB1 inhibiting it (Saouros et al, 
2012).  
MIC3 is a soluble adhesive protein that has been found to form a complex with MIC8, an 
escorter protein. MIC3 is exocytosed from the micronemes and secreted all over the surface 
of the parasite. The structure of MIC3 has five partially overlapping EGF-like domains and a 
chitin binding-like domain, which can be involved in protein–protein or protein–carbohydrate 
interactions (Garcia-Réguet et al, 2000). MIC8 has a transmembrane domain and it interacts 
with MIC3 forming a complex in the transit during the secretory pathway. MIC8 is necessary 
for efficient invasion as it is required for the formation of the moving junction (Meissner et al, 
2002). 
 
 
 
 
 
 
 
 
 
Figure 1.8: Figure showing cartoon representation of MIC5 in rainbow colours from N to C 
terminus of the protein 
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1.6.4 AMA1 
AMA1 is a transmembrane protein which is secreted from micronemes and localised to the 
parasite membrane upon invasion. Structural studies of AMA1 homologues from T. gondii, P. 
vivax and P. falciparum have shown that the ectodomain of the protein has a hydrophobic 
trough (Tonkin et al, 2011). The crystal structure of the ectodomain of TgAMA1 was solved 
to 2 Å resolution and is shown in figure 1.9.  The ectodomain consists of three domains – DI, 
DII and DIII. The DI domain consists of α helices, short β twists and coiled coils held 
together by three disulphide bonds. The DII domain consists of a loop region called the DII 
loop, followed by the DII core domain. The DII loop is stabilised by a disulphide bond and 
the DII core also contains a disulphide bond. The DII core domain is followed by a long 
linker that connects the DII domain to the DIII domain. The long linker facilitates the 
positioning of the DIII domain at the posterior end of the ectodomain. The DIII domain 
consists of three disulphide bonds that form a highly stable cysteine knot (Crawford et al, 
2010). 
1.7 Rhoptry and Rhoptry Neck Proteins 
Rhoptries are bulb-shaped organelles which secrete proteins which are localised either to their 
duct shaped neck or the bulb (Louis & Kami, 2007). The proteins secreted from the neck are 
called rhoptry neck or RON proteins and those secreted from the bulb are called ROP 
proteins. The RON proteins are known to be mainly involved in the formation of the moving 
junction whereas the ROP proteins have a number of other functions including virulence and 
host cell signalling (Carruthers & Sibley, 1997). A complex of RON2, RON4, RON5 and 
RON8 proteins is necessary for successful invasion. Out of these RON proteins, RON8 is the 
only one which is conserved only in coccidian parasites. Mutagenesis studies have suggested 
that RON8 is necessary for stabilising the initial host-parasite interaction (Straub et al, 2011). 
RON2 is a membrane protein that inserts into the plasma membrane of the host cell with the 
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N-terminal end in the host cytoplasm and the C-terminal end forming a complex with AMA1 
(Tyler & Boothroyd, 2011). RON4, RON5 and RON8 proteins are injected into the host cell 
bound to RON2 as a complex (Straub et al, 2011; Tyler & Boothroyd, 2011). The ectodomain 
of AMA1 binds RON2 and the C-terminal end of AMA1 interacts with the actin-myosin 
motor system within the parasite (Tyler & Boothroyd, 2011).  
1.8 AMA1-RON2 complex 
The crystal structure of AMA1 in complex with RON2 peptide has been solved to 1.7 Å 
resolution (Tyler & Boothroyd, 2011). This structure shows that the RON2 peptide interacts 
with AMA1 in a U shaped conformation. It has also been found that AMA1 undergoes a 
significant conformational change for the RON2 peptide to bind as shown in figure 1.9. In the 
unbound form, the DII loop in AMA1 is situated in a hydrophobic groove in the structure. In 
the bound form, the DII loop is displaced from this position exposing a basic binding 
interface for the acidic residues of RON2. The exposed binding surface complements RON2 
structurally and electrostatically (Tyler & Boothroyd, 2011). Following the formation of the 
moving junction, the conoids in the parasite extrude, putting a large amount of stress on the 
AMA1-RON2 complex. The extrusion of the conoids is dependent on a rise in Ca
2+ 
concentration (Mondragon & Frixione, 1996). It is suggested that the complementarity of the 
AMA1-RON2 binding interface, in terms of charge and conformation makes the interaction 
robust enough to withstand the stress of the extrusion (Tyler & Boothroyd, 2011). 
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Figure 1.9: Figure showing (A) cartoon representation (left) and surface representation (right) of 
AMA1 ectodomain with DI domain in magenta, DII loop in gold, DII domain in green and DIII 
domain in blue and (B) cartoon representation of unbound AMA1 ectodomain shown in green and 
DII loop shown in purple and AMA1 ectodomain bound to RON2 fragment (pink) 
 
42 
 
1.9 Eimeria tenella - Life Cycle 
The Eimeria species under study in this project is Eimeria tenella. Although E. necatrix is the 
most pathogenic parasite, E. tenella is also highly pathogenic in chickens as pathology is 
primarily associated with the second generation schizonts on account of their size and deep 
location within the lamina propia. Schizony in chickens has been found to occur in the crypts 
and lamina propria of the ceca and the Lieberkühn of the small intestine, respectively 
(Gerhold, 2014). Parasites are ingested by chickens as oocysts. Once the oocysts reach the gut 
of the chicken, sporozoites are released which invade the epithelial cells lining the intestine. 
Following this, the sporozoites undergo replication to form merozoites. Merozoites can 
invade fresh host cells and differentiate into male and female gametes. The gametes fuse to 
form a zygote which matures into an oocyst. Oocysts are then released in the faeces of the 
chicken (Fernando, 1990) as shown in Figure 1.10.  
 
 
Figure 1.10: Figure showing the various stages in the life cycle of E. tenella within chickens. The 
stages of the parasite are labelled in the figure. 
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1.10 Plasmodium falciparum  
1.10.1 P. falciparum – Life cycle 
P. falciparum has a complex life cycle which involves asexual and sexual development both 
in the female Anopheles mosquito and within humans as shown in figure 1.11. The parasite is 
transmitted to humans by the vector, as sporozoites, during a blood meal. The sporozoites 
then enter the liver, invade and multiply within the hepatocyte cells in the liver. This stage of 
multiplication is called the pre-erythrocytic development. The parasites are released from the 
hepatocytes, as merozoites, into the bloodstream. The merozoites then invade the erythrocytes 
and multiply within the erythrocytes asexually. A fraction of these merozoites form 
gametocytes possibly in the bone marrow as the immature gametocytes are present in the 
bone marrow (Aguilar et al, 2014). The mature gametocytes are released into the blood 
stream and can be found in the peripheral blood stream. The parasites can be transmitted to 
the female Anopheles mosquito only as mature gametocytes, which occurs during the blood 
meal. Once the gametocytes enter the mosquito, the gametocyte either matures into a female 
macrogamete or into eight male microgametes. The gametes fuse within the mosquito midgut 
to form a zygote, which develops into a motile ookinete. The ookinete then penetrates the 
midgut wall and forms oocysts. The oocysts grow in size and burst releasing sporozoites. 
These sporozoites enter the salivary gland of the mosquito ready to be transmitted to humans 
during a blood meal, thus completing the cycle (Bousema et al, 2014). 
1.10.2 P. falciparum – Erythrocytic Schizogony 
P. falciparum undergoes two stages of development within humans – pre-erythrocytic and 
erythrocytic development. During the erythrocytic development stage, the merozoite goes 
through four stages – ring, trophozoite, immature and mature schizont as shown in figure 
1.11. The ring or immature trophozoite is the first stage which then develops into a mature 
trophozoite. The trophozoite cannot digest the haem but digests the globin and the haem is 
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Figure 1.11: Figure showing the various stages in the life cycle of P. falciparum within the 
mosquito and humans. The stages of the parasite are labelled in the figure. 
stored as a haemozoite crystal. The trophozoite then matures into a schizont. The morphology 
of these different stages are different and can be seen in Figure 1.11 (Petri et al, 2006). 
 
1.11 Vaccine development 
Efforts are currently being made to develop vaccines against toxoplasmosis, coccidiosis and 
malaria. Most of the vaccine studies which are taking place are species specific without any 
cross reactivity. There are three types of approaches to develop vaccines – using live or 
attenuated parasites, DNA vaccines and protein vaccines. Although numerous studies have 
been performed in all three approaches, only the studies involving protein vaccines will be 
discussed in detail in this thesis. 
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1.11.1 Protein Vaccines  
Toxoplasmosis in immunocompromised individuals is usually treated with anti-parasitic 
drugs like pyrimethamine, spiramycin and sulfadiazine. Since these drugs can cause toxic 
hypersensitivity reactions and are teratogenic, alternative methods to treat toxoplasmosis are 
becoming a rising necessity (Lim & Othman, 2014). It has been established that the IFN-γ 
secreting CD8+ cells are the major subset of cytotoxic T cells necessary for providing long 
term protective immunity against toxoplasmosis (Brown & McLeod, 1990; Gazzinelli et al, 
1991). This suggests that any antigen that raises a Th1-type immune response is a good 
candidate to battle pathogenesis and provide protection against chronic infection.  
The most important protein antigen which was initially used for vaccination studies was the 
SAG proteins. Immunisation of mice with SAG1, with QuilA (Khan et al, 1991) and cholera 
toxin (Debard et al, 1996) as adjuvants, showed reduced brain cysts after infection. QuilA is a 
saponin based adjuvant which induces strong cytotoxic CD8+ lymphocyte responses (Kensil, 
1996). However, the use of a non-toxic adjuvant, labile enterotoxin, showed decreased 
protection and much lower reduction in brain cysts (Bonenfant et al, 2001). However, in 
recent years it has been found that using multimeric protein antigens provide better protection 
against infection. Recent studies have shown that the oral administration of TgMIC1, 
TgMIC4 and TgMIC6 as a combination vaccine is effective as it increases host survival rate 
and reduces brain cyst burden in mice. The same study also reports that mice immunised with 
these proteins elicit a strong Th1-type immune response and an equilibrated production of IL-
10 (Pinzan et al, 2015). Another recent approach to developing an effective vaccine has been 
the use of short peptides of different parasite proteins in combination. A recent study has 
shown that the use of the T/B cell epitopes from TgAMA1 and TgRON2 as a combination 
vaccine in mice leads to increased host survival rate and reduced brain cyst burden. The study 
also reports that mice immunised with a combination of TgAMA1 and TgRON2 epitopes 
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showed a stronger immune response than the mice immunised with one of the two protein 
epitopes. The combination vaccine has been found to increase both Th1 and Th2 type 
immune responses (Zhang et al, 2015).  Although many antigens that induce a Th1 immune 
response to the parasite have been identified, none of them have been able to provide sterile 
immunity against infection.         
AMA1 has also been found to induce antibodies and protection against malarial 
infection in a strain-specific manner in rodent and monkey models. Thus, AMA1 is 
considered a potential blood stage malarial vaccine. Phase 2 trials of AMA1-Combination 1 
(C1) malaria vaccine were performed in children in Mali. This vaccine is a combination of 
the ectodomains of AMA1 homologues from two divergent strains of P. falciparum - FVO 
and 3D7 – in equal amounts, adjuvanted with Alhydrogel. The results from this study showed 
that this vaccine is only moderately immunogenic and a more immunogenic formulation of 
the vaccine may be more likely to be protective (Sagara et al, 2009). Another recent study 
tested the efficacy of FMP2.1/AS01 vaccine in controlling parasite multiplication rate in 
mosquito-bite controlled human malaria infection (CHMI) models. FMP2.1 is a protein 
vaccine based on the sequence of AMA1 from the P. falciparum 3D7 strain. This vaccine also 
demonstrated no efficacy after blood stage CHMI (Payne et al, 2016).     
1.11.2 DNA Vaccines 
DNA vaccines against toxoplasmosis would be beneficial because they are much cheaper in 
terms of cost (Lim & Othman, 2014). DNA vaccines generally induce a Th1-type immune 
response in addition to an increase in IFN-γ and IL-2 production. The major disadvantage of 
using DNA vaccines is that the immune response induced by these vaccines is generally too 
weak in humans. Similar to proteins vaccines, DNA vaccines encoding a combination of 
multiple antigens have also been found to be more immunogenic than those encoding a single 
antigen. Studies have shown that the use of a multimeric DNA vaccine encoding the T cell 
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epitopes of a combination of micronemal proteins – MIC2, MIC3, MIC4, M2AP and AMA1 
– showed 84% reduction in brain cyst burden and longer survival time in mice than DNA 
vaccine encoding a single antigen (Beghetto et al, 2005). Recent studies have also shown that 
DNA vaccine encoding 12 T and B cell epitopes from SAG1, GRA2, GRA7 and ROP16 
sequences provide partial protection against acute infection in mice. This vaccine has been 
found to increase the Th1 type immune response. However, this vaccine did not provide 
complete protection (Cao et al, 2015). Another study has found that the use of an adjuvant 
with the DNA vaccine increases the efficacy of the vaccine. A DNA vaccine encoding MIC8 
showed increased survival time in mice when administered with mIL-21 and mIL-15 
cytokines than when administered on its own (Li et al, 2014; Liu et al, 2010). Although many 
more multi-epitope DNA vaccines have been found, sterile immunity against toxoplasmosis 
has not been achieved with DNA vaccines so far. 
1.11.3 Live, vectored Vaccines 
Another vaccination strategy used against toxoplasmosis is the use of live, vectored vectors as 
vehicles to carry and express antigenic epitopes from T. gondii. A number of attenuated 
vectors being used in various studies tend to be bacteria and viruses. This method of 
vaccination tends to be more effective due to the intrinsic adjuvant properties of the vectors. 
Studies have shown that delivering the recombinant GRA4 antigen in attenuated vaccinia 
vaccine provided 100% survival from infection and no brain cysts 45 days post infection in 
mice. On the other hand, vaccination with DNA vaccine encoding GRA4 antigen only 
provided 70% survival from infection in mice (Zhang et al, 2007).  
 Currently, the only successful vaccine against toxoplasmosis is Toxovax (Schering-
Plough Animal Health Ltd, New Zealand). Toxovax is a live, attenuated vaccine which is 
used to vaccinate sheep against toxoplasmosis infections. T. gondii infection in sheep leads to 
congenital transmission resulting in abortions and stillbirths. Toxovax consists of a particular 
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strain of T. gondii which can only undergo limited multiplication in sheep and has lost the 
ability to form bradyzoites (Buxton & Innes, 1995; Buxton et al, 1991). This vaccine is 
administered to uninfected sheep prior to mating and induces protective immunity for 18 
months following a single shot. The vaccine needs to be repeated after 2 years (HiszczyŃSka-
Sawicka et al, 2014). Although this method of vaccination is effective, there are many safety 
concerns regarding the use of attenuated viruses and parasites as vaccines against 
toxoplasmosis. The danger of the attenuated parasite reverting back to the active form is an 
ever present risk.  
1.12 Immune Mapped Protein 1 
Immune Mapped Protein 1 (IMP1) is an immunogenic protein that was first identified in 
Eimeria maxima. It has been shown to confer immunity against E. maxima infections through 
unknown mechanisms (Blake et al, 2011). An orthologue of this IMP1 protein has also been 
recently identified in the T. gondii RH strain (TgIMP1), in addition to other apicomplexan 
parasites. Recent studies have shown that immunisation of BALB/c mice with the pcDNA-
IMP1 from the RH strain of T. gondii has increased the survival time of mice challenged with 
the lethal T. gondii RH strain tachyzoites compared to the control mice that were immunised 
with the empty plasmid. pcDNA is a vector which is designed for high level, constitutive 
protein expression in mammalian cell lines (ThermoFisher, UK) The vaccine causes an 
increase in IFN-γ, IL-2, and IL-10 levels, which are indicative of humoral and Th1 type 
response. The same study has also shown that TgIMP1 is a 43 kDa protein that seems to 
localise at the parasite plasma membrane and it induces both cellular and humoral immune 
responses in mice (Cui et al, 2012). Predicted orthologues of this IMP1 protein have also been 
identified in the genome of T. gondii ME49 strain, which is one of the strains under study in 
this project. 
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Studies have shown that a fragment of IMP1 from Eimeria tenella Houghton strain 
fused with a molecular adjuvant produces a stronger cellular immune response against E. 
tenella infections in chickens in a species-specific manner. This further confirms that IMP1 is 
an antigenic protein which produces an immunogenic response in the host by some unknown 
mechanism (Yin et al, 2013). A recent study by the same group has shown that chickens 
immunised with a C-terminal fragment (AA151-AA387) of EtIMP1 (EtIMP1-C) showed 
reduced faecal oocyst shedding and diminished intestinal pathology in comparison to non-
immunised chickens. The study has also confirmed that the efficacy of EtIMP1-C was the 
same as that of full length EtIMP1 suggesting that the C-terminal region is the immune-
dominant region in the protein (Yin et al, 2014). 
1.13 Project Aims and Objectives 
The immunogenic properties of IMP1 made this protein an interesting candidate to study it 
further. The aims of this project are as follows: 
 Clone, express and purify the IMP1 homologues from T. gondii, E. tenella and P. 
falciparum for structural studies. 
 Study the structure of IMP1 using NMR and X-ray Crystallography. Solving the 
structure of IMP1 will allow us to compare and analyse the IMP1 structure with 
existing protein structures. The structure of IMP1 might also guide us towards its 
possible function. 
 Few studies have reported that IMP1 proteins are localised to the inner leaflet of the 
plasma membrane. The immunogenic nature of the protein, however, suggests that the 
protein has to be exposed on the parasite surface. Since the IMP1 protein lacks a 
transmembrane domain, it was hypothesised that the protein might localise to the 
plasma membrane by interacting with a transmembrane protein. Perform localisation 
studies and identify potential binding partners of IMP1 in the host organism.  
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Chapter 2  
Nuclear Magnetic Resonance  
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2.1 Structural Biology Techniques 
Protein structure determination is an important step in understanding protein biology. The 
function of a protein is determined by the three dimensional structure of the protein. The three 
major techniques which are used to determine protein structure to atomic resolution are X-ray 
crystallography, Nuclear Magnetic Resonance (NMR) and Cryo-Electron Microscopy (Cryo-
EM). 
2.1.1 X-ray crystallography 
X-ray crystallography is a technique that is used to solve the structure of macromolecular 
proteins to atomic resolution. In order to study a protein using this technique, high quality 
protein crystals are required. Protein crystallisation is generally achieved by bringing the 
protein solution to a super-saturation state. In the super-saturation state, the protein is 
“forced” out of solution to form crystals. Protein purity and homogeneity are important 
factors that determine the quality of the protein crystal (Drenth, 2010). Super-saturation can 
also be achieved by varying several conditions such as protein concentration, pH, 
temperature, salt concentration, buffers etc. When the protein is in the right condition, it 
forms crystals which can be used for structural studies (Abola et al, 2000). Advances in 
automation of high throughput protein crystallisation in the past decade allow us to screen a 
vast range of crystallisation conditions rapidly. Very low amounts of pure protein are required 
to screen each condition.  
Once a protein crystal is obtained, the crystal is shot with an X-ray beam. The X-rays 
in the beam are diffracted elastically by the electron cloud surrounding the nuclei in the 
protein (Drenth, 2010). The intensity of the diffracted X-rays relies on the interference of the 
rays diffracted by the atoms in the protein. These diffracted rays are then recorded by a 
detector (as shown in figure 2.1.1) and are called the X-ray diffraction pattern. A backward 
transformation of the diffracted waves will provide us with information about the electron 
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density of the protein. The diffraction pattern provides information about the amplitude of the 
diffracted rays but not the phase. The inability to determine the phase of the diffracted waves 
from the diffraction pattern is termed the phase problem (Drenth, 2010).  
The phase problem is usually solved by using Isomorphous Replacement (MIR and 
SIR), Molecular Replacement (MR) or Anomalous Dispersion (MAD and SAD). MR is used 
to calculate the phase when the structure of a close homologue of the protein is known. 
Isomorphous Replacement involves recording the diffraction pattern of crystals of the protein 
with heavy atoms in known positions. Anomalous Dispersion uses the native crystal but 
involves recording diffraction patterns with the same crystal at different wavelengths of the 
X-ray. In MIR and anomalous displacement, the heavy atoms and variations in the 
wavelength cause changes in the diffraction pattern, respectively. Comparison of the two 
diffraction patterns will allow determination of the phase of the diffracted waves (Drenth, 
2010). 
Although X-ray crystallography is an effective method for structure determination of 
proteins to atomic resolution, the technique requires a vast amount of pure protein to screen 
numerous crystallisation conditions prior to successful crystallisation. Crystallisation to 
produce protein crystals which diffract to high resolution is a limiting step and requires 
homogenous protein samples of high purity. The diffraction quality of a crystal also 
determines the resolution of the final structure. A good quality crystal can produce a high 
resolution structure.  However, this technique does have its advantages. There is no size limit 
on the protein sample that can be studied using this technique.     
  
53 
 
Figure 2.1.1: Figure showing an overview of the various stages in protein structure calculation 
using X-ray crystallography 
 
The structure of a protein from a Plasmodium parasite was recently solved using X-ray 
crystallography. The symptoms that occur during malarial infections are caused by blood 
stage infection by merozoites. Plasmodium species merozoites invade human blood cells in a 
multistep process. The initial step in this invasion process is host selectivity by the parasite. 
PvRBP (Reticulocyte binding protein) is a family of adhesin proteins that are involved in host 
cell selectivity. The full length PvRBP2a protein is 286 kDa in size. The protein construct 
used for crystallographic studies included amino acids 169 to 1135 with a theoretical 
molecular weight of 98.4 kDa (Gruszczyk et al, 2016).  
The structure of Plasmodium vivax RBP2a (PvRBP2a) protein was solved using the 
Single Isomorphous Replacement with Anomalous Scattering method (SIRAS) using iodine-
derivatised crystal and refinement was performed against the native diffraction data set. The 
resolution of the final structure was 2.12 Å. The high resolution structure of the PvRBP2a 
protein solved by X-ray crystallography is shown in Figure 2.1.2. The protein contains two 
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sub-domains which are related to each other by pseudo two-fold rotational symmetry. The N-
terminal domain consists of the 310 helix, the beta hairpin, α1 to α3b helices and the C-
terminal domain consists of α4 to α7 helices. Although the crystal structure contains two 
molecules in the asymmetric unit (Figure 2.1.2) with extensive contact over an area of 1349 
Å
2
, the same study goes on to show that the protein exists as a monomer in solution. This 
confirms that the dimeric existence of the protein is a crystal artefact which is not biologically 
relevant (Gruszczyk et al, 2016). 
 
  
Figure 2.1.2: Figure showing a cartoon representation of the crystal structure of PvRBP2a protein 
with the secondary structure elements labelled. The beta hairpin in the structure has been labelled β-
h. The two molecules found in the asymmetric unit of a crystal are shown. One molecule is coloured 
purple and the other coloured green. However, this dimer is not biologically relevant (Gruszczyk et 
al, 2016). 
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2.1.2 Cryo-Electron Microscopy 
Cryo Electron Microscopy (Cryo-EM) is another technique used for protein structure 
determination. Although this technique has limitations due to difficulty in sample preparation 
and limitations in resolution, there is no limit on the size of the sample that can be studied 
using this technique.  
Sample preparation is a crucial step in Cryo-EM as sample quality affects the quality 
of the data. Once a homogenous sample is obtained, the sample is prepared on an EM grid. 
These are copper grids which have a thin layer of carbon support film deposited on them. The 
protein sample rests on this carbon film. In Cryo-EM studies, a holey carbon grid is used 
which is a grid in which the carbon is deposited in such a way that there are holes in the 
carbon layer. The holes in the carbon layer allow the solvent to form pockets wherein the 
protein remains hydrated and can, therefore, be frozen in its native state (Thompson et al, 
2016).  
The sample is frozen rapidly so that the water that is present in and around the protein 
sample is frozen in a vitreous state. Ice formation can occur if the sample is not frozen fast 
enough or if the sample warms up, causing the water to devitrify. This can have detrimental 
effects on sample integrity and image quality. Cryo-immobilisation of the sample is usually 
achieved by blotting to produce a thin layer of liquid containing the sample and plunging it 
into a cryogen to freeze it. This is performed using commercially available freezing 
apparatus. It is essential to ensure that the sample is completely embedded in liquid in order 
to prevent radiation damage to the exposed regions in the sample (Thompson et al, 2016). 
The protein sample is then bombarded with an electron beam and the electrons are 
scattered elastically. The last decade has seen numerous advances in the detectors used to 
record electron scattering. Photographic films were originally used as detectors in cryo-EM. 
However, they have recently been replaced by Monolithic Active Pixel Sensors (MAPS). 
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These sensors are also referred to as ‘direct electron detectors’ and the electrons pass through 
a thin semi-conductor membrane where they deposit energy. This is detected by electronics 
fabricated into the membrane. Behind the membrane, there is a support matrix which back-
scatters the electrons into the membrane. This back-scattering leads to noise and can be 
eliminated by thinning the support matrix in a process known as back-thinning (Bai et al, 
2015).  
Commercial detectors which have a total thickness of 50 µm and allow all the 
electrons to completely pass through them are now available. Since low doses of electrons are 
enough to saturate these detectors, the dosage needs to be spread out over multiple low doses. 
Movie-mode functionality is also provided by the latest detectors. Development of improved 
detectors and improvements in image characterisation and alignment algorithms have made 
cryo-EM a viable structural biology tool (Bai et al, 2015). A schematic representation of the 
various stages of data analysis in cryo-EM is shown in figure 2.1.3 (Pintilie, 2009). 
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Figure 2.1.3: Figure showing an overview of various stages in protein structure calculation using 
Cryo - Electron Microscopy. Source: (Pintilie, 2009) 
Image classification 
and alignment 
Recorded Data 
Cryo-EM density map 
  
 
 
Cryo-EM is becoming a prominent tool in deducing the structure of large protein 
complexes. The structure of the 20S proteasome in P. falciparum bound to the Mor-WLW 
vinyl sulphone inhibitor has been solved using Cryo-EM and single particle analysis as shown 
in figure 2.1.4 (Li et al, 2016). The structure of the inhibitor bound human 20S proteasome 
was also solved previously using a similar strategy (da Fonseca & Morris, 2015). The 
Plasmodium proteasome is a protease complex, which is crucial for protein turnover within 
the parasite. Due to the rapid multiplication of the parasite within the host cell, rapid protein 
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turnover is required for parasite survival. This makes the proteasome an important anti-
malarial drug target (Voges et al, 1999).  
The study has also shown that the inhibitor under study can selectively inhibit the 
parasite proteasome with a minimum impact on the human proteasome. The basis behind 
selective inhibition was understood by analysing and comparing the high resolution structures 
of the parasite and human proteasomes. The structures revealed that steric restraints in the 
active site of the parasite and human 20S proteasome are the cause for selective inhibition (Li 
et al, 2016).  
The molecular weight of the P. falciparum 20S proteasome – inhibitor complex is 760 
kDa. The protein concentration that was used to prepare the sample was 0.1 mg/ml. It is 
evident that the structure of such a large complex cannot be solved by NMR due to the size 
restraints in this technique. Crystallography, on the other hand, requires large quantities of 
protein samples for screening and optimising crystallisation conditions. This high resolution 
structure is a fine example that shows that cryo-EM is a valuable tool that can be used for 
high resolution structure determination of large complexes which are not suited for structural 
studies by NMR and crystallography (Li et al, 2016). This study is an excellent example that 
demonstrates that cryo-EM is increasingly becoming an important structural biology 
technique that can be used to obtain high resolution structures. 
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Figure 2.1.4: Figure showing two views of the cartoon representation of the cryo-EM structure of 
Plasmodium falciparum 20s proteasome (Li et al, 2016). 
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2.2 NMR for Protein Structure Determination 
NMR is a powerful technique which allows the study of protein structures in solution. This 
technique provides information about the dynamics of the protein and allows us to study 
protein-protein interactions in addition to protein structure in atomic detail. The Matthews’ 
lab mainly uses X-ray crystallography and NMR for structural studies. Since the protein 
structure was solved using NMR, this technique is described in detail. Most of the technical 
details about NMR have been taken from Keeler, 2010 and Gunther, 2013 unless otherwise 
specified. 
2.2.1 Nuclear spin      
The identity of an atomic nucleus is defined by two aspects – the atomic number and the mass 
number. These define the number of protons and neutrons present within a particular nucleus. 
The protons and neutrons within the nucleus have an intrinsic property called spin which 
gives rise to an overall nuclear spin. When the number of protons and the number of neutrons 
is even, their spins are paired and the nucleus has no overall spin. In atoms where the number 
of neutrons plus the number of protons is odd, the nuclei have a half integer spin. In atoms 
where the number of neutrons plus the number of protons is even, the nuclei have integer 
spin. For purposes of protein structure determination, we work with ½ spin nuclei - 
1
H, 
13
C 
and 
15
N (Keeler, 2010).  
2.2.2 The Classical model 
A spin ½ nucleus is a spinning charge which creates a small magnetic field. When a spin ½ 
nucleus experiences an external magnetic field (B0), the small magnetic field of the nucleus 
interacts with B0. The torque from B0 causes the spinning nucleus to precess around the axis 
of B0 as shown in Figure 2.1.1. The frequency of this precession is called the Larmor 
frequency (ν0). The strength of the magnetic field generated by a particular nucleus is termed 
magnetogyric ratio, γ and it is different for every nucleus. The larmor frequency of a nucleus 
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Figure 2.2.1: Figure depicting (A) magnetic field produced by a spinning nucleus and (B) precession 
of the spinning nucleus in the presence of an external magnetic field, B0. Adapted from (Keeler, 
2010). 
is directly proportional to B0 and γ and can be calculated using the following equation 
(Gunther, 2013): 
 
ν0  =  
𝛾𝐵0
2𝜋
      (Equation 1) 
2.2.3 The Quantum model 
According to quantum mechanics, a nucleus with an overall spin of I, can have 2I+1 possible 
quantum states. Nuclei with ½ spin, therefore, have two possible quantum states. In the 
absence of a magnetic field, both states have the same energy in thermal equilibrium. When a 
spin ½ nucleus experiences an external magnetic field (B0), the two states have different 
energy levels. The +½ state is aligned with the axis of B0 and is the lower energy state (α) and 
the -½ state is aligned against B0 and is the higher energy state (β). In the absence of B0, the 
nuclei are in random orientations as there is no preferable one. In the presence of B0, when 
the sample is in thermal equilibrium, the population of nuclei in the α state is slightly more 
than the population in the β state as shown in Figure 2.1.2. The energy difference between the 
two states can be calculated using the following equation derived from equation 1: 
∆𝐸 = ℎ𝜈0  = ℎ
𝛾𝐵0
2𝜋
                                (Equation 2) 
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Figure 2.2.2: Figure showing a depiction of the population distribution of nuclei in an energy diagram 
in the presence of an external magnetic field, B0. Adapted from (Gunther, 2013). 
where h is Planck’s constant (Gunther, 2013). 
 
2.2.4 Bulk Magnetisation 
In the absence of a magnetic field, the nuclei do not have a preferential orientation. When a 
sample is placed in a magnetic field, the nuclei preferentially adopt the lower energy state by 
aligning with B0 as shown in Figure 2.1.2. This preferential alignment occurs slowly over 
time and the net magnetisation of the sample is aligned along the direction of the B0, which is 
along the z axis. This is called the bulk magnetisation or net magnetisation of the sample.  
Radio frequency pulse 
The detector that records the signal in NMR experiments is a small coil that is placed along 
the x-y plane. In order to record a signal, the net magnetisation needs to be in the x-y plane. 
The detector coil applies a radiofrequency (RF) pulse that rotates the net magnetisation from 
the z axis by 90°, aligning it along the y axis. When the pulse is removed, the net 
magnetisation precesses in the x-y plane around the B0 axis (z axis) at the larmor frequency. 
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The frequency of precession is the signal that is recorded by the detector. The precessing net 
magnetisation vector induces an oscillating voltage in the receiver coil which is detected on 
an oscilloscope as free induction decay (FID). This process has been shown in Figure 2.1.3. 
Fourier transform, which is a mathematical function, converts the time domain in the FID to a 
frequency domain in the NMR spectrum. This whole experiment can be repeated as many 
times as necessary to obtain a stronger signal (Gunther, 2013). 
 
2.2.5 Chemical Shift 
The signal that is detected in NMR experiments is the frequency of precession of the net 
magnetisation of the sample. Based on equation 1, this resonant frequency of a particular 
nucleus in the sample is dependent on B0. This means that the resonant frequency of a nucleus 
will not be consistent when the data is recorded in magnets of different strengths. In order to 
make the measurement independent of B0, the position of the signal from a nucleus is 
Figure 2.2.3: Figure depicting the process of developing free induction decay (FID) from an NMR 
sample. The bulk magnetisation of the sample is shown in the second part of the figure. The 
application of the 90° radiofrequency pulse rotates the bulk magnetisation to the y axis. Precession 
of the bulk magnetisation in the x-y plane is recorded by the detector as a FID. The FID is converted 
to an NMR spectrum through Fourier transform. Adapted from Gunther, 2013. 
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expressed relative to the signal from a universally accepted standard reference compound. 
This value is called the chemical shift, δ, and the unit of chemical shift is ppm (parts per 
million). The standard that is used for 
1
H and 
13
C is Tetramethylsilane (TMS). The position of 
a particular peak in a spectrum is calculated using the following equation: 
δ =  
𝜈−𝜈𝑟𝑒𝑓
𝜈𝑟𝑒𝑓
 ×  106                              (Equation 3)  
where ν is the frequency of the nucleus of interest and νref is the frequency of the standard 
reference compound. Based on equation 3, the peak of the reference compound will always 
appear at 0. Since δ is a ratio between two frequencies, δ of a nucleus is no longer dependent 
on B0. The 10
6
 in the equation allows for the unit to be ppm. δ of a nucleus is affected by 
shielding and anisotropy effects (Gunther, 2013). 
Shielding effects 
As established by equation 1, the resonant frequency of a nucleus is dependent on the B0 
experienced by the nucleus. In an atom, the nucleus is surrounded by a cloud of electrons 
which circulate around the nucleus. Since the electrons are also charged particles, they also 
generate their own magnetic field in B0 which alters the magnetic field experienced by the 
nucleus that they surround. This effect caused by the electrons is called the shielding effect. 
This effect alters the magnetic field experienced by the nucleus as follows: 
𝐵𝑒𝑓𝑓 =  𝐵0(1 − 𝜎)                                  (Equation 4) 
where Beff is the effective magnetic field experienced by the nucleus and σ is the shielding 
constant which has units of ppm. This alters equation 1 as follows: 
ν0 =  
𝛾𝐵0(1−𝜎) 
2𝜋
                                       (Equation 5) 
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Based on equation 3, a change in the resonant frequency of the nucleus will affect the δ of the 
nucleus. This variation in δ allows us to identify and differentiate nuclei present in different 
environments in the sample (Gunther, 2013).  
Anisotropic effects 
As established already, the electronic environment around a nucleus is anisotropic which 
means that the chemical shift of the nucleus varies depending on the orientation of the 
molecule with respect to B0. In solution state NMR, anisotropic effects are averaged out by 
the fast tumbling rate of the molecules due to Brownian motion. This averaging leads to each 
nucleus having one sharp isotropic peak in the NMR spectrum. In large molecules, the 
tumbling rate is slower than in smaller molecules. In such cases, chemical shift anisotropy 
leads to each nucleus having more than one chemical shift which is observed as a broad peak 
on the NMR spectrum as shown in Figure 2.1.4. Chemical shift anisotropy is one of the 
reasons for the size limitation in NMR experiments (Gunther, 2013). 
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Figure 2.2.4: A schematic showing the NMR spectra produced by a sample when CSA is not 
averaged (red) and when the CSA is averaged (blue). 
 
2.2.6 Coupling 
Another aspect that a spinning nucleus is affected by is coupling. Coupling occurs when a 
spinning nucleus is in close proximity to another spinning nucleus. When two spins (spinning 
nuclei) are in close proximity such that the energy state of one nucleus affects the energy state 
of the neighbouring nucleus, the two nuclei are coupled. There are two mechanisms by which 
two nuclei can be coupled – Scalar coupling and dipolar coupling. 
Scalar coupling 
Scalar coupling between nuclei is mediated by chemical bonds. When two spins are 
connected by chemical bonds, we see multiplets in the NMR spectrum. If two spin-half nuclei 
are coupled, each of the individual peaks of the two nuclei becomes a doublet. Each peak is 
split into two peaks which are at equal distances from the chemical shift of the nuclei. The 
distance between the two peaks is called the coupling constant, J. Each peak is at a distance 
of J/2 from the chemical shift of the nucleus. For nucleus 1, one peak corresponds to when 
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nucleus 2 is in a spin “up” state and the other peak corresponds to when nucleus 2 is in a spin 
“down” state. Similarly, for nucleus 2, one peak corresponds to when nucleus 1 is in the spin 
“up” state and the other peak corresponds to when nucleus 1 is in the spin “down” state. This 
phenomenon has been shown in figure 2.1.5. When nucleus 2 is in the “up” state, the Beff 
experienced by nucleus 1 is more than B0 leading to a higher frequency signal leading to a 
higher chemical shift for nucleus 1 than expected. The reverse of this phenomenon happens 
when nucleus 2 is in the “down” state. The Beff experienced by nucleus 1 is lower than B0 
leading to a lower frequency signal and a lower chemical shift than expected. The same 
phenomenon occurs to nucleus 2 depending on the spin state of nucleus 1 (Keeler, 2010). 
 
Dipolar coupling 
Dipolar coupling is an effect that happens through space. When two spins are in close 
proximity in space, the magnetic field of one spin affects the magnetic field experienced by 
Figure 2.2.5: Schematic representation of the NMR spectrum of two nuclei which are decoupled 
(top) and which are J coupled (bottom). The green arrows represent the spin orientation of Nucleus 
2 and the red arrows represent the spin orientation of Nucleus 1. The different orientations of the 
nuclei can lead to peak splitting. Adapted from Keeler, 2010. 
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the other spin. Similar to scalar coupling, this depends on the orientation of one spin relative 
to the other. The strength of dipolar coupling between nuclei is affected by three factors: 
 The distance between the two spins, r. The strength of dipolar coupling is 
inversely proportional to r
3
 
 The magnetogyric ratio, γ, of both the nuclei 
 The direction of the axis that connects the two nuclei relative to the axis of B0 
Dipolar coupling is only effective up to a distance of 5Å. In solution state NMR, dipolar 
coupling is usually not observed as it is averaged out by fast tumbling rates due to Brownian 
motion (Keeler, 2010).  
2.2.7 Relaxation mechanisms 
Relaxation is the process by which the net magnetisation of the sample returns to equilibrium. 
At equilibrium, the net magnetisation is aligned along the z axis and is stationary. There are 
two mechanisms of relaxation that the sample undergoes – longitudinal relaxation and 
transverse relaxation. 
Longitudinal relaxation 
The return of the net magnetisation to its equilibrium along the z axis is called longitudinal 
relaxation. Within the NMR sample, there are numerous spin nuclei which generate their own 
magnetic field by spinning called the local field. This means that every spin in the sample 
experiences a magnetic field from numerous nuclei which are in close proximity to this spin. 
Therefore, the effective magnetic field experienced by a particular spin in the sample at any 
particular time is variable. When a spin experiences this varied magnetic field, it leads to 
changes in orientation of the spin. Overall, this could lead to random reorientations of spins at 
random times within the sample. When the sample is at equilibrium, the net magnetisation of 
the sample is aligned along the z axis. When a RF pulse is applied, the net magnetisation is 
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rotated to the y axis. The RF pulse increases the energy in the sample as the number of spins 
oriented along the axis of B0, the low energy state, is decreased. In order to return to 
equilibrium, the system needs to lose energy. This loss of energy occurs by interaction 
between the spin energy of local fields and energy of thermal molecular motion. The two 
energy reservoirs come to thermal equilibrium with one another. This method of relaxation is 
called longitudinal relaxation or spin-lattice relaxation. The rate of longitudinal relaxation is 
called T1 (Gunther, 2013). 
Transverse relaxation 
The decay of transverse magnetisation (along the y axis) to zero to reach equilibrium is called 
transverse relaxation. When the net magnetisation is rotated from the z axis to the y axis, net 
magnetisation is referred to as transverse relaxation. This magnetisation needs to return to 
equilibrium before the net magnetisation can return to equilibrium along the z axis. The 
transverse magnetisation is coherent following the 90° pulse and this coherence is lost to 
reach equilibrium. The loss of coherence occurs due to inhomogeneity in the magnetic field 
and interactions between spins due to variations in the local field. This loss of coherence does 
not occur by spin-lattice relaxation. The transverse magnetisation returns to its equilibrium 
value of zero by exponential decay. The rate of transverse relaxation is called T2 (Gunther, 
2013).  
2.2.8 Nuclear Overhauser Effect (NOE) 
Nuclear Overhauser effect or NOE is the enhancement or depletion of signal of a spin in a 
dipolar coupled spin system through magnetisation transfer via cross relaxation. The intensity 
of NOE is inversely proportional to the sixth power of the distance between the spins and is 
effective when the distance between the two spins is less than 5 Å.  
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NOE transitions 
When a spin (A) is in close proximity to another spin (B), saturation of B by low power 
irradiation will perturb the population distribution such that the populations of Bα and Bβ are 
equal. In order to return to equilibrium, magnetisation is transferred from B to A via cross 
relaxation. This magnetisation transfer leads to enhancement or depletion of signal from A. 
This effect is called the Nuclear Overhauser Effect (NOE).  
There are two pathways through which cross relaxation can occur – double quantum 
transition and zero quantum transition (Figure 2.1.6). If both A and B are in the β state, cross 
relaxation causes both spins to be flipped to the α state, this transition is called the double 
quantum transition (W2). This transition is possible when the neighbouring spins are tumbling 
at the sum of the frequency of the two spins (νA+νB) which is approximately twice the larmor 
frequency. This is a significant pathway in small molecules (MW < 1000 Da) as they tumble 
rapidly. The second scenario is when A is in the α state, B is in the β state and cross 
relaxation causes A to be flipped to the β state and B to be flipped to the α state. This 
transition is called the zero quantum transition (W0). This occurs when the tumbling rate is 
close to the difference in frequency of the two spins (νA-νB) and is usually observed with 
large molecules as they tumble slowly.  
Double quantum relaxation leads to an increase in the population difference of A 
following relaxation, which causes an enhancement in the signal from A. On the other hand, 
zero quantum relaxation leads to a decrease in the population difference of A following 
relaxation, which causes a decrease in the signal intensity from A. Relaxation can also occur 
by spin-lattice relaxation mechanisms via single quantum transitions (W1). W1 transitions 
decrease the intensity of NOEs and need to be minimised when recording NOE data (Keeler, 
2010).   
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Figure 2.2.6: Figure depicting the various transitions of two nuclei which are less than 5Å apart in 
space. Nucleus 1 is depicted in red and nucleus 2 is depicted in green. The spin states are labelled 
in the figure. W0 represents zero transition, W1 represents single transition and W2 represents 
double transition. Adapted from Keeler, 2010. 
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Figure 2.3.1: Figure depicting the two phases of recording a 1D NMR experiment – preparation 
and detection. The waiting time between pulses is termed evolution time, t1. Adapted from 
Gunther, 2013. 
2.3 NMR Experiments 
NMR experiments can provide vital information about the folded state and structure of a 
protein in solution. Different experiments provide different levels of information about the 
protein.       
2.3.1 1D NMR 
A 1D NMR experiment consists of two phases – preparation and detection as shown in Figure 
2.2.1. In a 1D experiment, preparation involves applying a 90° pulse to the sample along the 
x-axis. This rotates the net magnetisation of the spins from the z-axis to the y-axis. This 
magnetisation rotates around the B0 axis (z-axis) and this precession is recorded as a signal 
and forms the detection phase of the experiment. The magnetisation eventually loses 
coherence due to T2 relaxation, leading to decay of the signal. This is why the recorded signal 
is referred to as the free induction decay (FID). The experiment is repeated numerous times 
and the signal is averaged to increase the signal to noise ratio. The FID signal is then subject 
to Fourier transform to obtain the 1D NMR spectrum of the particular nucleus (Gunther, 
2013).  
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2.3.2 2D NMR 
A 2D NMR spectrum has two frequency axes – the horizontal axis is the direct frequency 
recorded as a FID and the vertical axis is the indirect frequency. There are four steps in 
recording a 2D NMR spectrum – preparation, evolution, mixing and detection. In order to 
record a 2D NMR spectrum with nuclei A and B, a 90° pulse is applied to A to rotate the net 
magnetisation of A to the x-y plane. Following this, the chemical shift of A is indirectly 
measured in the evolution step. During the mixing step, the magnetisation is transferred from 
A to B either via scalar coupling or NOE using different pulse sequences. The chemical shift 
of nucleus B is then measured in the final detection step. This experiment is repeated 
numerous times and the waiting time before recording the magnetisation of A (evolution 
time, t1) is incremented by a fixed amount each time. This delay in evolution time is subjected 
to Fourier transform separately which gives the frequency of nucleus A (Gunther, 2013).    
TROSY-HSQC  
Heteronuclear Single Quantum Coherence Spectroscopy (HSQC) is a 2D NMR experiment 
that involves transfer of magnetisation from one nucleus to another via scalar coupling. When 
studying proteins by NMR, HSQC is usually recorded between 
1
H and 
13
C or 
1
H and 
15
N. In 
both cases, 
1
H frequency is the direct frequency and 
13
C or 
15
N is the indirect frequency. In 
1
H-
15
N HSQC, magnetisation is transferred from 
1
H to 
15
N, evolved on 
15
N and transferred 
back to 
1
H, which is then detected. Thus, it correlates the 
1
H to the 
15
N atom, to which the 
1
H 
atom is bound, on the protein backbone. Every peak on the HSQC spectrum corresponds to 
the amide 
1
H of an amino acid residue in the protein, with the exception of proline. The 
HSQC can, therefore, be used as a preliminary experiment to check if the protein sample can 
be studied further by NMR.  
 Size is a major limitation in NMR mainly due to the issue with signal overlap. As the 
chemical shift range for a specific nucleus is fixed, signals recorded from a large protein will 
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be heavily overlapped. This is further complicated by the fact that large proteins tumble 
slowly in comparison to small proteins. Large molecules have short T2 relaxation times which 
lead to broadening of signals and loss of resolution. In addition to this, at high magnetic 
fields, chemical shift anisotropy (CSA) and dipolar coupling (DC) do not average out for 
large molecules. Decoupling the amide 
1
H and 
15
N atoms produces only one peak. In the 
absence of decoupling, peaks of large proteins appear as multiplets due to J coupling. These 
multiplets have different shapes because of cross correlation between CSA and DC. 
Transverse Relaxation Optimised Spectroscopy (TROSY) is a technique that selects the 
component in the signal wherein CSA and DC cancel each other out as shown in Figure 2.2.2, 
giving a sharp peak for every amide 
1
H in the protein sequence in the HSQC (Keeler, 2010). 
 
NOESY   
NOESY experiments provide valuable information which is required for structure 
determination of proteins using NMR. 
15
N-NOESY and 
13
C-NOESY experiments are used for 
Figure 2.3.2: Figure depicting the signal recorded for a large protein when there is no decoupling 
(left panel), when the sample is decoupled (middle panel) and when the TROSY technique is used 
(right panel). Adapted from (Tomas, 2010). 
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calculating distance restraints for structure calculation. Every strip in the 
15
N-NOESY and 
13
C-NOESY spectra contains signal from all the 
1
H which are less than 5 Å away from the 
1
H 
bound to the amide 
15
N or backbone 
13
C atom respectively. 
2.3.3 Three dimensional NMR 
A three dimensional NMR experiment can be described as a 2D NMR experiment with an 
additional evolution and mixing time (t2) step between the first mixing time and the final 
detection step. The two indirect frequency dimensions are created by gradually incrementing 
the two evolution times, t1 and t2. There are two types of 3D NMR experiments which are 
crucial for structure determination – triple resonance and NOESY-HSQC experiments. Triple 
resonance experiments are vital in assigning the chemical shifts to the appropriate backbone 
and side chain atoms in a sequential manner. All the triple resonance experiments used for the 
purposes of this project have been described in this section. NOESY-HSQC experiments are 
used to obtain distance restraints for structure calculation. The NOESY-HSQC spectra used in 
this project have also been described in this section. 
Triple Resonance Experiments 
Triple resonance experiments are experiments which correlate three different nuclei – 1H, 13C 
and 
15
N. The signals recorded in triple resonance experiments are intense as magnetisation is 
transferred via scalar coupling. Chemical shift assignment of atoms is generally done in two 
stages – backbone assignment and side chain assignment. Backbone assignment involves 
assignment of atoms which are present in the backbone of the protein sequence. These 
include the amide 
1
H and 
15
N, 
13
Cα, 
13
Cβ and the carbonyl 
13
C atoms as shown in figure 2.2.3. 
Following the assignment of these atoms, the side chain atoms are assigned. The 
nomenclature used for triple resonance experiments describes the pathway of magnetisation 
transfer and will be described further in this section. The atoms mentioned in brackets only 
relay the magnetisation and the signal from these atoms are not recorded. 
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Figure 2.3.3: Schematic showing two consecutive amino acids in a protein sequence. The atoms 
studied during NMR experiments are labelled in the figure. The atoms of Residue i-1 are shown in 
red and the atoms of Residue 1 are shown in green. 
 
 
CBCANH and CBCA(CO)NH 
In the CBCANH experiment, the magnetisation is transferred from Hα and Hβ to the Cα and 
Cβ respectively. The magnetisation is then transferred from Cβ to Cα to the amide 
15
N and 
1
H 
for detection. The chemical shift evolution is performed together on the two 
13
C atoms so that 
they appear on one dimension. Chemical shift evolution is also performed on 
15
N and 
1
H, 
which form the two other dimensions of the spectrum. As shown in figure 2.2.4a, 
magnetisation transfer occurs from the 
13
Cα and 
13
Cβ atoms of the current and the previous 
residues in the sequence. Thus, every strip in this spectrum will contain four peaks – two 
peaks corresponding to the Cα and Cβ atoms of the previous residue and two peaks 
corresponding to the Cα and Cβ atoms of the current residue. This spectrum is used to assign 
the Cα and Cβ atoms in conjunction with the CBCA(CO)NH spectrum (Grzesiek & Bax, 
1993).  
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In the CBCA(CO)NH experiment, magnetisation is transferred from the Hα and Hβ 
atoms of the previous residue to the Cα and Cβ atoms respectively. The magnetisation is then 
transferred from the Cβ atom to the Cα atom, relayed through the carbonyl 
13
C to the amide 
15
N and 
1
H of the current residue as shown in figure 2.2.4b. Similar to the CBCANH, the 
chemical shift evolution of the 
13
C atoms is performed simultaneously so that the two 
13
C 
atoms are on the same dimension. Chemical shift evolution of the amide 
15
N and 
1
H atoms 
provide the other two dimensions of the spectra. Thus, every strip in the CBCA(CO)NH 
spectrum only contains two peaks – one peak that corresponds to the Cα atom of the previous 
residue and another peak that corresponds to the Cβ atom of the previous residue. Using the 
CBCANH spectrum in conjunction with the CBCA(CO)NH spectra will allow us to 
determine which peaks correspond to the atoms in the previous residue and which peaks 
correspond to the atoms in the current residue. The Cα and Cβ atoms in the protein sequence 
can be sequentially assigned using these spectra (Grzesiek & Bax, 1993). 
Figure 2.3.4a: Figure depicting the magnetisation transfer between the nuclei labelled by the brown 
arrows in the CBCANH experiment. The chemical shifts of the brown atoms are not evolved whereas 
the chemical shifts of the blue atoms are evolved. Residue i-1 (red) and residue 1(green) are labelled 
in the figure. 
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HNCO and HN(CA)CO 
In the HNCO experiment, magnetisation is transferred from the amide 
1
H to the amide 
15
N 
and then to the carbonyl 
13
C of the previous residue. The magnetisation is then transferred 
from the carbonyl 
13
C to the amide 
15
N and 
1
H, which is then detected as shown in figure 
2.2.4c. Chemical shift evolution of the carbonyl 
13
C, amide 
15
N and 
1
H nuclei is performed 
separately and they form the three dimensions of the spectrum. Every strip in the HNCO 
spectrum contains only one peak corresponding to the carbonyl 
13
C of the previous residue 
(Grzesiek & Bax, 1993; Kay et al, 1990; Muhandiram & Kay, 1994). This spectrum can be 
used in conjunction with the HN(CA)CO spectrum to assign the carbonyl 
13
C atoms in the 
protein backbone. 
 
Figure 2.3.4b: Figure depicting the magnetisation transfer between the nuclei labelled by the brown 
arrows in the CBCA(CO)NH experiment. The chemical shifts of the brown atoms are not evolved 
whereas the chemical shifts of the blue atoms are evolved. Residue i-1 (red) and residue 1(green) are 
labelled in the figure. 
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Figure 2.3.4c: Figure depicting the magnetisation transfer between the nuclei labelled by the brown 
arrows in the HNCO experiment. The chemical shifts of the blue atoms are evolved. Residue i-1 (red) 
and residue 1(green) are labelled in the figure. 
 
In the HN(CA)CO experiment, magnetisation is transferred from the amide 
1
H to the amide 
15
N, which is then transferred to the Cα of the current and previous residue through scalar 
coupling. The magnetisation is then transferred from the Cα to the carbonyl 
13
C through scalar 
coupling as shown in figure 2.2.4d. Chemical shift evolution of the Cα atom and the amide 
15
N and 
1
H atoms are performed separately, producing the three dimensions of the spectrum. 
Thus, every strip in the HN(CA)CO spectrum contains two peaks – one peak corresponds to 
the carbonyl 
13
C of the current residue and the other peak corresponds to the carbonyl 
13
C of 
the previous residue (Clubb et al, 1992). Using the HNCO and the HN(CA)CO spectra in 
conjunction will allow us to determine which peak corresponds to the carbonyl 
13
C of the 
current residue and which peak corresponds to the carbonyl 
13
C of the previous residue. The 
carbonyl 
13
C can be assigned using the HNCO and HN(CA)CO spectra. 
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Figure 2.3.4d: Figure depicting the magnetisation transfer between the nuclei labelled by the brown 
arrows in the HN(CA)CO experiment. The chemical shifts of the brown atoms are not evolved 
whereas the chemical shifts of the blue atoms are evolved. Residue i-1 (red) and residue 1(green) 
are labelled in the figure. 
 
 
HBHA(CBCACO)NH 
In the HBHA(CBCACO)NH experiment, magnetisation is transferred from the Hα and Hβ 
atoms of the previous residue to the Cα and Cβ atoms respectively. The magnetisation is then 
transferred from the Cβ atom to the Cα atom, relayed through the carbonyl 
13
C to the amide 
15
N and 
1
H of the current residue, similar to the CBCA(CO)NH experiment as shown in 
figure 2.2.4e. However, in this experiment, chemical shift evolution of the two 
1
H is 
performed simultaneously to obtain one dimension. Chemical shift evolution of the current 
amide 
15
N and 
1
H atoms yields two more dimensions (Grzesiek & Bax, 1993). Every strip in 
the HBHA(CBCACO)NH spectrum contains peaks corresponding to Hα and Hβ of the 
previous residue.  
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Figure 2.3.4e: Figure depicting the magnetisation transfer between the nuclei labelled by the brown 
arrows in the HBHA(CBCACO)NH experiment. The chemical shifts of the brown atoms are not 
evolved whereas the chemical shifts of the blue atoms are evolved. Residue i-1 (red) and residue 
1(green) are labelled in the figure. 
 
CC(CO)NH 
In the CC(CO)NH experiment, magnetisation is transferred from all the side chain 
1
H of the 
previous residue to the 
13
C that they are bound to. Following this, isotropic 
13
C mixing is 
performed to transfer magnetisation between the 
13
C atoms. Magnetisation is then transferred 
to the carbonyl 
13
C, then to the amide 
15
N and 
1
H of the current residue as shown in figure 
2.2.4f. Chemical shift evolution of all the 
13
C atoms of the previous residue except the 
carbonyl 
13
C is performed creating one of the dimensions for the spectrum. Then, the 
chemical shifts of the amide 
15
N and 
1
H of the current residue are also performed to obtain the 
two other dimensions for the spectrum (Grzesiek & Bax, 1993). Every strip in the 
CC(CO)NH spectrum contains peaks corresponding to all the side chain 
13
C of the previous 
residue. 
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Figure 2.3.4f: Figure depicting the magnetisation transfer between the nuclei labelled by the brown 
arrows in the CC(CO)NH experiment. The chemical shifts of the brown atoms are not evolved 
whereas the chemical shifts of the blue atoms are evolved. Residue i-1 (red) and residue 1(green) are 
labelled in the figure. 
 
HCCH-TOCSY 
In the HCCH-TOCSY experiment, magnetisation is transferred from the side chain 
1
H to the 
13
C atoms they are bound to. Isotropic 
13
C mixing is performed, following which 
magnetisation is transferred back to the side chain 
1
H and detected as shown in figure 2.2.4g 
(Bax et al, 1990; Olejniczak et al). Every strip in the HCCH-TOCSY spectrum contains peaks 
corresponding to the side chain 
1
H of the same residue. 
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Figure 2.3.4g: Figure depicting the magnetisation transfer between the nuclei labelled by the brown 
arrows in the HCCH-TOCSY experiment. The chemical shifts of the blue atoms are evolved. Residue 
i-1 (red) and residue 1(green) are labelled in the figure. 
 
NOESY-HSQC 
Two types of NOESY-HSQCs are used for assigning the 
1
H which are less than 5 Å away 
from the 
1
H bound to the amide 
15
N and the aliphatic/aromatic 
13
C atoms. These are the 
15
N-
NOESY-HSQC and 
13
C-NOESY-HSQC. The 
15
N-NOESY-HSQC involves magnetisation 
transfer between all the neighbouring 
1
H with the 
1
H bound to the amide 
15
N via NOE. The 
magnetisation is then transferred to the amide 
15
N atom and back to the 
1
H, which is then 
detected. Thus, every strip in the 
15
N-NOESY-HSQC contains signal from all the 
1
H which 
are less than 5 Å away from the 
1
H bound to the amide 
15
N atom. Similarly, the 
13
C-NOESY-
HSQC experiment involves magnetisation transfer between all the neighbouring 
1
H via NOE. 
The magnetisation is then transferred either to the 
1
H bound to the aliphatic 
13
C in the protein 
backbone/side chain or to the aromatic 
13
C atom in the side chain, depending on the atom 
targeted by the pulse sequence. The magnetisation is then transferred back to the 
1
H for 
detection. Every strip in the 
13
C-NOESY-HSQC spectrum contains signals from all 
1
H atoms 
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which are less than 5 Å away from the 
1
H bound to the targeted 
13
C atom. These spectra 
provide information about 
1
H nuclei which are close to the 
1
H bound to the 
15
N or 
13
C atoms 
in space even though they may be far away from them in the sequence (Marion et al, 1989a; 
Marion et al, 1989b; Zuiderweg & Fesik, 1989). Thus, this provides us with information 
about the three dimensional structure of the protein.   
2.4 ARIA – Ambiguous Restraints for Iterative Assignment 
In order to perform a structure calculation, sequential chemical shift assignment is performed 
for the protein sequence using the data from the three dimensional NMR spectra. Following 
this, the peaks on the 
13
C and 
15
N NOESY spectra are picked to create two peak lists. 
Dihedral angle restraints are also generated from the chemical shift assignments, using 
TALOS+. TALOS+ uses the chemical shift assignments of the amide 
1
H and 
15
N, Hα, Cβ, Cα 
and carbonyl 
13
C atoms to predict the protein phi and psi backbone torsion angles. The 
limiting step in structure calculation by NMR is the assignment of NOE peaks. ARIA uses 
iterative assignments and ambiguous distance restraints (ADR) to assign the NOE peaks 
(Rieping et al, 2007). Structure calculation and refinement are performed by CNS 
(Crystallography and NMR System) using the simulated annealing refinement method 
(Brunger, 2007). The explanation of the concepts involved in the functioning of ARIA is 
from Nilges et al (1997) and Linge et al (2003).    
ARIA was provided the manual chemical shift assignment, 
13
C and 
15
N NOESY peak 
lists and the dihedral angle restraints for the protein. ARIA separates the data provided into 
two parts – the first part consists of the manually assigned chemical shifts and the second part 
consists of the NOESY peak lists which are not assigned. As a first step, ARIA uses the 
manual assignments to generate an ensemble of structures (Nilges et al, 1997). This step is 
called the zero iteration and any ambiguous assignment is treated with ambiguous distance 
restraints (ADR) (Nilges, 1995). The dihedral angle restraints from TALOS+ provide 
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convergence in the protein structure in the initial stages (Linge et al, 2003). Following zero 
iteration, the structures in the ensemble are ordered based on their total energy. The structure 
which is of lowest energy is chosen as the reference.  
In the next step, the NOESY peak lists are calibrated using the average distances 
calculated from the chosen reference structure. The unassigned peaks in the NOESY peak list 
are then compared to the chemical shift assignments and for every match, an ADR is added to 
the list. All the restraints that are extracted from the NOESY peaklists are then analysed to 
check for violations based on the reference structure. Any restraint that causes a systematic 
violation is removed from the list. There are many reasons that can contribute to the removal 
of a peak. This can occur when noise is picked as a peak, when a peak is not picked 
accurately due to overlap or when the picked peak is not associated with a peak in the 
spectrum.  
The restraints from the list are then partially assigned. This procedure is performed for 
every spectrum that is provided to ARIA, and the lists generated from these spectra are 
merged to avoid duplicates. Following this, a new ensemble of structures is generated based 
on these restraints by CNS. This procedure is repeated through every iteration step with the 
creation of a new ensemble of structures, until the ensemble of structures and the data set do 
not change significantly (Nilges et al, 1997). This process is also shown in Figure 2.3. 
The latest version of ARIA provides a graphic user interface (GUI) to set up the ARIA 
run. Once the chemical shifts, the NOESY peaklist files and the dihedral angle restraint files 
are converted into the .xml format, the run can be set up using the GUI. Following the initial 
run, ARIA provides violation files which provide a list of the NOE peaks which are causing 
violations. The NOESY peaklists can be analysed and any noise peaks and incorrectly picked 
peaks can be removed or corrected. Following this, a new run can be set up on ARIA with the 
altered NOESY peaklists and chemical shifts. ARIA ultimately provides an ensemble of 
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structures calculated by CNS, assigned distance restraints, distance restraints which were 
assigned but rejected because the method considers them to be artefacts and distance 
restraints which were rejected because they do not have any chemical shift that corresponds 
to them (Nilges et al, 1997). The structures obtained from ARIA can then be validated using 
various validation softwares to ensure that they are biologically relevant.          
  
Figure 2.4: Figure showing a flowchart of the various stages followed by ARIA for protein 
structure calculation. 
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Chapter 3 
Materials & Methods  
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Table 3.1: Table showing the concentration of reaction components used for the two PCR reactions 
performed to selectively amplify the DNA of the TgIMP1 homologue from the T. gondii transcriptome.  
3.1 T. gondii IMP1 homologue 
3.1.1 PCR amplification 
Primers were designed using GENtle (University of Cologne, Germany), for selective 
amplification of TgIMP1 from the pET32 Xa/LIC vector (Merck Millipore, US), with 
additional 5’ sequences that allow LIC cloning (see Appendix Table 1). PCR reactions were 
performed following the Q5 HF Polymerase protocol (Fermentas, US) in Mastercycler 
gradient machine (Eppendorf, Germany) and conditions used for the different reactions are 
given in Tables 3.1 and 3.2. The PCR products were run on a 1% Agarose gel (Appendix 
Table 3) at 120 V for 60 min with a 100 bp Quickload DNA ladder (NEB, UK). The PCR 
products were purified for the positive reactions using a PCR purification kit (Fermentas, 
US).  
 
 
 
 
 
 
 
 
 
Reaction Components (Initial 
concentration) 
Final concentrations 
Sense (5’) Primer (10 µM) 1 µM 
Anti-sense (3’) Primer (10 µM) 1 µM 
Template DNA (90 ng/µl) 50 ng 
5x Q5 HF Buffer 1x 
dNTP Mix, 2mM each 0.02 mM  
Q5 HF DNA Polymerase 1 unit 
Total Volume 50 µl 
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Table 3.2: Table showing the PCR reaction conditions set for the thermocycler. 
 
 
 
 
 
 
 
3.1.2 Screening for positive colonies 
The amplified TgIMP1 gene was cloned into the pET46 Ek/LIC vector (Merck Millipore, 
US) following the LIC protocol. The plasmid containing the TgIMP1 encoding sequence and 
a carbenicillin resistance gene was transformed in DH5α cells (NEB, UK) and plated on LB-
agar plate (Sigma-Aldrich, UK) containing 50 µg/ml carbenicillin (Sigma-Aldrich, UK). 
These colonies were duplicated on another LB-agar plate (Sigma-Aldrich, UK) and PCR 
amplified using the Ready-to-go PCR beads (GE Healthcare, UK). The PCR products were 
run on a 1% agarose gel (Sigma-Aldrich, UK). Gels were visualised and imaged in the 
UGenius Gel system (Syngene, UK). 
One of the positive colonies detected by PCR was used to inoculate 10 ml LB (50 µg/ml 
carbenicillin) (Sigma-Aldrich, UK) and incubated overnight at 37°C with 220 rpm shaking. 
Plasmid DNA was purified from the overnight culture using the Plasmid miniprep kit 
(Fermentas, US). The purified DNA was sent for sequencing with T7 forward and reverse 
primers to Source Bioscience. The sequencing results were analysed using GENtle 
(University of Cologne, Germany) to verify the sequence of the sample. 
Thermocycler: 30x 
Polymerase Activation - 95°C for 2 min 
Denaturation - 95°C for 20 s 
Annealing - 60°C for 30 s 
Extension - 72°C for 45 s 
Repeat steps 2 to 4 for 30 cycles 
Extension - 70°C for 30 s 
End of reaction 
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3.1.3 Plasmid purification 
Plasmid pET46 Ek/LIC (Merck Millipore, US) encoding TgIMP1 protein with a His tag at the 
N terminus and the ampicillin resistance gene was purified using the Fermentas Plasmid 
Miniprep kit. The concentration of DNA was measured using a Nanodrop Spectrophotometer 
(Thermofisher, UK). All plasmids were purified following this method. 
3.1.4 Transformation of E. coli 
Plasmid encoding the TgIMP1 protein and carbenicillin resistance gene was used to transform 
competent E. coli Rosetta 2 (DE3) cells (Merck Millipore, US) or DH5α cells (NEB, UK). 3 
µl of plasmid DNA (~50 ng) was added to 50 µl of cells and left on ice for 30 min. The cells 
were then heat shocked at 42°C for 45 sec on a heat block and immediately transferred to ice 
for 2 min. 400 µl of LB media (Sigma-Aldrich, UK) was added and incubated at 37°C for 1 
hour with shaking at 220 rpm. These were then plated on LB-Agar plates (Sigma-Aldrich, 
UK) with the correct antibiotic to select for transformants. 
3.1.5 Expression test 
For the expression, the sequenced plasmid containing the TgIMP1 encoding sequence was 
transformed into Rosetta 2 cells (DE3 E. coli cells which supply the tRNAs for seven rare 
codons which aid in translation, on a plasmid containing the chloramphenicol resistance gene) 
(Merck Millipore, US). They were plated on a LB-agar plate (Sigma-Aldrich, UK) containing 
50 µg/ml carbenicillin (Sigma-Aldrich, UK) and 34 µg/ml chloramphenicol (Sigma-Aldrich, 
UK). 10 ml LB media (Sigma-Aldrich, UK) was inoculated with each of these colonies 
separately and grown at 37ºC with 220 rpm shaking till OD600 reached 0.6. OD600 was 
measured on a spectrophotometer (Jenway, UK). A 1 ml sample was taken from each culture 
and the culture induced with 0.1 mM IPTG (Isopropyl β-D-1-thiogalactopyranoside) (Sigma-
Aldrich, UK). The cultures were grown at 18°C and 25°C overnight with 220 rpm shaking for 
aeration. A 1 ml sample was taken after this. All samples were spun down at 12000g and the 
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pellet treated with BPER II (Thermo Scientific, USA) following the given protocol. All 
samples were then run on a 12% SDS-PAGE gel (Serva, Germany). 
3.1.6 Expression 
Expression was performed following the same protocol described in Section 3.1.5 with larger 
volumes of 1 L. The inoculated cultures were grown at 18°C with 220 rpm shaking overnight 
after induction. The cells were centrifuged at 4000g at 4°C for 15 min in a Sorvall centrifuge 
(ThermoFisher, UK).   
3.1.7 Protein Purification 
The cell pellet was resuspended in phosphate lysis buffer (Appendix Table 3) and then lysed 
in a cell disrupter (Constant systems, UK) at a pressure of 25 kpsi. The cell lysate was 
centrifuged at 30000 g for 45 min in a Sorvall centrifuge (ThermoFisher, UK). The 
supernatant was purified using pre-packed Nickel column, 5 ml Histrap FF (GE Healthcare, 
UK) in the AKTAprime (GE Healthcare, UK). The column was equilibrated with phosphate 
wash buffer (Appendix Table 3). The clear lysate was then loaded on to the column, the 
column equilibrated with the wash buffer until the UV dropped to zero and stabilised. Then, 
the protein eluted with an imidazole gradient that required 50 ml to reach 250 mM imidazole. 
The eluted protein was pooled and concentrated. The concentration was measured using a 
Nanodrop Spectrophotometer (Thermofisher, UK). 
The protein was further purified by Gel filtration using a Superdex 75 Hiload 16/600 
column (GE Healthcare, UK) with AKTAprime (GE Healthcare, UK). The column was first 
equilibrated with one column volume (120 ml) of phosphate GF buffer pH 8 (Appendix Table 
3). The protein was injected into the column with a 2 ml syringe and 1.5 ml fractions were 
collected.   
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3.1.8 SDS-PAGE 
Samples for SDS PAGE were mixed with 2x loading buffer (Serva, Germany), vortexed and 
heated at 100°C on a heat block for 5 min. Samples were run at 180 V for 60 min in a 12% 
SDS-PAGE gel (Serva, Germany) with 1X diluted 20X SERVA run buffer (Serva, Germany) 
and stained with Instant Blue (Expedeon, UK) for 15 min and destained with dH2O for one 
hour. Gels were visualised and imaged in the UGenius Gel system (Syngene, UK). 
3.1.9 Limited Proteolysis 
50 µl of 10 µg/ml chymotrypsin (Sigma-Aldrich, UK) in Digestion buffer (Appendix Table 3) 
was incubated with 50 µl of 10 mg/ml protein at 37°C and 20 µl aliquots were taken at 5 min, 
15 min, 1 hour, 2 hours and 1 day. 100 µl of 9 µg/ml Chymotrypsin was also incubated at 
37°C and aliquots were taken after the same time periods as a control. Trypsin (Sigma-
Aldrich, UK) digest was also performed following a similar protocol. Samples were run on a 
12% gel by SDS PAGE. Gels were visualised and imaged in the UGenius Gel system 
(Syngene, UK). 
3.1.10 Membrane transfer for N-terminal amino acid sequencing 
The chymotrypsin digested protein from the gel was transferred to a PVDF membrane 
(Thermo Scientific, UK) following the given protocol. The membrane was stained using 
PVDF stain (Appendix Table 3) and destained with 50% Methanol. The membrane was 
washed with water and air dried. Sequencing was performed by PNAC facility, University of 
Cambridge. 
3.1.11 NMR experiments 
Deuteration of TgIMP1 
10 ml LB media (50 µg/ml carbenicillin and 34 µg/ml chloramphenicol) (Sigma-Aldrich, 
UK) was inoculated with a single colony and incubated at 37°C with 220 rpm shaking until 
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OD600nm reached 0.6. 10 ml of 50% D2O M9 minimal media (50 µg/ml carbenicillin and 34 
µg/ml chloramphenicol) was inoculated with 50 µl of LB culture and incubated overnight at 
37°C at 220 rpm shaking. 1 L of 100% D2O M9 minimal media (50 µg/ml carbenicillin and 
34 µg/ml chloramphenicol) was inoculated with the 50% D2O M9 minimal media overnight 
culture and incubated at 37°C with 220 rpm shaking. Cells were induced with 1 mM IPTG 
(Sigma-Aldrich, UK) once the OD600nm of the samples reached around 0.6 and incubated at 
18°C with 220 rpm shaking overnight. The cells were centrifuged at 4000 g at 4°C for 15 min 
in Sorvall centrifuge (ThermoFisher, UK) and purified as described in Section 2.7.  
NMR sample preparation 
Unlabelled, 
15
N, 
13
C/
15
N and 
13
C/
15
N/
2
H labelled samples were concentrated and buffer 
exchanged into phosphate NMR buffer (Appendix Table 3) by repeatedly washing the sample 
with the buffer in a 10 kDa MWCO (Molecular Weight cut off) concentrator (Sartorius, UK). 
10% D2O (Sigma-Aldrich, UK) was added to the sample (for the field-frequency lock) and 
the sample transferred to a 5 mm NMR tube (Sigma-Aldrich, UK) for NMR analysis.  
NMR 
1
H 1D and 
15
N-
1
H HSQC measurements    
Data was recorded at 303 K on a Bruker Avancell 800 (800 MHz). 
NMR backbone assignment  
13
C/
15
N labelled TgIMP1 clone 7 (200 µM) was used to collect 
15
N-HSQC, HNCACB and 
HNCOCACB NMR spectra at 303 K on a Bruker Avancell 800 (800 MHz) and backbone 
assignment was reached using standard double- and triple-resonance techniques. 
13
C/
15
N/
2
H 
labelled TgIMP1 was used to collect 
15
N-HSQC, HNCO, HNCACO, HNCACB and 
HNCOCACB NMR spectra at 303 K on a Bruker Avancell 800 (800 MHz). 
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3.1.12 Crystallisation trials 
Crystallisation sample preparation 
TgIMP1 Clone 6 and Clone 7 (Table 4.1) samples were concentrated and buffer exchanged 
into crystallisation buffer by repeatedly washing the sample with the buffer in a 10 kDa 
MWCO concentrator (Sartorius, UK).  
96 – well Crystallisation plates 
Two 100 nl drops of TgIMP1 clone 6 at 25 mg/ml were added to the two wells for each 
condition in the 14 commercially available screens pre-dispensed into 96-well MRC plates 
(provided by the Centre for Structural Biology at Imperial College London) using the 
Mosquito nano-litre high throughput robot (TTP labtech, UK). One drop was mixed with 100 
nl of the corresponding reservoir solution and the second drop was mixed with 200 nl of the 
same reservoir solution. Two plates – plates 1 and 2 from the commercially available screens 
were set up with TgIMP1 Clone 7 at 50 mg/ml the same way as with TgIMP1 Clone 6. 
3.2 Eimeria tenella IMP1 homologue 
3.2.1 PCR Amplification 
The E. tenella cDNA library produced from merozoite stage parasites was provided by Dr. 
Damer Blake. EtIMP1 clone 2 was amplified from the E. tenella cDNA library, with 
additional 5’ sequences for LIC cloning (Appendix Table 1). PCR Amplification of the 
EtIMP1 clone 2 gene was performed the same way as described in section 3.2.1, except that 
the Tm was 59°C for EtIMP1 clone 2 and the elongation time was adjusted to 20 seconds. 
3.2.2 Screening for positive colonies 
The amplified EtIMP1 clone 2 gene was cloned into the pET30 Xa/LIC vector (Merck 
Millipore, UK) following the LIC protocol. The plasmid containing the EtIMP1 clone 2 
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encoding sequence and kanamycin resistance gene was transformed in DH5α cells (NEB, 
UK) and plated on a LB-agar plate (Sigma-Aldrich, UK) containing 50 µg/ml kanamycin 
(Sigma-Aldrich, UK). 
Colony screening, transformation, protein expression and purification, SDS-PAGE 
and limited proteolysis were performed following the same protocol described for TgIMP1. 
3.2.3 NMR experiments 
NMR sample preparation    
500 µl of 
15
N labelled EtIMP1 clone 2 in phosphate NMR buffer pH 8 (Appendix Table 3) 
was prepared. 10% D2O (Sigma-Aldrich, UK) was added to this sample and the sample 
transferred to a 5 mm NMR tube (Sigma-Aldrich, UK) for NMR analysis. 
NMR 
1
H 1D and 
15
N-
1
H HSQC measurements    
Data was recorded at 303 K on a Bruker Avancell 600 (600 MHz). 
3.3 P. falciparum IMP2 homologue 
3.3.1 PCR Amplification 
The IMP1-like homologue from P. falciparum (Accession number: XP_001349200) was 
codon optimised and synthesised (GeneArt, ThermoFisher). Various primers were designed 
with additional 5’ sequences for LIC cloning using GENtle (University of Cologne, 
Germany) to clone the PfIMP2 gene into different vectors (Appendix Table 1) – pET30 
Xa/LIC (Merck Millipore, US), pET32 Xa/LIC (Merck Millipore, US) and pNIC-ZB 
(Genbank GU452710). pNIC-ZB was a gift from Opher Gileadi (Addgene plasmid # 26107). 
The pNIC-ZB vector contains a His tag and Z-tag, followed by a TEV protease cleavage site. 
The Z-tag is sequence derived from protein A, modified to have a highly positive surface 
charge.    
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For ectopic expression of PfIMP2 in the P. falciparum 3D7 parasite, the PfIMP2 gene was 
synthesised without codon optimisation (GeneArt, ThermoFisher). PCR reactions were 
performed following the Q5 HF Polymerase protocol (Fermentas, UK) in Mastercycler 
gradient machine (Eppendorf, Germany) as described in section 3.1.1. The PfIMP2 gene was 
cloned into the pRM2_DD-3HA-GFP vector and transformed into Stellar DE3 cells following 
the Infusion HD Cloning Kit (Clontech, UK). The pRM2_DD-3HA-GFP vector contains the 
strong, schizont-specific msp2 promoter and a triple HA and GFP tag at the C-terminus (de 
Azevedo et al, 2012). Stellar DE3 cells lack the gene cluster for degrading methylated DNA. 
PCR amplification was performed the same way as described in section 3.1.1 in both 
cases except that the Tm given in Appendix Table 1 were used for the relevant PCR runs and 
the elongation time was decreased to 20 seconds. Transformation and colony screening were 
performed as described in section 3.1.2 for the codon optimised construct.  
3.3.2 Plasmid purification 
Plasmid purification was performed as described in section 3.1.3 for the codon optimised 
construct. The pRM2_DD-3HA-GFP vector containing the PfIMP2 gene was purified using 
the GeneJet Plasmid Midiprep Kit (ThermoFisher, UK). The concentration of DNA was 
measured using a Nanodrop Spectrophotometer (Thermofisher, UK). 
 The codon optimised PfIMP2 plasmids were transformed into BL21 cells (NEB, UK), 
Rosetta 2 cells (Merck Millipore, US) and ArcticExpress cells (Agilent technologies, US) 
following the recommended protocols. Expression tests and large scale protein expression 
was performed as described in section 3.1.5. 
3.3.3 Protein Purification 
The cell pellet was resuspended in hepes lysis buffer (Appendix Table 3) and 1 µg/ml PMSF 
and then lysed in a Sonopuls HD 2070 sonicator (Bandelin, Germany) at 60% power for 6 
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cycles in 6 minutes. The cell lysate was centrifuged at 30000 g for 45 min in a Sorvall 
centrifuge (ThermoFisher, UK). The supernatant was purified using pre-packed Nickel 
column, 5 ml Histrap FF (GE Healthcare, UK) in the AKTAprime (GE Healthcare, UK). The 
column was equilibrated with Hepes wash buffer (Appendix Table 3). The clear lysate was 
then loaded on to the column, the column equilibrated with the wash buffer until the UV 
dropped to zero and stabilised. Then, the protein eluted with an imidazole gradient that 
required 50 ml to reach 250 mM imidazole. The eluted protein was pooled and concentrated. 
The concentration was measured using a Nanodrop Spectrophotometer (Thermofisher, UK). 
The protein was further purified by Gel filtration using a Superdex 75 Hiload 16/600 
column (GE Healthcare, UK) with AKTAprime (GE Healthcare, UK). The column was first 
equilibrated with one column volume (120 ml) of Hepes GF buffer 10 mM DTT. The protein 
was injected into the column with a 2 ml syringe and 1.5 ml fractions were collected.   
3.3.4 Factor Xa Cleavage 
10 µg of PfIMP2 (pET32 Xa/LIC) in 50 mM Tris pH 8 150 mM NaCl was cleaved with 0.5 U 
of Factor Xa protease (NEB, UK) at room temperature following the given protocol. This was 
then scaled up to cleave 10 mg of protein. 
3.3.5 DSF Buffer Screen 
PfIMP2 (pNIC-ZB) construct in 50 mM NaH2PO4 150 mM NaCl pH 7 buffer was used to 
perform a buffer screen. 40 µM PfIMP2 was used for each condition in the screen with 1x 
SYPRO Orange dye (Sigma-Aldrich, UK). The screens were set up in a 96-well thin wall 
PCR plate (Bio Rad, US) and heated from 26°C to 97°C using the Stratagene Mx3005P 
QPCR system (Agilent technologies, US). Fluorescence was monitored at excitation 
wavelength of 380 nM and emission wavelength of 440 nM. The conditions used for the 
buffer screen are given below. 
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Buffer composition pH 
50mM NaH2PO4 100mM NaCl pH4 pH5 pH7 pH8 
50mM NaH2PO4 100mM NaCl 10mM DTT pH4 pH5 pH7 pH8 
50mM NaH2PO4 150mM NaCl (CONTROL) pH4 pH5 pH7 pH8 
50mM NaH2PO4 150mM NaCl 10mM DTT pH4 pH5 pH7 pH8 
50mM NaH2PO4 200mM NaCl pH4 pH5 pH7 pH8 
50mM NaH2PO4 200mM NaCl 10mM DTT pH4 pH5 pH7 pH8 
50mM NaH2PO4 250mM NaCl pH4 pH5 pH7 pH8 
50mM NaH2PO4 250mM NaCl 10mM DTT pH4 pH5 pH7 pH8 
50mM Hepes 100mM NaCl pH4 pH5 pH7 pH8 
50mM Hepes 100mM NaCl 10mM DTT pH4 pH5 pH7 pH8 
50mM Hepes 150mM NaCl pH4 pH5 pH7 pH8 
50mM Hepes 150mM NaCl 10mM DTT pH4 pH5 pH7 pH8 
50mM Hepes 200mM NaCl pH4 pH5 pH7 pH8 
50mM Hepes 200mM NaCl 10mM DTT pH4 pH5 pH7 pH8 
50mM Hepes 250mM NaCl pH4 pH5 pH7 pH8 
50mM Hepes 250mM NaCl 10mM DTT pH4 pH5 pH7 pH8 
50mM Tris 100mM NaCl pH7 pH8 
50mM Tris 100mM NaCl 10mM DTT pH7 pH8 
50mM Tris 150mM NaCl pH7 pH8 
50mM Tris 150mM NaCl 10mM DTT pH7 pH8 
50mM Tris 200mM NaCl pH7 pH8 
50mM Tris 200mM NaCl 10mM DTT pH7 pH8 
50mM Tris 250mM NaCl pH7 pH8 
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Table 3.3: Table showing the different conditions used for the buffer screen performed for PfIMP2 
(pNIC-ZB). 
 
50mM Tris 250mM NaCl 10mM DTT pH7 pH8 
 
3.3.6 Western blot 
Western blots were performed on recombinant PfIMP2 expressed in E. coli using the 
recommended protocol (GE Healthcare, UK) and was probed with anti-His antibody (GE 
Healthcare, UK). Western blot performed on the ectopically expressed PfIMP2 in P. 
falciparum 3D7 strain was probed with 0.1 µg/ml anti-HA (rat) primary antibody and 0.1 
µg/ml anti-rat secondary antibody (ThermoFisher, UK). 
3.3.7 TEV cleavage 
1 mg TEV protein was incubated with 20 ml of PfIMP2 (1 mg/ml) in 50 mM Tris pH 8, 250 
mM NaCl 200 mM Imidazole 10 mM DTT in dialysis tubing (ThermoFisher, UK).  This 
reaction was incubated at 4°C overnight and dialysed against TEV buffer (Appendix Table 3). 
3.3.8 Site-directed mutagenesis 
The PfIMP2 C71S mutant was generated using Q5 Quickchange Mutagenesis Kit (NEB, 
UK). Once the plasmid was mutated, the plasmid was transformed into DH5α cells (NEB, 
UK) as described in section 3.1.2. 
3.4 NMR     
3.4.1 NMR Sample preparation 
Unlabelled and 
13
C/
15
N labelled samples were concentrated and buffer exchanged into Hepes 
GF buffer 10 mM DTT (Appendix Table 3) by repeatedly washing the sample with the buffer 
in a 10 kDa MWCO concentrator (Sartorius, UK). 10% D2O (Sigma-Aldrich, UK) was added 
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to the sample and the sample transferred to a 5 mm NMR tube (Sigma-Aldrich, UK) for NMR 
analysis. 
3.4.2 NMR experiments 
1
H 1D and 
15
N-HSQC spectra were recorded at 303 K on a Bruker Avancell 600 (600 MHz). 
13
C/
15
N labelled PfIMP2 (1.5 mM), with and without His tag, were used to collect 
15
N-HSQC, 
HNCACB and HNCOCACB NMR spectra at 303 K on a Bruker Avancell 600 (600 MHz) 
and backbone assignment was reached using standard double- and triple-resonance 
techniques. The same samples were used to collect HBHA(CBCACO)NH, HCCH-TOCSY, 
(H)CC(CO)NH-TOCSY and 
1
H-C
13
NOESY-HMQC spectra at 303 K on Bruker Avancell 
600. Side chain assignment of aliphatic and aromatic 
1
H and 
13
C atoms were reached using 
the data from these experiments. 
3.5 ARIA 
ARIA calculations were set up following successful backbone and side chain assignments 
using NMRView. TALOS+ was used to generate the dihedral angle restraints based on the 
chemical shift assignment. CCpnmr Analysis was used to create the NOESY peaklists. ARIA 
runs were set up under the following tolerance levels given in table 3.4. 
13C-NOESY (800 MHz) 15N-NOESY (800 MHz) 
Direct 
1
H frequency 
window (ppm) 
0.04 
Direct 
1
H frequency 
window (ppm) 
0.04 
Direct 
13
C frequency 
window (ppm) 
0.6 
Direct 
15
N frequency 
window (ppm) 
0.5 
Indirect 1H frequency 
window (ppm) 
0.06 
Indirect 1H frequency 
window (ppm) 
0.06 
Indirect 
13
C frequency 
window (ppm) 
0.5 
Indirect 
15
N frequency 
window (ppm) 
0.5 
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Table 3.4: Table showing the tolerance levels set for the 13C- and15N-  NOESY datasets recorded on 
the Bruker Avancell 800 (800 MHz)   
 
Chemical shift difference 
between 
13
C planes (ppm) 
0.25 
Chemical shift difference 
between 
15
N planes (ppm) 
0.195 
  
 
3.6 In vitro Experiments 
3.6.1 Culturing P. falciparum parasites 
P. falciparum 3D7 strain transfected with the pRM2_DD-3HA-GFP plasmid containing the 
PfIMP2 gene was cultured in 10 ml of complete media (Appendix Table 3) with 20 nM 
WR99210 (Sigma-Aldrich, UK). The parasites were cultured in complete media with 4% 
RBC, gassed with 5% CO2, 5% O2 and incubated at 37°C.       
3.6.2 Sorbitol synchronisation 
Parasites were synchronised when ring parasitemia was high in the culture. Synchronisation 
was performed following the standard sorbitol treatment protocol with 5% sorbitol (Lambros 
& Vanderberg, 1979).  
3.6.3 Immunofluorescence assay 
Samples were prepared in suspension and as fixed samples for IFA. The samples were fixed 
with 4% paraformaldehyde/ 0.01% gluteraldehyde/PBS (Sigma-Aldrich, UK). The samples 
were prepared following standard protocol. Both fixed and suspension samples were 
incubated with Anti-HA (rat) and Anti-GAP45 (rabbit) primary antibodies (ThermoFisher, 
UK) and with Anti-GFP (mouse) and Anti-GAP45 (rabbit) primary antibodies 
(ThermoFisher, UK). Following this, they were incubated with anti-rat 488 and anti-rabbit 
594 secondary antibodies (ThermoFisher, UK) and anti-mouse 488 and anti-rabbit 594 
secondary antibodies (ThermoFisher, UK), respectively with DAPI (ThermoFisher, UK).  
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The suspension samples were spread on a slide and air dried. Coverslips were mounted on 
both suspension and fixed sample slides with Prolong Gold (ThermoFisher, UK). The slides 
were allowed to dry flat overnight and observed under the Leica TCS SP5 II confocal 
microscope using the Leica LAS AF software (Imperial College London). 
3.6.4 Pull down Assay 
Wild type 3D7 strain parasites and parasites transfected with the pRM2_DD-3HA-GFP 
plasmid with the PfIMP2 gene were harvested at 6 % parasitemia and resuspended in parasite 
lysis buffer (Appendix Table 3). Following protein lysis, the samples were incubated with 
500 µl of Pierce anti-HA magnetic beads (ThermoFisher, UK) in consecutive batches of 500 
µl each. After each incubation period, the beads were separated on the magnetic stand and the 
supernatant was removed. Two washes were performed with the lysis buffer and a final 
elution was performed with parasite elution buffer (Appendix Table 3). The supernatant was 
analysed following the final elution by SDS-PAGE on a 12% SDS-PAGE gel (Serva, 
Germany).  
3.6.5 Silver staining 
The gel was silver stained using the SilverQuest Silver Stain kit (ThermoFisher, UK) 
following the protocol given in the kit. 
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Chapter 4 
Characterisation of coccidian 
IMP-like homologues  
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MGGACGKSRGTAAAAEPPVSAADKAAEAAASAASQAEKAQEAAAAA
AAAAANGAAAAAALTGEDRSEREPANASDGKDTNPTNPTTAEQQQQ
QEQEQQQQEQQQQEQQQQEQQQEAAAAQQPASPVVALSAADAELL
AAAQQQAAAAAAAGSNANLPHAYLFYAAELNEGSLILQWTAAAMQQ
QEMQDKKLLLLASFVPPKYKTVTKSKLQQNGGITFLLQEMKYKWDI
WNKAQRQAYFQGWAKFLKAADEMEASLLLHPFELPAPPATVFLLHT
GPIENKVVPVKLGEPIGISMFGFAAVAPPPAPYKAGANITPKRFGELAT
QAGGAYIQLSRRGGDAAFSEADVVKWLAEDGLEIQQGNGITLDSTGA
YERRSDKKGGNVAAAT   
Figure 4.1.1: Figure showing the amino acid sequence of full length EtIMP1 and the short 
construct (clone 2) produced for structural studies in brown. The sequence has numerous Ala 
(green) and Gln (purple) repeats. The plasma membrane localisation signal is labelled blue, 
predicted myristoylation site labelled grey, predicted palmitoylation site labelled black, linker 
labelled red and the IMP domain labelled brown. 
Three IMP1 homologues were initially chosen for structural studies – TgIMP1, EtIMP1 and 
PfIMP2. The results obtained from cloning, expression, purification and preliminary NMR 
studies of the coccidian homologues (EtIMP1 and TgIMP1) have been discussed in this 
chapter.  
4.1 Characterisation of IMP1-like homologue in E. tenella 
In this study, the IMP1-like homologue gene from E. tenella (GenBank: JN987546) was 
amplified and cloned for recombinant expression in bacteria. 
4.1.1 PCR Amplification 
A short construct of the E. tenella IMP1 homologue was cloned into pET30 Xa/LIC (NEB, 
UK). The amino acid sequence of EtIMP1 clone 2 is given in Figure 4.1.1. The start point of 
EtIMP1 clone 2 is homologous to the start point of TgIMP1 clone 7 (optimised construct). 
The EtIMP1 amino acid sequence contains alanine and glutamine repeats and has the same 
domain architecture as TgIMP1. 
 
 
 
 
4.1.2 Colony screening 
Following cloning of EtIMP1 clone 2 into pET30 Xa/LIC vector and transformation in DH5α 
cells, the PCR products from colony PCR were run in a 1% agarose gel and the result is 
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kbp   MW         1           2             3       4           5          6  
1.5 
 
1.2 
1.0 
0.8 
0.7 
0.6 
0.5 
0.4 
 
0.3 
0.2 
 
0.1 
Figure 4.1.2: Figure showing the PCR products obtained from colony PCR of EtIMP1 clone 2 (pET30 
Xa/LIC). Six colonies were tested out of which five were positive (white box). The band is around 1.0 
kb which is the expected size of EtIMP1 clone 2. The six labelled lanes refer to colonies 1 to 6.  
 
EtIMP1 clone 2 (~1kb) 
shown in Figure 4.1.2. The pET30 Xa/LIC vector contains C-terminal His and S tags. 
Sequencing results confirmed that the positive colonies contain the plasmid encoding EtIMP1 
clone 2. 
 
 
 
 
 
4.2.3 Expression test 
EtIMP1 clone 2 (pET30 Xa/LIC) was transformed into Rosetta2 DE3 cells and expression 
was tested on small scale to check for protein overexpression and solubility. The molecular 
weight of the protein (including the His and S tags) is 28.3 kDa. The SDS PAGE results are 
shown in figure 4.1.3. 
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4.1.4 Protein expression and purification 
The average mass of cells, once harvested, was 5 g per litre of culture (with a standard 
deviation of ±0.5 g) for EtIMP1 clone 2 expression. The concentration of protein after Nickel 
affinity chromatography was 51.33 mg/ml in 1 ml. The SDS PAGE gel obtained from 
running the fractions from Nickel affinity chromatography for EtIMP1 clone 2 (pET30 
Xa/LIC expressed in Rosetta 2 cells) shows that the protein is pure following purification 
(Figure 4.1.4).  
kDa         MW    1        2       3       4        5       6        7       8 
212 
158 
116 
97.2 
66.4 
55.6 
42.7 
34.6 
 
27 
 
20 
 
14.3 
6.5 
Figure 4.1.3: Figure showing the expression test results obtained from EtIMP1 clone 2. The white 
box shows the bands that correspond to EtIMP1 clone 2. This confirms soluble overexpression of the 
protein. The lanes in the gel are (1) Pre-induction (soluble fraction) (2) Pre-induction (insoluble 
fraction) (3) 24 hours after induction at 18°C (soluble fraction) (4) 24 hours after induction at 18°C 
(insoluble fraction) (5) 24 hours after induction at 22°C (soluble fraction) (6) 24 hours after 
induction at 22°C (insoluble fraction) (7) 24 hours after induction at 37°C (soluble fraction) (8) 24 
hours after induction at 37°C (insoluble fraction). 
 
EtIMP1 clone 2 (28.3 kDa) 
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kDa         MW    1      2       3     4        5      6       7      8      9 
212 
 
158 
116 
97.2 
 
66.4 
55.6 
42.7 
34.6 
 
 
27 
 
20 
 
14.3 
 
6.5 
Figure 4.1.4: Figure showing the SDS PAGE gel of the samples obtained during Nickel affinity 
chromatography of EtIMP1 clone 2. The white box shows the bands that correspond to EtIMP1 
clone 2 at the expected molecular weight of 28.3 kDa. The lanes in the gel are (1) Pre-lysis 
sample (2) Post-lysis sample (3) Clear Lysate (4) Insoluble pellet (5) Flow through following 
Nickel affinity chromatography (6) Wash (7) Eluent 1 (8) Eluent 2 (9) Eluent 3 
 
EtIMP1 clone 2 (28.3 kDa) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.5 Limited proteolysis 
Trypsin digestion of EtIMP1 clone 2 was not successful and no cleavage was observed. 
Chymotrypsin digestion of EtIMP1 clone 2 was performed to identify any stable fragments of 
EtIMP1 clone 2 which may be suitable for NMR studies (Figure 4.1.5a). Two stable bands 
were observed in an SDS-PAGE gel and sequence analysis of this band following Western 
blotting showed chymotrypsin cleavage sites as shown in Figure 4.1.5b. However, these 
protein fragments are too small compared to the full length EtIMP1 protein suggesting that 
the folded domain is being broken down by Chymotrypsin. 
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Figure 4.1.5: Figure showing (A) the SDS PAGE gel of the samples obtained during limited proteolysis 
of EtIMP1 clone 2 using chymotrypsin. The white box shows the bands that correspond to the bands 
produced by limited chymotrypsin digestion. The lanes in the gel are (1) 5 minutes after addition of 
trypsin to EtIMP1 clone 2 (2) 15 minutes after trypsin addition (3) 30 minutes after trypsin addition 
(4)1 hour after trypsin addition (5) 1 day after trypsin addition (6) 5 minutes after addition of 
chymotrypsin to EtIMP1 clone 2 (7) 15 minutes after chymotrypsin addition (8) 30 minutes after 
chymotrypsin addition (9) 1 hour after chymotrypsin addition (10) 1 day after chymotrypsin addition. 
(B) Sequence of full length EtIMP1. The Ala (green) and Gln (purple) repeats are labelled in 
the sequence. Two Chymotrypsin digestion sites were found and chymotrypsin cleaves between 
the residues labelled orange. The plasma membrane localisation signal is labelled blue, predicted 
myristoylation site labelled grey, predicted palmitoylation site labelled black, linker labelled red and 
the IMP domain labelled brown. 
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6.5 
kDa        MW  1      2    3     4    5   6    7     8      9    10 
MGGACGKSRGTAAAAEPPVSAA
DKAAEAAASAASQAEKAQEAAA
AAAAAAANGAAAAAALTGEDRS
EREPANASDGKDTNPTNPTTAEQ
QQQQEQEQQQQEQQQQEQQQQ
EQQQEAAAAQQPASPVVALSAAD
AELLAAAQQQAAAAAAAGSNAN
LPHAYLFYAAELNEGSLILQWTA
AAMQQQEMQDKKLLLLASFVPP
KYKTVTKSKLQQNGGITFLLQE
MKYKWDIWNKAQRQAYFQGWA
KFLKAADEMEASLLLHPFELPAP
PATVFLLHTGPIENKVVPVKLGE
PIGISMFGFAAVAPPPAPYKAGANI
TPKRFGELATQAGGAYIQLSRRG
GDAAFSEADVVKWLAEDGLEIQ
QGNGITLDSTGAYERRSDKKGGN
VAAAT   
 
(A) (B) 
Band following limited proteolysis 
 
4.1.6 
1
H 1D NMR 
1
H 1D NMR experiment was performed on the pET30 Xa/LIC construct of EtIMP1 clone 2 
expressed in Rosetta 2 cells. The 
1
H 1D NMR spectrum of this construct shows that it is 
folded (Figure 4.1.6). It is evident from figure 4.1.6 that the signal from the unfolded domain 
of the protein (0.8 ppm) is much more intense than the signal from the folded domain as 
observed in the methyl region of the spectrum. 
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4.1.7 
15
N TROSY-HSQC 
Double labelled (
13
C/
15
N) EtIMP1 clone 2 sample in 50 mM NaH2PO4 150 mM NaCl pH 7 
buffer was used to record 
15
N TROSY-HSQC spectrum (Figure 4.1.7). Although this 
spectrum shows that the protein is folded, there are ~170 peaks in the spectrum which is less 
than the number of amino acids (236 amino acids) in the protein suggesting that the data is 
not complete. The molecular weight of this construct is 28.3 kDa which is higher than the 
optimum sample size for NMR studies. 
 
 
 
Figure 4.1.6: Figure showing the 
1
H 1D spectrum of the EtIMP1 clone 2 (pET30 Xa/LIC). On the 
top left, a zoom in of the methyl region of the spectrum between 1.5 ppm and -2.00 ppm is shown. 
The presence of ring current shifted peaks in the methyl region shows that the protein is folded. 
However, the large signal from the unfolded domain of the protein at 0.8 ppm is masking the signal 
from the folded domain. 
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Figure 4.1.7: Figure showing the 2D 
15
N TROSY- HSQC spectrum of double labelled EtIMP1 clone 
2. The number of peaks observed in the spectrum is ~170 whereas there are 236 amino acids in the 
protein sequence suggesting that the data observed in the 
15
N HSQC spectrum is incomplete. 
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4.2 Characterisation of IMP1-like homologue in T. gondii 
In this study, the IMP1-like homologue gene from T. gondii ME49 (GenBank JN657189) was 
amplified and cloned for recombinant expression in bacteria. 
4.2.1 Bioinformatics analysis 
A BLAST search of the TgIMP1 amino acid sequence showed that TgIMP1 protein has 
homologues only within apicomplexans. The first six hits obtained from BLAST are shown in 
Figure 4.2.1a (Altschul et al, 1990). None of the IMP1 homologues have a known structure or 
function. Secondary structure predictions of TgIMP1 were performed using Phyre (Bennett-
Lovsey et al, 2008) and JPred (Cuff et al, 1998) using the TgIMP1 amino acid sequence. 
Results from both prediction servers suggested that TgIMP1 has a disordered N-terminal 
region. Sequence alignment was performed using ESPript 3.0 (Robert & Gouet, 2014). The 
sequence identity scores calculated based on the sequence alignments of these homologues is 
also shown in Figure 4.2.1b. 
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TgIMP1 
(ME49) 
100% 
TgIMP1 
(GAB2) 
99.75% 100% 
TgIMP1 
(RUB) 
99.5% 99.75% 100% 
TgIMP1 
(VAND) 
99.25% 99.5% 99.5% 100% 
HhIMP 94% 94.25% 94% 93.75% 100% 
NcIMP1 72.26% 72.51% 72.51% 72.77% 75.31% 100% 
EmIMP1 28.64% 28.64% 28.91% 28.64% 28.38% 28.64% 100% 
 
TgIMP1 
(ME49) 
TgIMP1 
(GAB2) 
TgIMP1 
(RUB) 
TgIMP1 
(VAND) 
HhIMP1 NcIMP1 EmIMP1 
 
 
Figure 4.2.1a: Figure showing the top six results from the BLAST search performed with the 
Toxoplasma gondii ME49 IMP1 homologue sequence (Robert & Gouet, 2014). Residues highlighted 
red are identical and those highlighted yellow are conserved. The secondary structure prediction of 
the TgIMP1 (ME49) protein generated by JPred is shown above the sequences (Cuff et al, 1998).  
The host organisms that the homologues are from are – TgIMP1 ME49 is T. gondii ME49 strain, 
TgIMP1 (GAB2) is T. gondii GAB2-2007-GAL-DOM2, TgIMP1 (RUB) is T. gondii RUB strain, 
TgIMP1 (VAND) is T. gondii VAND strain, HhIMP1 is Hammondia hammondi, NcIMP1 is Neospora 
caninum Liverpool strain and EmIMP1 is Eimeria mitis. 
Figure 4.2.1b: Figure showing the sequence identity scores calculated using the BLOSUM62 scoring 
matrix based on the sequence alignments of the homologues shown in Figure 4.2.1a (Henikoff & 
Henikoff, 1992). 
The host organisms that the homologues are from are – TgIMP1 ME49 is T. gondii ME49 strain, 
TgIMP1 (GAB2) is T. gondii GAB2-2007-GAL-DOM2, TgIMP1 (RUB) is T. gondii RUB strain, 
TgIMP1 (VAND) is T. gondii VAND strain, HhIMP1 is Hammondia hammondi, NcIMP1 is Neospora 
caninum Liverpool strain and EmIMP1 is Eimeria mitis. 
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Table 4.1: Table showing a list of the TgIMP1 constructs, the amino acids in these constructs and 
their molecular weights in kDa. 
4.2.2 Optimisation of TgIMP1 construct 
The TgIMP1 gene was amplified from the cDNA library and cloned into the pET46 Ek/LIC 
vector (NEB, UK). Seven constructs of TgIMP1 were designed based on the secondary 
structure prediction. Based on the secondary structure prediction, the N-terminal start point of 
two homologues were set at amino acids 90 and 138, to remove disordered regions from the 
constructs. The C-terminal truncation was defined at residue 350 as it is the natural stop point 
for some homologous sequences (not shown). The list of the constructs and their molecular 
weights are given in Table 4.1. 
Construct Name Amino acids Molecular Weight (kDa) 
TgIMP1 Clone 1 (Full length) 1 to 400 43.5 
TgIMP1 Clone 2 1 to 350 38.1 
TgIMP1 Clone 3 91 to 350 28.7 
TgIMP1 Clone 4 91 to 400 34.1 
TgIMP1 Clone 5 138 to 350 23.6 
TgIMP1 Clone 6 138 to 400 29.0 
TgIMP1 Clone 7 196 to 400 27.0 
 
 
4.2.3 Expression tests 
Once the TgIMP1 constructs were cloned into pET46 Ek/LIC vector, E. coli was transformed 
and plated on Agar plates. Cells were then checked for expression, as this is the first attempt 
to express TgIMP1 in E. coli. The results from the expression test showed bands around the 
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Figure 4.2.2: Figure showing the expression test results obtained for full length TgIMP1 expressed in 
Rosetta 2 cells. The white box shows that the bands are around 43.5 kDa which corresponds to the 
molecular weight of full length TgIMP1 protein. The lanes in the gel are (1) Pre-induction (insoluble 
fraction) (2) Pre-induction (soluble fraction) (3) 2 hours after induction at 37°C (insoluble fraction) 
(4) 2 hours after induction at 37°C (soluble fraction) (5) 24 hours after induction at 37°C (insoluble 
fraction) (6) 24 hours after induction at 37°C (soluble fraction) (7) 24 hours after induction at 22°C 
(insoluble fraction) (8) 24 hours after induction at 22°C (soluble fraction) (9) 24 hours after 
induction at 18°C (insoluble fraction) (10) 24 hours after induction at 18°C (soluble fraction) 
  
kDa     MW 1     2    3     4     5    6    7     8    9   10 
Full length TgIMP1 
(43.5 kDa) 
expected molecular weight confirming the overexpression of TgIMP1. A figure showing the 
expression test performed for full length TgIMP1 is shown in Figure 4.2.2.  
 
 
 
 
 
4.2.4 
1
H 1D NMR 
1
H 1D NMR experiments were performed on all the TgIMP1 constructs produced to check if 
the protein is folded and if the construct is suitable for further NMR studies. A comparison of 
the intensity of signal from the folded and unfolded regions in the protein would indicate 
whether or not the construct is suitable for structural studies. The signal from the random coil 
regions in the protein can be observed around 0.8 ppm. The 
1
H 1D NMR spectrum of the full 
length TgIMP1 protein is shown in Figure 4.2.3. All the 
1
H 1D experiments were performed 
on samples in 50 mM NaH2PO4 150 mM NaCl pH 7 buffer at 303 K. The full length protein 
was found to have a long, unfolded region which was masking the signal from the folded 
domain (Figure 4.2.3). 
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Following successful cloning, expression and purification of TgIMP1 clone 6, a 
1
H 1D 
spectrum was recorded as shown in Figure 4.2.4. This spectrum shows an improvement 
compared to the full length TgIMP1 as the intensity of signal from the unfolded region is 
lower and the signal from the folded domain appears more resolved.  
 
 
 
 
Figure 4.2.3: Figure showing the 
1
H 1D spectrum of the full length TgIMP1 protein. On the top left, 
a zoom in of the methyl region of the spectrum between 1.5 ppm and -2.00 ppm is shown. The 
presence of ring current shifted peaks in the methyl region shows that the protein is folded. However, 
the large signal from the random coil regions in the protein at 0.8 ppm is masking the signal from the 
folded domain. 
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4.2.5 Limited proteolysis 
Chymotrypsin digestion of full length TgIMP1 was performed to identify any stable 
fragments of TgIMP1 that may be suitable for NMR studies. A short stable band was 
observed on an SDS-PAGE gel (Figure 4.2.5a) and sequence analysis of the band following 
Western blotting showed three chymotrypsin cleavage sites which are shown in Figure 4.2.5b.  
 
 
 
Figure 4.2.4: Figure showing the 
1
H 1D spectrum of TgIMP1 clone 6. On the top left, a zoom in of 
the methyl region of the spectrum between 1.5 ppm and -2.00 ppm is shown. The presence of ring 
current shifted peaks in the methyl region shows that the protein is folded. The signal from the 
unfolded domain of the protein at 0.8 ppm is smaller than for full length TgIMP1. 
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Figure 4.2.5: Figure showing (a) SDS-PAGE analysis of samples obtained following limited 
proteolysis of full length TgIMP1 with Chymotrypsin. The lanes in the gel are (1) Full length 
TgIMP1 (2) 15 min following Chymotrypsin digestion (3) 30 min following Chymotrypsin 
digestion (4) After 1 hour (5) After 2 hours (6) After 3 hours (7) Empty lane and (8) After 1 day. 
The full length TgIMP1 protein ran at a higher molecular weight of ~70 kDa (expected molecular 
weight = 43 kDa). 
(b) Sequence of full length TgIMP1. Three Chymotrypsin digestion sites were found and 
chymotrypsin cleaves between the amino acids labelled green. The plasma membrane localisation 
signal is labelled blue, predicted myristoylation site labelled grey, predicted palmitoylation site 
labelled black, linker labelled red and the IMP domain labelled brown. 
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kDa   MW     1       2         3       4        5       6        7        8 
MGTVCTKNRVDTTKTAGTSKATADEAERTVAVEEGLKAAKEIEALTGAPAAVTR
DGEVIAAIDEEDRKQLNEERTNSVDEAAAAVVQQSPEPAAVIRKEEVVTVKSDNG
DTRVHVAVVEAVIRSDLPDLPDHVENVSAEDLELLRQARKQVMAVGGPVVTDIT
KSDQQTSQINKPSASAYGYLLFLPDKGGSLTLLWSKQQLSAEEEENAGKVLLSFVP
ALHKNVPRMKYEKKGGKTELLTDIEAKWSVWKVNEKQRYYAAWATVLKAANE
YEAKVTVREWTEEMPPQVFISLLHVGLVGNKVASLPRGHPVDLGVFSHIAVVPAD
KNKEFKDGFNLSEKKFQDLAVAAGGADQRFAPRGIATALGQDDVVAWMKEDGI
DISKNERGLTLDGRMVDRANA 
(a) 
(b) 
Full length TgIMP1 (43 kDa) 
Stable band following limited proteolysis 
 
 
 
 
 
4.2.6 Optimised TgIMP1 construct 
The start point for TgIMP1 clone 7 was decided to be S176 based on the results from limited 
proteolysis of TgIMP1 (Figure 4.2.5b) in conjunction with the secondary structure 
predictions. TgIMP1 clone 7 was cloned into pET46-Ek/LIC vector (NEB, UK). This 
construct starts at S176 and ends at A400, which is the C-terminal residue in full length 
TgIMP1. The molecular weight of this construct is 27 kDa including the N-terminal His tag. 
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15     
Figure 4.2.6: Figure showing the PCR products obtained from colony PCR of TgIMP1 clone 7. 15 
colonies were tested but only two colonies were positive (white box). The band lies between 0.5 kb 
and 1.0 kb which is the expected range for TgIMP1 clone 7. The 15 lanes labelled refer to colonies 
1 to 15.  
 
  
1.5 
1.2 
1.0 
 
0.5 
0.4 
0.3 
0.2 
0.1 
TgIMP1 Clone 7 (675 
bp) 
TgIMP1 Clone 7 (675 
bp) 
Following cloning and transformation into DH5α cells, the PCR products from colony PCR 
were run on a 1% agarose gel. The result for TgIMP1 clone 7 is shown in Figure 4.2.6. 
 
Sequencing results confirmed that the positive colonies contain the plasmid encoding 
TgIMP1 clone 7. 
4.2.7 Protein Expression and Purification 
The average mass of cells, once harvested, was 5 g per litre of culture for all clones of 
TgIMP1. The concentration of TgIMP1 clone 7 after nickel affinity chromatography was 41.6 
mg/ml in 2 ml and following size exclusion chromatography was 51.9 mg/ml in 500 µl. The 
SDS PAGE gels obtained from running the fractions from nickel purification and gel 
filtration for TgIMP1 clone 7 are shown in Figure 4.2.7a and Figure 4.2.7b, respectively. The 
results from SDS-PAGE following purification by size exclusion chromatography shows a 
single intense band at 27 kDa which shows that the protein is pure. 
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Figure 4.2.7: Figure showing (a) SDS-PAGE analysis of samples obtained during Nickel affinity 
chromatography of TgIMP1 clone 7. The white box shows the band around 27 kDa which 
corresponds to the molecular weight of TgIMP1 clone 7. The lanes in the gel are (1) Insoluble pellet 
(2) Clear lysate (3) Wash following Nickel purification (4) Flow through following Nickel 
purification (5) Eluent 1 and (6) Eluent 2 
(b) SDS-PAGE analysis of samples obtained during Size exclusion chromatography of TgIMP1 
clone 7. The white box shows the bands around 27 kDa which correspond to the molecular weight 
of TgIMP1 clone 7. The lanes in the gel are (1) Eluent from Nickel purification (2) Void (3) Peak 1 
from size exclusion chromatography (4) Middle of Peak 2 and (5) End of Peak 2 
60 
80 
80 
kDa   MW     1       2       3       4        5       6   kDa     MW       1        2         3          4        5    
(a) (b) 
TgIMP1 Clone 7 (27 kDa) 
TgIMP1 Clone 7 (27 kDa) 
 
 
4.2.8 
1
H 1D NMR 
A 
1
H 1D spectrum of 
13
C/
15
N labelled TgIMP1 clone 7 in 50 mM NaH2PO4 150 mM NaCl 
pH 7 buffer was recorded at 303 K (Figure 4.2.8). This showed that the signal from the 
unfolded region of the protein was lower than that observed for Clone 6 (Figure 4.2.4). The 
signal from the folded domain is also more resolved in the TgIMP1 clone 7 spectrum. 
 
 
121 
 
 
4.2.9 
15
N TROSY-HSQC 
Double labelled (
13
C/
15
N) TgIMP1 clone 7 sample in 50 mM NaH2PO4 150 mM NaCl pH 7 
buffer was used to record 
15
N TROSY-HSQC spectrum (Figure 4.2.9). The peaks were 
dispersed across the 
15
N TROSY-HSQC spectrum which showed that the protein is folded 
and suitable for further structural studies. 
 
 
 
 
Figure 4.2.8: Figure showing the 
1
H 1D spectrum of the TgIMP1 clone 7 (
13
C/
15
N labelled). The 
presence of ring current shifted peaks in the methyl region (1 ppm to -1 ppm) shows that the protein is 
folded. The signal from the unfolded domain of the protein at 0.8 ppm is smaller than for TgIMP1 
clone 6. 
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Figure 4.2.9: Figure showing the 
15
N TROSY-HSQC spectrum of the TgIMP1 clone 7 (
13
C/
15
N 
labelled). The presence of dispersed peaks shows that the protein is folded.  
 
4.2.10 First attempt at backbone assignment  
To assign the backbone resonances of TgIMP1 clone 7, a 2D 
1
H/
15
N HSQC spectrum was 
recorded under the optimized conditions (303K, pH 7). A series of 3D experiments were then 
recorded in order to assign the specific residues in the 
15
N HSQC: HNCO, HNCACO, 
HNCACB and HNCOCACB. Backbone assignment was not feasible as majority of the 
protein lacked 3D data.  
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Figure 4.3.1a: Figure showing the expression test results obtained for TgIMP1 clone 7 
expression in Rosetta 2 cells in D2O minimal media. The white box shows the band is slightly 
lower than the expected molecular weight of 27 kDa for TgIMP1 clone 7. The lanes in the gel are 
(1) Pre-induction (soluble fraction) (2) Pre-induction (insoluble fraction) (3) 24 hours after 
induction at 18°C (soluble fraction) (4) 24 hours after induction at 18°C (insoluble fraction) (5) 
Clear lysate (6) Flow through following Nickel purification (7) Wash (8) Eluent 1 (9) Eluent 2 
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TgIMP1 clone 7 (27 kDa) 
4.3 Further NMR studies of TgIMP1 
Preliminary studies of both coccidian homologues of IMP1 show that TgIMP1 is preferable 
for further NMR studies due to the lower molecular weight of the construct and the well 
dispersed nature of the 
15
N TROSY-HSQC. However, lack of complete 3D data for this 
construct raised the need for deuteration of the protein. 
4.3.1 Deuteration of TgIMP1 clone 7 
Expression tests were performed to test for soluble protein overexpression of TgIMP1 clone 7 
by Rosetta 2 cells in D2O minimal medial. SDS-PAGE results, following Nickel affinity 
chromatography, show that soluble overexpression of TgIMP1 clone 7 is obtained in D2O 
minimal media. 
 
 
 
 
1
H 1D NMR of TgIMP1 clone 7 shows that deuteration was successful (Figure 4.3.1b). The 
intensity of the methyl peaks is lower in the deuterated sample which shows that the signal 
from the protons has decreased owing to the replacement of 
1
H with 
2
H atoms. 
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4.3.2 
15
N TROSY-HSQC 
Triple labelled (
13
C/
15
N/
2
H) TgIMP1 clone 7 sample in 50 mM NaH2PO4 150 mM NaCl pH 7 
buffer was used to record 
15
N TROSY-HSQC spectra. Comparison of the double and triple 
labelled spectra shows that some peaks are missing in the spectrum of the deuterated sample 
possibly due to lack of proton exchange in some regions of the deuterated protein (Figure 
4.3.2). 
 
 
 
Figure 4.3.1b: Figure showing the 
1
H 1D spectrum of the TgIMP1 clone 7 (
13
C/
15
N/
2
H labelled). The 
intensity of the methyl peaks in the deuterated spectrum is lower in comparison to the intensity of 
methyl peaks in the protonated spectrum (Figure 4.1.8). 
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4.3.3 Backbone assignment of TgIMP1 clone 7 
To assign the backbone resonances of TgIMP1 clone 7, a 2D 
15
N HSQC spectrum was 
recorded under the optimized conditions (303K, pH 7) with the 
13
C/
15
N/
2
H TgIMP1 clone 7 
sample. A series of 3D experiments were then recorded in order to assign the specific 
residues in the 
15
N HSQC: HNCO, HNCACO, HNCACB and HNCOCACB. The chemical 
shifts were assigned using a modified version of the program NMRview (Marchant et al, 
2008) and the program MARS (Jung & Zweckstetter, 2004) was used to fit the individual 
Figure 4.3.2: Figure showing an overlay of the 2D 
15
N HSQC spectra of the double (green) and 
triple (purple) labelled TgIMP1 clone 7 protein. Some of the peaks present in the double labelled 
spectrum are missing in the triple labelled spectrum due to incomplete proton exchange of the 
deuterated sample. 
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residues into the sequence, based on matching the chemical shift values between residues. 
Attempts to fully assign the sequence were not successful as a third of the protein sequence 
still lacked 3D data following deuteration. Due to lack of data, less than 50% of the 
assignments made by MARS were 100% confident. The peaks assigned with 100% 
confidence have been labelled in Figure 4.3.3a. The strips of a stretch of assigned residues 
K100 to R104 are also shown below in Figure 4.3.3b. 
Figure 4.3.3a: Figure showing the 2D 
15
N TROSY-HSQC spectrum of double (
13
C/
15
N) labelled 
TgIMP1 clone 7. The peaks are labelled with single letter amino acid code followed by their 
position in the recombinant TgIMP1 clone 7 sequence. Less than 50% of the peaks were assigned 
with 100% confidence.      
127 
 
(A) (B) 
Figure 4.3.4: Figure showing (A) clear drop in ICL1-A1 and (B) precipitation in ICL1-E2 
observed in the crystal trial set up with 50 mg/ml of TgIMP1 Clone 7 
 
 
 
 
 
 
 
 
4.3.4 Crystallisation trials of TgIMP1 clone 7 
Crystals were not obtained in any of the conditions present in the screens that were set up. 
Clear drops were predominantly present (around 70%) in the plates set up with TgIMP1 
Clone 7 at 50 mg/ml which suggests that this protein concentration was not high enough for 
the protein to crystallise. An example of clear drops and precipitation observed in crystal 
plates is shown in Figure 4.3.4. 
 
 
 
Figure 4.3.3b: Figure showing the strips that were obtained from the CBCACONH (1) and 
CBCACNH (2) experiments for triple labelled (
13
C/
15
N/
2
H) TgIMP1 clone 7. Data is shown for 
residues K100 to R104. The blue lines connect the peaks that were used to assign the backbone 
atoms of the labelled residues. The atoms corresponding to the peaks are labelled in the figure.    
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4.4 Summary 
Characterisation of TgIMP1 and EtIMP1 shows that both proteins have a flexible N-terminal 
domain which is highly dynamic. Limited proteolysis of TgIMP1 revealed the presence of a 
globular C-terminal domain which appears to be structurally independent. Recent studies by 
Jia et al (Appendix 1.4) have shown that the first 11 amino acids are necessary for the 
localisation of the TgIMP1 protein to the plasma membrane in the parasite.  
 The 
1
H 1D NMR data for the long and short constructs of TgIMP1 have confirmed the 
presence of a long flexible domain at the N-terminus of the protein. Truncation of the N-
terminus of TgIMP1 showed a decrease in the random coil signal. The NMR data of TgIMP1 
clone 7 and EtIMP1 clone 2 also suggest that the IMP domains of both homologues are 
globular and suitable for structural studies. Truncation of the N-terminal region does not seem 
to affect the folding of the IMP domain which further suggests that there is a linker sequence 
between the plasma membrane localisation signal and the IMP domain.  
Recent studies of EtIMP1 have shown that a fragment of EtIMP1 (EtIMP1-C), AA151 
to AA387, is sufficient to raise immunity against Eimeria infections. Further studies have 
confirmed that the efficacy of EtIMP1-C is the same as the efficacy of the full length EtIMP1 
protein (Nolan et al, 2015; Yin et al, 2014). This study confirms that EtIMP1-C is the 
immune-dominant region in the protein. EtIMP1 clone 2 consists of residues AA152 to 
AA387 of full length EtIMP1. This confirms that the C-terminal IMP domain is the immune-
dominant region in IMP1 proteins. 
 Limited proteolysis of EtIMP1 clone 2 was not successful as this construct only 
contains the IMP domain of EtIMP1. Cleavage within this globular domain could have led to 
complete degradation of the construct as observed in the SDS PAGE gel and the sequencing 
results following limited proteolysis.  
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 Further structural studies of both TgIMP1 and EtIMP1 constructs were not possible as 
the 3D data collected for both samples were incomplete. This could be because the IMP 
domains of both homologues still contain intrinsic flexible regions which are dynamic. 
Dynamic regions in the protein cannot be observed in the NMR spectrum leading to gaps in 
the NMR data. 
BLAST results (not shown) show that there are two classes of IMP proteins. The first 
class of proteins contain the plasma membrane localisation signal followed by a linker and 
the IMP domain and will be referred to as Class I throughout this thesis. The second class of 
proteins lack the plasma membrane localisation signal and the linker and only contain the 
IMP domain and will be referred to as Class II throughout this thesis.  
The localisation of Class II proteins is unknown as they lack the plasma membrane 
localisation domain. However, most apicomplexan parasites contain both classes of IMP 
proteins which shows that the IMP family of proteins is redundant in apicomplexan parasites. 
The redundancy of this protein suggests that IMP proteins play an important role in the 
parasite, which is yet to be deduced. Attempts to crystallise TgIMP1 clone 7 were also 
unsuccessful, possibly due to the highly dynamic nature of the protein.  
Since structural studies of Class I IMP1 homologues from T. gondii and E. tenella 
were unsuccessful due to the flexible nature of both proteins, characterisation of Class II IMP 
homologue from Plasmodium falciparum was attempted. 
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Chapter 5 
Characterisation of 
Plasmodium falciparum 
homologue of IMP (Class II) 
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Figure 5.1.1: Figure showing the PCR products obtained from colony PCR of full length PfIMP2 
cloned into pNIC-ZB vector. Ten colonies were tested, all of which were positive (white box). The 
bands are around 0.6 kb which is the expected molecular weight of full length PfIMP2. The ten 
lanes labelled refer to colonies 1 to 10. 
Full length PfIMP2 (~600 bp) 
5.1 Cloning, Protein expression and purification 
In this study, the IMP1-like homologue from P. falciparum (Accession number: 
XP_001349200) was codon optimised, cloned and transformed for recombinant expression in 
bacteria. 
5.1.1 PCR Amplification 
Full length PfIMP2 was codon optimised for expression in E. coli and synthesised in pMA-T 
vector (GeneArt, Life Technologies). The PfIMP2 sequence was then cloned into various 
vectors – pET32 Xa/LIC (NEB, UK), pET30 Xa/LIC (NEB, UK) and pNIC-ZB. pNIC-ZB 
was a gift from Opher Gileadi (Addgene plasmid # 26107). 
5.1.2 Colony screening 
Following cloning of PfIMP2 into pNIC-ZB vector and transformation in DH5α cells, the 
PCR products from colony PCR were run in a 1% agarose gel and the result is shown in 
Figure 5.1.1. 
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Figure 5.1.2a: Figure showing the expression test results obtained for full length PfIMP2 
(pET32 Xa/LIC) expressed in ArcticExpress and BL21 cells. No soluble overexpression is 
observed. 
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The sequencing results confirmed that the positive colonies contain plasmid encoding 
PfIMP2.  
5.1.3 Expression test 
Following cloning of PfIMP2 gene into various vectors, different strains of E. coli (BL21, 
Rosetta 2 and ArcticExpress) were transformed to express PfIMP2 and plated on Agar plates. 
Then, the cells were checked for expression as this is the first attempt of expressing PfIMP2 
in E. coli. The results from the expression test showed bands around the expected molecular 
weight (~35 kDa) confirming the soluble overexpression of PfIMP2 in pET32 Xa/LIC vector 
only in Rosetta 2 cells.  A figure showing the expression test performed for PfIMP2 (pET32 
Xa/LIC vector) is shown in Figure 5.1.2. Expression tests were also performed for PfIMP2 in 
pNIC-ZB vector but overexpression was not observed (Figure 5.1.3). 
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Figure 5.1.2b: Figure showing the expression test results obtained for full length PfIMP2 
(pET32 Xa/LIC) expressed in Rosetta 2 cells. The white box shows the bands that 
correspond to the molecular weight of full length PfIMP2 protein. Soluble overexpression is 
only observed in Rosetta 2 cells. 
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Figure 5.1.3: Figure showing the expression test results obtained for full length PfIMP2 (pNIC-
ZB) in BL21 and Rosetta2 cells. Overexpression of PfIMP2 is not observed. 
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Figure 5.2.1a: Figure showing the SDS PAGE gel of the samples obtained during Nickel 
affinity chromatography of full length PfIMP2 (pET32 Xa/LIC) expressed in Rosetta 2 
cells. The white box shows the bands that correspond to full length PfIMP2 with the 
thioredoxin tag at a lower molecular weight (~28 kDa) than expected (32 kDa). The lower 
molecular weight of the protein could be due to degradation of improperly folded protein. 
The lanes in the gel are (1) Clear Lysate (2 Flow through following Nickel affinity 
chromatography (3) Wash (4) Eluent 1 (5) Eluent 2 (6) Eluent 3 
 
PfIMP2 in R2 cells (32 kDa) 
5.2 pET32Xa/LIC construct 
5.2.1 Protein expression and purification 
The average mass of cells, once harvested, was 5 g per litre of culture for PfIMP2. The 
concentration of protein after Nickel affinity chromatography was 10.08 mg/ml in 2 ml. The 
SDS PAGE gel obtained from running the fractions from Nickel affinity chromatography for 
PfIMP2 (pET32 Xa/LIC expressed in Rosetta2 cells) shows that the molecular weight of the 
overexpressed protein sample is lower than expected (Figure 5.2.1). The expected molecular 
weight of PfIMP2 (with N-terminal His, S and thioredoxin tags) is 32 kDa whereas the 
purified protein sample runs at an apparent molecular weight of 20 to 27 kDa. 
 
 
 
 
 
 
 
 
 
Expression and purification of PfIMP2 (pET32 Xa/LIC) in BL21 cells also gave soluble 
protein of a lower molecular weight (Figure 5.1.4b). 
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Figure 5.2.1b: Figure showing the SDS PAGE gel of the samples obtained during Nickel 
affinity chromatography of full length PfIMP2 (pET32 Xa/LIC) expressed in BL21 cells. The 
black box shows the band that corresponds to full length PfIMP2 with the thioredoxin tag 
between 6.5 kDa to 14.3 kDa which is lower than the expected molecular weight of 35 kDa. 
The band is at a lower molecular weight than expected possibly due to degradation of 
improperly folded protein. The lanes in the gel are (1) Clear Lysate (2) Flow through 
following Nickel affinity chromatography (3) Wash (4) Eluent 1 (5) Eluent 2 
 
PfIMP2 in BL21 cells (35 kDa) 
 
 
 
 
 
 
 
 
 
5.2.2 
1
H 1D NMR 
1
H 1D NMR experiments were performed on all the PfIMP2 constructs produced to check if 
the protein is folded. 
1
H 1D NMR was performed on pET32 Xa/LIC-PfIMP2 construct that 
was expressed in BL21 cells and the spectrum for this protein (Figure 5.2.2a) showed that this 
construct is unfolded. 
1
H 1D NMR was performed on pET32 Xa/LIC-PfIMP2 construct that was expressed 
in Rosetta 2 cells (Figure 5.2.2b).  
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Figure 5.2.2a: Figure showing the 
1
H 1D spectrum of PfIMP2 (pET32 Xa/LIC construct) 
expressed in BL21 cells. The lack of ring current shifted methyl peaks beyond 0.5 ppm shows that 
the protein is unfolded. 
Figure 5.2.2b: Figure showing the 
1
H 1D spectrum of PfIMP2 (pET32 Xa/LIC construct) 
expressed in Rosetta2 cells. This construct appears to be folded as it has two ring current shifted 
methyl peaks beyond 0 ppm. 
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The PfIMP2 (pET32 Xa/LIC) construct, expressed in Rosetta 2 cells, has ring-current shifted 
methyl peaks which suggests that it is folded but an overlay of a 
1
H 1D spectrum of 100% 
thioredoxin showed that these peaks may be from the thioredoxin tag rather than from the 
protein (Figure 5.2.2c). The presence of an amide peak around 10 ppm shows that the protein 
under study has a tryptophan which is absent in thioredoxin. This shows that this signal is 
from the protein. However, the lack of additional ring current shifted methyl peaks other than 
the ones from thioredoxin suggests that although the protein is present in the sample, it is not 
folded. 
 
 
 
Figure 5.2.2c: Figure showing the overlay of 
1
H 1D spectra of PfIMP2 (pET32 Xa/LIC construct) 
expressed in Rosetta2 cells (blue) and thioredoxin (red). The ring current shifted methyl peaks of 
PfIMP2 (pET32 Xa/LIC) and thioredoxin are the same suggesting that there is very little signal 
from the protein.  
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Figure 5.3.1: Figure showing the SDS PAGE gel of the samples obtained during Nickel 
affinity chromatography of full length PfIMP2 (pET30 Xa/LIC) expressed in Rosetta 2 cells. 
The white box shows the band that corresponds to full length PfIMP2 with the His and S 
tags. The band is at a lower molecular weight than expected possibly due to degradation of 
improperly folded protein. The lanes in the gel are (1) Lysate (2) Clear Lysate (3) Flow 
through following Nickel affinity chromatography (4) Wash (5) Eluent 1 (6) Eluent 2 (7) 
Eluent 3 
 
PfIMP2 in R2 cells (~22 kDa) 
5.3 pET30Xa/LIC construct 
5.3.1 Protein expression and purification 
Expression of 
15
N labelled PfIMP2 (pET30 Xa/LIC) was performed in Rosetta 2 cells. The 
SDS PAGE gel obtained from running the fractions from nickel purification shows that there 
is overexpression but the size of the protein is much lower than expected (Figure 5.3.1).  
 
 
 
 
 
 
 
 
 
5.3.2 
1
H 1D NMR 
The 
1
H 1D NMR spectrum of the full length PfIMP2 (pET30 Xa/LIC) protein expressed in 
Rosetta 2 cells shows that this construct is unfolded (Figure 5.3.2). 
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5.3.3 
15
N TROSY-HSQC 
Single labelled (
15
N) PfIMP2 (pET30 Xa/LIC) sample expressed in Rosetta 2 cells was used 
to record 
15
N TROSY-HSQC spectrum (Figure 5.3.3). The 
15
N HSQC further confirms that 
the protein is unfolded. 
 
 
 
 
 
 
 
 
Figure 5.3.2: Figure showing the 
1
H 1D spectrum of PfIMP2 (pET30 Xa/LIC construct) expressed 
in Rosetta 2 cells. The lack of ring current shifted methyl peaks beyond 0.5 ppm shows that the 
protein is unfolded. 
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5.4 pNIC-ZB construct 
5.4.1 Protein expression and purification 
Expression of PfIMP2 (pNIC-ZB) in Rosetta 2 cells was performed. The SDS PAGE gel 
obtained from running the fractions from nickel purification for PfIMP2 (pNIC-ZB expressed 
in Rosetta 2 cells) shows that the protein is overexpressed (Figure 5.4.1a). 
 
 
 
 
 
 
Figure 5.3.3: Figure showing the 2D 
15
N TROSY-HSQC spectrum of single (
15
N) labelled PfIMP2 
(pET30 Xa/LIC). The clustering of peaks around 8 ppm on the proton scale shows that the protein is 
unfolded as this signal corresponds to random coil. 
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Figure 5.4.1a: Figure showing the SDS PAGE gel of the samples obtained during Nickel 
affinity chromatography of full length PfIMP2 (pNIC-ZB) expressed in Rosetta 2 cells. The 
black box shows the band that corresponds to full length PfIMP2 with the His tag. The band 
is a little higher than the expected molecular weight of 20 kDa. The lanes in the gel are (1) 
Pre-lysis (2) Post-lysis (3) Insoluble pellet (4) Clear lysate (5) Wash during Nickel affinity 
chromatography (6) Flow through following Nickel affinity chromatography (7) Eluent 1 
(8) Eluent 2 (9) Eluent 3 (10) Pooled eluents 
 
PfIMP2 in R2 cells (20 kDa) 
 
 
 
 
 
 
 
 
 
 
 
Following nickel affinity chromatography, unlabelled and 
13
C/
15
N labelled PfIMP2 (pNIC-
ZB) samples were purified by size exclusion chromatography. The SDS PAGE gel obtained 
from running the fractions from size exclusion chromatography are shown in figure 5.4.1b. 
The results show that the protein is pure. Since the protein runs as a smear, the PfIMP2 
sample was run on the gel at various concentrations from 20 mg/ml to 0.5 mg/ml (Figure 
5.1.4c).  The protein ran as a smear under all these concentrations. 
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Figure 5.4.1b: Figure showing the SDS PAGE gel of the samples obtained during size exclusion 
chromatography of unlabelled and 
13
C/
15
N labelled full length PfIMP2 (pNIC-ZB) expressed in 
Rosetta 2 cells. The white box shows the band that corresponds to full length PfIMP2 with the His 
tag. The band is at the expected molecular weight of 20 kDa. 
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Figure 5.4.1c: Figure showing SDS-PAGE gel with various concentrations of PfIMP2 sample. The 
lanes in the gel are – M is the marker, 1 is 20 mg/ml (1 mM) PfIMP2, 2 is 15 mg/ml (0.75 mM) 
PfIMP2, 3 is 10 mg/ml (0.5 mM) PfIMP2, 4 is 5 mg/ml (0.25 mM) PfIMP2, 5 is 2 mg/ml (0.1 mM) 
PfIMP2, 6 is 1 mg/ml (0.05 mM) PfIMP2 and 7 is 0.5 mg/ml (0.025 mM) PfIMP2.  
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Figure 5.4.2: Figure showing the Western blot of full length PfIMP2 (pNIC-ZB) with the His tag. 
The entire smear shows positive results which shows that it corresponds to the His tagged PfIMP2 
protein. The lanes in the figure are MW – protein molecular weight marker, Gel showing PfIMP2, 
(1) His tagged PfIMP2 and (2) Positive control 
Smear is PfIMP2 with 
His tag (20 kDa) 
5.4.2 Western Blot analysis 
As PfIMP2 runs as a smear on the SDS PAGE gel, western blot was performed to confirm the 
identity of the band. The results shown in Figure 5.4.2 show that the smear is the His tagged 
PfIMP2 protein. 
 
 
 
 
 
 
 
 
 
 
5.4.3 Differential Scanning Fluorimetry (DSF) 
The PfIMP2-NTH construct was initially in 50 mM NaH2PO4 150 mM NaCl pH 7 buffer. 
The protein precipitated rapidly at room temperature in this buffer. DSF was used to perform 
a buffer screen to determine the condition which is optimum for protein stability. The screen 
showed that the protein was most stable in 50 mM Hepes, 150 mM NaCl 10 mM DTT pH 8. 
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Figure 5.4.3: Figure showing the buffer screen results using DSF for PfIMP2 (pNIC-ZB). 
The control is 50 mM NaH2PO4 150 mM NaCl pH 7. The five conditions which gave the 
highest Tm have been shown in the figure. Each curve has been labelled in the figure 
legend. The best condition is 50 mM Hepes pH8 150 mM NaCl 10 mM DTT. 
 
5.4.4 
1
H 1D NMR 
1
H 1D NMR was performed on pNIC-ZB-PfIMP2 construct that was expressed in Rosetta 2 
cells. The spectrum of this protein shows that this construct is folded (Figure 5.4.4).  
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5.4.5 
15
N TROSY-HSQC of PfIMP2 with the His tag 
Double labelled (
13
C/
15
N) PfIMP2 (pNIC-ZB) sample expressed in Rosetta 2 cells was used 
to record 
15
N TROSY-HSQC. The 
15
N HSQC has dispersed peaks which shows that the 
protein is folded and suitable for further structural studies by NMR. 
 
 
 
 
 
 
 
Figure 5.4.4: Figure showing the 
1
H 1D spectrum of the PfIMP2 (pNIC-ZB). On the top left, a 
zoom in of the methyl region of the spectrum between 1.5 ppm and -2.00 ppm is shown. The 
presence of ring current shifted peaks in the methyl region shows that the protein is folded. 
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Figure 5.4.5: Figure showing the 2D 
15
N TROSY-HSQC spectrum of double labelled PfIMP2 
(pNIC-ZB) protein with the N-terminal His tag. The dispersed peaks in the spectrum show that the 
protein is folded.  
Backbone assignment could not be completed for this construct as the data from the 3D 
experiments was not complete. This could have been due to interference from the flexible N-
terminal His tag. 
5.4.6 TEV cleavage 
Following Nickel affinity chromatography, the N terminal His tag was cleaved off from the 
protein by TEV cleavage. Following TEV cleavage, the protein was further purified by size 
exclusion chromatography. The SDS PAGE gel obtained from running the fractions from the 
TEV cleavage and size exclusion chromatography are shown in Figure 5.4.6. 
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Figure 5.4.6: Figure showing the SDS PAGE gel of the samples obtained following TEV 
cleavage and size exclusion chromatography of 
13
C/
15
N labelled full length PfIMP2 
(pNIC-ZB) expressed in Rosetta 2 cells. The white box shows the band that corresponds to 
full length PfIMP2 without the His tag. The band is at the expected molecular weight of 18 
kDa. The lanes in the gel are (1) Pooled eluents from Nickel affinity chromatography (2) 
Following overnight incubation with TEV (3) to (6) Purified fractions following size 
exclusion chromatography  
 
PfIMP2 without His 
tag (~18 kDa) 
PfIMP2 with His tag        
(~20 kDa) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4.7 
15
N TROSY HSQC of PfIMP2 without the His tag 
15
N TROSY-HSQC was recorded following TEV cleavage of PfIMP2 to remove the His tag. 
Comparison of the 
15
N HSQC recorded with and without the tag shows that some peaks are 
missing in the 
15
N HSQC recorded without the tag as shown in Figure 5.4.7. The spectrum 
shows that the peaks are dispersed which shows that the protein is folded following removal 
of the His tag. 
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5.4.8 PfIMP2 C71S mutant 
The PfIMP2 sequence has only one cysteine residue, C71. This residue was mutated to a 
serine and the C71S mutant (pNIC-ZB) was expressed in Rosetta 2 cells and purified using 
Nickel affinity chromatography. The SDS PAGE results obtained from running the Nickel 
affinity chromatography fractions of the wildtype and the C71S mutant is shown in figure 
5.4.8. Overexpression of soluble protein was not observed for the C71S mutant. 
 
 
 
Figure 5.4.7: Figure showing the 2D 
15
N TROSY-HSQC spectrum of double labelled PfIMP2 (pNIC-
ZB) protein with (spectrum 1) and without (spectrum 2) the N-terminal His tag, as shown in the 
figure. Unaliased peaks in spectrum 1 are shown with the red box and the corresponding aliased 
peaks in spectrum 2 are shown with red circles. Two peaks in spectrum 1 have merged in spectrum 2 
and this is highlighted by the purple arrow. The peaks in spectrum 1 which are missing in spectrum 
2 are shown by the blue boxes. 
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Figure 5.4.8: Figure showing the SDS PAGE gel of the samples obtained during Nickel 
affinity chromatography of full length PfIMP2 (pNIC-ZB) wild type and C71S mutant 
expressed in Rosetta 2 cells. The white box shows the band that corresponds to full 
length WT PfIMP2 with the His tag. The band is a little higher than the expected 
molecular weight of 20 kDa. Lanes (1) to (7) correspond to WT PfIMP2 and lanes (8) to 
(14) correspond to C71S mutant of PfIMP2. The lanes in the gel are (1) Clear lysate (2) 
Flow through following Nickel affinity chromatography (3) Wash during Nickel affinity 
chromatography (4) Eluent 1 (5) Eluent 2 (6) Eluent 3 (7) Blank lane (8) Insoluble 
pellet (9) Clear lysate (10) Flow through following Nickel affinity chromatography (11) 
Wash during Nickel affinity chromatography (12) Eluent 1 (13) Eluent 2 (14) Eluent 3. 
No overexpression is observed for the C71S mutant. 
 
WT PfIMP2 with His 
tag (20 kDa) 
Expected molecular weight of 
PfIMP2 C71S (20 kDa). 
No soluble expression of PfIMP2 
C71S mutant 
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5.5 Summary 
Class II IMP homologue from P. falciparum has shown promising results which suggest that 
this protein is suitable for structural studies. Various vectors were used to express PfIMP2 but 
soluble expression of folded PfIMP2 was only obtained with the pNIC-ZB vector. Although 
soluble overexpression was observed with other vectors, the NMR data confirmed that all the 
constructs were unfolded except for the pNIC-ZB construct. The apparent lower molecular 
weight of these unfolded constructs could have been due to degradation of these unfolded 
proteins. 
Following expression using the pNIC-ZB vector, PfIMP2 was found to run as a smear 
on SDS-PAGE gels at concentrations of 0.5 mg/ml and above (Figure 5.1.4c). However, at 
lower concentrations of 0.2 mg/ml and below, PfIMP2 can be seen as a clear band on the gel 
(Figure 5.1.4b). At concentrations above 0.2 mg/ml, the protein is observed as smears of 
various intensities. This behaviour of PfIMP2 could be due to possible self-association of the 
protein via the single cysteine residue, C71, in the sequence. Another unusual feature of 
PfIMP2 is that the pI of this protein is 9.34 due to the high number of lysines in the protein 
(13%). Due to the amino acid composition of the protein, the protein is positively charged 
overall. The possible self association of the protein via the cysteine residue and the overall 
positive charge of the protein are possible reasons why this protein runs as a smear at high 
concentrations.    
BLAST searches of PfIMP2 sequence (class II) against apicomplexan proteins have 
shown that there are other homologues of Class II IMP proteins within apicomplexans (Figure 
5.5). Analysis of the PfIMP2 sequence shows that the protein has only one cysteine residue 
(C71) which appears to be conserved across the Class II IMP homologues (figure 5.5).  
During purification of PfIMP2, precipitation was observed in the absence of a 
reducing agent. This suggests that C71 might be forming intermolecular disulphide bonds 
151 
 
leading to aggregation of the protein. Addition of a reducing agent (10 mM DTT) to the 
sample eliminated precipitation which confirms this theory. The optimum buffer for this 
protein was found to be 50 mM Hepes 150 mM NaCl 10 mM DTT pH 8 using DSF. PfIMP2 
C71S mutant was not expressed solubly. This suggests that C71 is necessary for proper 
folding of the protein.  
The 3D NMR data recorded for PfIMP2 with the His tag had a few gaps which could 
have been due to the flexible nature of the N-terminal His tag. In order to overcome this issue, 
the N-terminal His tag was removed by TEV cleavage. The 3D data for PfIMP2 without the 
His tag was complete and complete backbone assignment was possible. 
The lack of homologous structures of IMP suggests that the protein has a novel fold. 
Further studies into the structure of PfIMP2 might help us to understand the mechanism by 
which this protein induces immunogenic responses in the host against the parasite. 
Figure 5.5: Figure showing the sequence alignment of PfIMP2 against the top six sequences from the 
BLAST search. The residues highlighted red are identical and the ones highlighted yellow are 
conserved. The secondary structure of the sequence based on the PfIMP2 structure is shown above 
the sequences and the secondary structure elements are labelled above the schematic. TT refers to 
beta turns, η refers to 310 helix, helices are shown as squiggles and beta strands are shown as 
arrows. The C71 residue appears to be conserved across all seven homologues. 
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Chapter 6 
NMR assignments and 
Structure Determination of 
PfIMP2  
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6.1 NMR assignment 
Double labelled (
13
C/
15
N) full length PfIMP2 without the His tag in 50 mM Hepes pH 7.5 150 
mM NaCl 10 mM DTT was used to record NMR data. Following TEV cleavage, the PfIMP2 
construct contains a first serine residue, followed by the PfIMP2 sequence. The molecular 
weight of PfIMP2 without the His tag is 17.89 kDa. The final construct used for NMR studies 
contains 159 residues but the methionine residue that follows the first serine residue (left over 
from the TEV cleavage) will be referred to as residue 1 throughout this thesis. 
6.1.1 Backbone assignment 
A 2D 
1
H/
15
N HSQC spectrum was recorded under the optimized conditions (303K, pH 7.5) to 
assign the backbone atoms of PfIMP2. A series of 3D experiments – HNCO, HNCACO, 
HNCACB and HNCOCACB – were then recorded to assign the specific residues in the 15N 
HSQC. Backbone assignment of PfIMP2 was performed semi-automatically using MARS 
and then confirmed and completed manually. Figure 6.1.1a shows the assigned 
1
H/
15
N HSQC 
spectrum (Benjamin et al, 2015).  
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Figure 6.1.1a: Figure showing assigned 
1
H/
15
N HSQC spectrum of recombinant PfIMP2 without 
the His tag. The peaks are labelled with single letter amino acid code followed by their position in 
the recombinant PfIMP2 sequence. The underlined residues are aliased signals (G82, G51 and 
G149). 
 
13% of the residues in the PfIMP2 sequence are lysines. This led to challenges in backbone 
assignment as the data from these lysine residues were heavily overlapped. ~96 % of all 
possible backbone atoms were assigned. The strips of CBCACONH and CBCANH and those 
of HNCO and HN(CA)CO for a stretch of assigned residues K100 to R104 are shown below 
in Figure 6.1.1b (Benjamin et al, 2015).  
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Figure 6.1.1b: Figure showing the strips that were obtained from the CBCACONH (1) and 
CBCACNH (2) experiments for double labelled (
13
C/
15
N) full length PfIMP2. Data is shown for 
residues L100 to G105. The blue lines connect the peaks that were used to assign the backbone 
atoms of the labelled residues. The atoms corresponding to the peaks are labelled in the figure.  
6.1.2 Side chain assignments 
Following backbone assignment, assignment of side chain atoms of PfIMP2 were performed 
using data from side chain experiments – HBHA(CBCACO)NH, (H)CC(CO)NH-TOCSY, 
HCCH-TOCSY and 
1
H-C
13
NOESY-HMQC spectra. ~94% of the amino acid side chain 
atoms were assigned manually using a modified version of the program NMRview (Marchant 
et al, 2008). The 
13
C NOESY and 
15
N NOESY strips for residue I35 with the assigned NOE 
peaks are shown in figure 6.1.2. 
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Figure 6.1.2a: Figure showing the 
13
C-NOESY and 
15
N-NOESY strips for residue I35 of double 
labelled (
13
C/
15
N) full length PfIMP2. The red dotted lines connect the peaks that correspond to 
the side chain atoms of I35 and the (HN) amide 
1
H atom of the next residue, K36, across the 
NOESY strips as labelled in the figure. The NOE peaks labelled in the green box correspond to 
short range NOE from F34 Hε1 and the NOE peaks labelled in the blue box correspond to long 
range NOEs from other aromatic residues. The blue line shows the NOE peaks from F73 Hγ1 and 
the cyan line shows the NOE peaks from W23 Hζ1. 
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Figure 6.1.2b: Figure showing (A) the short range NOE between the F34 and I35 residues 
in the PfIMP2 structure. The distance between the atoms connected by the yellow dashed 
line is labelled in the figure. (B) the long range NOEs between the I35 (pink), W23 (cyan) 
and F73 (blue) residues in the PfIMP2 structure. The side chains of these residues are 
represented as sticks. 
1
H atoms are coloured white, oxygen atoms are coloured red and 
15
N atoms are coloured blue. 
(A) 
(B) 
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The peaks corresponding to the side chain 
1
H and 
13
C of the I35 residue in PfIMP2 are 
labelled in figure 6.1.2a. Figure 6.1.2c shows that the orientation of I35 is such that the side 
chain is protruding into the hydrophobic core of the protein. I35 is located in the third beta 
sheet in the protein and W23 and F73 are spacially proximal aromatic residues located in the 
second beta sheet and third alpha helix respectively. The distance between the Hβ of I35 and 
the Hε1 of F34 is 4.7 Å, the Hγ of I35 and the Hζ of W23 is 4.0 Å and the Hγ of I35 and the 
Hγ of F73 is 3.7 Å (Figure 6.1.2b). The NOE between F34 and I35 is a short range NOE and 
that between I35 and W23 and between I35 and F73 are long range NOEs. The NOESY strips 
in figure 6.1.2a show that there are additional long range NOEs to I35. 
 
Figure 6.1.2c: Figure showing a cartoon representation of PfIMP2 with the W23 (cyan), I35 (pink) 
and F73 (blue) residues represented as sticks. W23 is present in the second beta sheet, I35 is present 
in the third beta sheet and F73 is present in the third alpha helix. 
159 
 
6.2 Structure calculation 
Structure calculation was performed through ARIA/CNS using the NOE peaklists, the 
backbone and side chain atom assignments and the dihedral angle restraints (Table 6.1). A 
total of 2319 NOE peaks were used for structure calculation, out of which 924 were intra-
residual NOE peaks and 1395 were inter-residual NOE peaks. After several rounds of 
iteration, an ensemble of structures was obtained for PfIMP2 (figure 6.2). The structural 
statistics for the final structure of PfIMP2 are also given in Table 6.1. The average pairwise 
RMSD value for the heavy atoms shows that the resolution of the final structure is equivalent 
to a 0.55 Å crystal structure. 
NMR restraints 
Distance constraints  
  Total NOE 2319 
  Intraresidue 924 
  Interresidue 1395 
     Sequential (|i-j|)=1) 505 
     Short (2< (|i-j|)<3) 193 
     Medium range (4<(|i-j|)<5) 68 
     Long range (|i-j|)>5) 629 
Total Dihedral angle Restraints  
Φ 127 
Ψ 127 
Structural Statistics 
Violations (mean and SD) 
  Distance constraints (Å) 
0.03943382 ± 
0.003690475 
  Dihedral angle constraints (°) 1.0489 
  Maximum dihedral angle violation (°) 0.781025 
  Maximum distance constraint violation (Å) 0.3 ± 0.458258 
Deviations from idealized geometry 
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Figure 6.2: Figure showing a stereo representation of the ensemble of the 10 NMR structures 
obtained following the final ARIA run.      
Table 6.1: Table showing the NMR restraints used for structure calculation and the structural 
statistics for the final structure of PfIMP2. 
  Bond length (Å) 
0.004144955 ± 
0.0001096 
  Bond angle (°) 
0.583356 ± 
0.009882051 
  Impropers (°) 
1.59978 ± 
0.05995317 
Average Pairwise RMSD (Å) 
  Heavy 
0.55379 ± 
0.07666714 
  Backbone 0.2475 ± 0.05153124 
 
 
 
6.3 Ramachandran plot 
The Ramachandran plot for the PfIMP2 structure (figure 6.3a) shows that there is one residue 
which falls in the outlier region – H89. This residue has been highlighted in the structure as 
shown in Figure 6.3b.  
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Figure 6.3a: Figure showing the Ramachandran plot for the PfIMP2 structure solved by solution state 
NMR. One residue falls in the outlier region – H89.   
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Figure 6.3b: Figure showing a cartoon representation of the structure of PfIMP2 with 
secondary structure elements labelled and the outlier residue, H89, represented as sticks 
and coloured pink. The H89 residue lies in the loop region between β5 and α4.    
The Ramachandran plot shows that 99.3% of residues in the PfIMP2 structure fall in favoured 
or allowed regions with the exception of one outlier, H89. The structure shows that H89 is 
present in a loop region which is likely to be flexible and dynamic. The flexible nature of this 
region could possibly give rise to an unusual chemical shift for H89, causing it to appear as 
an outlier on the Ramachandran plot.  
 
 
 
 
 
 
 
 
 
 
 
  
163 
 
6.4 Solution state structure of PfIMP2 
The secondary structure of PfIMP2 consists of six alpha helices – between residues 42-48, 
58-60, 62-79, 89-92, 130-133 and 140-150. There are nine beta sheets – between residues 5-
12, 16-23, 31-35, 51-56, 82-85, 97-102, 105-108, 121-127 and 152-154. The secondary 
structure elements of PfIMP2 have been labelled in figure 6.4a.  
 
The structure of PfIMP2 consists of a long alpha helix surrounded by nine beta sheets and 
five alpha helices which appear to form half a beta barrel. This structure is a novel fold which 
does not seem to have any homologues within the apicomplexan family excluding other Class 
I and Class II IMP proteins. The structure was analysed using DALI to verify that the protein 
contains a novel fold (Holm & Rosenström, 2010). The results shows that a MDB1 protein 
(PDB: 4s3h-C) had a Z-score of 3.8. Although Z-scores above 2 are considered to be 
significant, the sequence identity of these two sequences is 9%. In addition to this, the 
Figure 6.4a: Figure showing three views of the cartoon representation of the structure of PfIMP2 
with the labelled secondary structure elements. Alpha helices are coloured red, beta sheets 
coloured yellow and loops coloured green.        
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structure of MDB1 shows that it is visually not similar to PfIMP2 as shown in figure 6.4b. 
The top three hits in DALI were to MDB1 protein homologues, all of which had a Z-score 
above 3.5. However, analysis of the structure of MDB1 confirms that MDB1 does not have a 
similar fold to PfIMP2 and PfIMP2 has a novel fold. 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.5 Structural features of PfIMP2 
Analysis of the PfIMP2 sequence shows that there are two predicted phosphorylation sites – 
S92 and S93 in the protein (figure 6.5a) (Florens et al, 2004). Both these residues are exposed 
Figure 6.4b: Figure showing a cartoon representation of the structure of MDB1 coloured in 
rainbow colours from the N-terminus to the C-terminus. Although this structure has a Z-score of 
3.8 on DALI, it is clear that MDB1 does not have a similar fold to PfIMP2.        
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on the surface and present on the fourth α helix. Various proteomic studies by Floren et al 
(2004) have not identified any other post-translational modification sites in the protein during 
the schizont and merozoite stages of the parasite. 
 
 
 
 
 
 
 
 
 
The only cysteine residue, C71, in the entire PfIMP2 amino acid sequence is present in the 
third α helix. The structure of PfIMP2 shows that the C71 residue is surface exposed which 
would allow it form inter-molecular disulphide bonds leading to protein aggregation which 
was observed following protein purification. Mutation of C71 to S71 was attempted. 
However, no soluble overexpression was observed. This suggests that C71 is necessary for 
proper folding and expression of PfIMP2. This cysteine residue is also conserved in other 
Class II IMP homologues. 
Figure 6.5a: Figure showing a cartoon representation of the structure of PfIMP2. The two 
predicted phosphorylation sites – S92 and S93 – are represented as sticks and coloured blue.       
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Analysis of the hydrophobicity of the surface of PfIMP2 shows the presence of a hydrophobic 
groove formed by the first three beta strands in the sequence. This groove could potentially 
form a binding pocket or an interface for the protein to interact with binding partners.  
 
 
 
Figure 6.5b: Figure showing a cartoon representation of the structure of PfIMP2. The only cysteine 
residue in the PfIMP2 amino acid sequence, C71, is represented as sticks and coloured pink.       
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Figure 6.5c: Figure showing a cartoon representation of the structure of PfIMP2 in three views (top) 
and the hydrophobic surface representation of PfIMP2 in the same orientations (bottom). 
Hydrophobic residues (I, L, V, W, Y, M and F) are coloured purple and the rest of the residues are 
coloured white.       
 
 
Analysis of the electrostatic surface representation of the protein shows that the protein is 
more positively charged overall due to the high amount of lysines in the sequence (13%). 
There is an extended patch of positive residues observed on the protein surface in the back 
view. This could potentially play a role in interacting with charged binding partners. 
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Further analysis of the conservation of the residues in the PfIMP2 structure shows that the 
hydrophobic groove is conserved to some extent. This further confirms that this groove may 
have a functional role. 
 
 
 
 
Figure 6.5d: Figure showing a cartoon representation of the structure of PfIMP2 in three views 
(top) with the alpha helices coloured red, beta sheets coloured yellow and loops coloured green 
and the electrostatic surface representation of PfIMP2 in the same orientations (bottom). Positive 
residues are coloured blue and negative residues are coloured red. An extended stretch of positive 
residues is observed on the protein surface in the back view. 
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6.6 Modelled structures of homologues – TgIMP1 and EtIMP1 
The structures of the IMP domains of TgIMP1 and EtIMP1 were modelled based on the 
structure of full length PfIMP2 using Phyre2. The sequence alignment of Class II PfIMP2 
with Class I TgIMP1 and EtIMP1 proteins shows that there are a few insertions in the Class I 
IMP sequences which are absent in the Class II sequence. These insertions appear to be 
present in similar positions in the TgIMP1 and EtIMP1 structures (Figure 6.6a and b). 
Figure 6.5e: Figure showing a cartoon representation of the structure of PfIMP2 in three views 
(top) and the level of conservation of the amino acid residues in PfIMP2 in the same orientations 
(bottom). The figure legend shows the conservation grades represented by the residue colours. The 
residues coloured yellow had insufficient data to calculate a reliable conservation grade. 
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Figure 6.6a: Figure showing a cartoon representation of the modelled structure of the IMP 
domain of TgIMP1 (green)  with the secondary structure elements labelled. The insertions in 
the structure are coloured blue. 
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Figure 6.6b: Figure showing a cartoon representation of the modelled structure of the IMP 
domain of EtIMP1 with the secondary structure elements labelled. The insertions in the 
structure are coloured blue. 
 
 
 
 
 
 
 
 
 
 
 
The conserved position of these insertions in the modelled structures of the Class I IMP 
homologues suggests that these insertions may have a functional role in the protein. It can 
also be observed that the IMP domain of TgIMP1 contains the hydrophobic groove similar to 
Class II PfIMP2 (Figure 6.6c). Although the IMP domain of EtIMP1 contains the conserved 
hydrophobic residues, the hydrophobic groove is not accessible for protein interaction (Figure 
6.6c). Finally, the cysteine residue is not conserved in TgIMP1 or EtIMP1 but appears to be 
conserved across other Class II IMP proteins (Figure 5.5). This suggests that this cysteine 
residue may have a functional role which is specific to Class II IMP proteins. 
172 
 
Figure 6.6c: Figure showing (top) a cartoon representation of the modelled structure of the IMP 
domain of TgIMP1 and EtIMP1 with the secondary structure elements labelled and (bottom) a 
hydrophobic surface representation of the same. The hydrophobic residues (I, L, V, W, Y, M and F) 
are coloured orange. The first three beta strands in the IMP domain of TgIMP1 appear to form a 
hydrophobic groove similar to PfIMP2. 
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6.7 Summary 
The high prevalence of lysines (13%) in the PfIMP2 sequence led to overlap in the NMR 
data. However, 94% of all possible backbone atoms were successfully assigned. The data for 
side chain experiments was incomplete when the sample contained the His tag. Removal of 
the His tag solved this issue and allowed assignment of 96% of the side chain atoms. 
Structure calculation was performed using 924 intra-residual NOE peaks and 1395 inter-
residual NOE peaks. 505 peaks of the inter-residual NOE peaks were sequential and 629 
NOE peaks were long range. Following assignment and structure calculation, it was found 
that PfIMP2 contains a novel fold. The resolution of the final structure of PfIMP2 is 
equivalent to a 0.55 Å crystal structure. Structure validation shows that the structure has one 
outlier in the Ramachandran plot – H89. However, it has been found that this residue lies in a 
loop region in the structure. The high flexibility of the loop regions can cause the residues in 
these regions to have unusual chemical shifts. This can lead to these residues to be classified 
as outliers in the Ramachandran plot.  
The structure of PfIMP2 appears to have a long alpha helix surrounded by half a beta 
barrel. Class II IMP proteins appear to have a conserved cysteine residue in the long alpha 
helix in the structure. This C71 residue is surface exposed and could potentially play a role in 
protein 173dhesion173ati by forming inter-residual disulphide bonds. However, the biological 
relevance of this potential dimer has not been explored. Bioinformatic analysis of the PfIMP2 
amino acid sequence showed that there are two possible phosphorylation sites – S92 and S93. 
Analysis of the PfIMP2 structure shows that both S92 and S93 are present in the fourth alpha 
helix in the structure and are surface exposed. This suggests that the protein could potentially 
undergo post-translational modification in the parasite. However, lack of post-translational 
phosphorylation does not seem to affect protein folding. The structure also reveals that 
PfIMP2 contains a hydrophobic groove formed by the first three beta helices. This 
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hydrophobic groove is also conserved in the IMP domain of the TgIMP1 homologue. This 
suggests that this hydrophobic groove may play a role in protein interaction or act as a 
binding pocket. However, the structure of the IMP domain of the EtIMP1 homologue shows 
that although the hydrophobic residues are conserved, the hydrophobic groove is not 
accessible for interaction with other proteins. This suggests that the hydrophobic groove may 
also play a different role to protein interaction, which is yet to be determined.  
Comparison of the modelled structures of the IMP domain of the TgIMP1 and EtIMP1 
homologues to the PfIMP2 structure shows that the Class I homologues contain a few 
insertions in the amino acid sequences. Mapping these insertions on the TgIMP1 and EtIMP1 
structures shows that these insertions are present in similar regions in the structure. This 
suggests that these insertions may have a functional significance, which is specific to the 
Class I homologues. It is also likely that these insertions are responsible for the species-
specific antigenicity of these proteins. 
Structural analysis of PfIMP2 has revealed many features of this protein which were 
previously unknown. Both TgIMP1 and EtIMP1 have been found to have immunogenic 
effects on the hosts in a species-specific manner. Analysis of the amino acid sequences and 
the structures of TgIMP1, EtIMP1 and PfIMP2 homologues has shown that the IMP domain 
is conserved across all three proteins. This suggests that the IMP domain is the functional 
domain in IMP homologues. Recent studies by Jia et al (Appendix 1.4) have shown that the 
TgIMP1 contains a plasma membrane localisation signal at the N-terminus which localises 
the TgIMP1 protein to the inner leaflet of the plasma membrane. Sequence alignment shows 
that this plasma membrane localisation signal is conserved across Class I IMP homologues. 
However, Class II IMP homologues including PfIMP2 lack this sequence which raises 
questions about the localisation of Class II IMP homologues, particularly PfIMP2.  
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Chapter 7 
Final Remarks  
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7.1 Immune Mapped Protein 1 (IMP1) – a novel immunogenic protein 
IMP1 is an immunogenic protein which was first identified in Eimeria maxina (Blake et al, 
2011). Bioinformatic analysis of this protein has shown that IMP1 has homologues across 
most apicomplexan parasites. This conservation of the protein across the apicomplexan 
family suggests that it plays an important role in the parasite. Further studies have shown that 
mice vaccinated with a DNA vaccine of TgIMP1 had a longer life span and increased 
immunity against T. gondii infections (Cui et al, 2012).  
Studies by another group have also shown that vaccination of chickens with a C-
terminal fragment of EtIMP1 (EtIMP1-C) is sufficient to protect chickens against Eimeria 
infections. The same group has gone on to show that the efficacy of the EtIMP1-C vaccine is 
the same as the efficacy of the full length EtIMP1 vaccine. This has shown that the C-
terminal domain is the immune-dominant region in IMP1 proteins (Nolan et al, 2015; Yin et 
al, 2014). All these studies have shown that IMP1 is an immunogenic protein that raises 
immunity against the parasite in a species-specific manner.  
The immunogenic nature of IMP1 protein made it an interesting candidate to study. 
IMP1 proteins do not share sequence similarities with any proteins other than with other IMP 
homologues. None of these homologues have a known structure. 
7.2 Domain architecture of IMP1 
TgIMP1 and EtIMP1 were initially chosen for structural studies. 
1
H 1D NMR of full length 
TgIMP1 showed that the protein has a large disordered domain which was masking the signal 
from the folded domain. The intensity and resolution of the folded signal improved upon 
truncation of the N-terminal region of the protein. Limited proteolysis of TgIMP1 showed 
that the folded globular domain of TgIMP1 starts close to S176. Bioinformatic analysis 
revealed that S176 was the start point for some IMP1 homologues. 
1
H 1D NMR of this 
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optimised construct of TgIMP1 (clone 7) revealed that the protein was more compact. The 2D 
1
H/
15
N HSQC further confirmed that this construct is suitable for structural studies by NMR. 
However, the data recorded from 3D experiments with this sample were incomplete. Since 
the molecular weight of TgIMP1 clone 7 is about 26 kDa including the His tag, it was 
assumed that the gaps in the data were caused by the large molecular weight of the sample. 
Since the molecular weight was above 25 kDa, the protein was deuterated. 3D NMR 
experiments were performed on the deuterated sample. However, the data was still 
incomplete and less than 50% of the backbone atoms could be assigned with 100% 
confidence. 
 EtIMP1 was also studied and it was found that a shorter construct of EtIMP1 starting 
from S152 consisted of the folded domain similar to TgIMP1. Limited proteolysis of the 
EtIMP1 short construct with chymotrypsin led to protein degradation, whereas limited 
proteolysis with trypsin did not affect the protein. These results suggested that the short 
construct does not have any disordered region at the N-terminus. Analysis of the 
1
H/
15
N 
TROSY-HSQC spectrum of EtIMP1 clone 2 revealed that the number of peaks observed in 
the spectrum was less than the total number of amino acids in the sequence. Thus, the NMR 
data for this construct was incomplete. This showed that EtIMP1 clone 2 was also not suitable 
for NMR studies. 
 Crystallisation trials of TgIMP1 clone 7 were unsuccessful even at concentrations of 
190 µM. This suggested that TgIMP1 clone 7 still contained dynamic regions within the 
folded domain which were unfavourable for crystal formation. Although structural studies of 
both these homologues were unsuccessful, these studies revealed that the folded domain in 
the IMP1 protein is present at the C-terminus and the N-terminal region of the protein is 
largely unfolded. However, recent studies by Jia et al (Appendix 1.4) have revealed that the 
first 11 amino acids in the TgIMP1 sequence are necessary for the localisation of the protein 
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to the plasma membrane. The study also reveals that TgIMP1 is localised to the inner 
membrane leaflet of the plasma membrane. Recent studies have also revealed that the 
immune dominant region in EtIMP1 is the same as EtIMP1 clone 2. This result confirms that 
the globular domain that was isolated for structural studies contained the IMP domain of the 
protein. IMP1 proteins, therefore, contain a plasma membrane localisation signal at the N-
terminus, followed by a long linker sequence and the C-terminal folded domain, which we 
refer to as the IMP domain.  
7.3 Two classes of IMP proteins 
BLAST searches against the TgIMP1 protein sequence revealed a homologue in P. 
falciparum. However, this homologue was much shorter than TgIMP1 and EtIMP1. The 
PfIMP2 homologue was homologous to the IMP domain of TgIMP1 and EtIMP1. Further 
178dhesion178atics analysis of this sequence revealed there are two classes of IMP 
homologues – Class I and Class II.  
The Class I IMP homologues (IMP1) contain a plasma membrane localisation signal 
at the N-terminus, followed by a linker and the IMP domain. The Class II IMP homologues 
(IMP2) lack the N-terminal plasma membrane localisation signal and the linker and contain 
only the IMP domain. PfIMP2 which is a Class II IMP homologue was studied to determine 
the structure of the IMP domain. As the Class II homologue lacks the localisation signal, the 
localisation of this homologue within the parasite is not known.  
7.4 PfIMP2 has a novel fold 
PfIMP2 was cloned into pNIC-ZB vector (with a TEV cleavable N-terminal His tag) and 
expression was tested in Rosetta2 DE3 cells. Overexpression of PfIMP2 was successful and 
1
H 1D NMR revealed that the protein is folded. However, constant precipitation was observed 
in the protein sample following purification. The PfIMP2 protein sequence contains a single 
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cysteine residue, C71, which could potentially form inter-molecular disulphide bridges. A 
buffer screen revealed that the optimum buffer for this protein is 50 mM Hepes pH 7.5 150 
mM NaCl 10 mM DTT. The use of a reducing agent eliminated protein precipitation. It was 
also observed that the protein runs as a smear on the gel at protein concentrations of 0.5 
mg/ml and above. The theoretical pI of this protein is 9.34, which is unusually high. The high 
pI is due to the high amount of lysines (13%) in the protein sequence. The overall positive 
charge of the protein and the possible self-association of the protein via the single cysteine 
residue are possible explanations for the unusual behaviour of the protein on the SDS-PAGE 
gel. The 
1
H/
15
N TROSY-HSQC spectrum of PfIMP2 showed that the protein is suitable for 
structural studies by NMR as the peaks in the spectrum were dispersed.  
The sample used for recording preliminary NMR data contained a N-terminal His tag, 
followed by a 22-amino acid long linker which was followed by the PfIMP2 protein. The 3D 
experiments recorded with this sample had gaps in the data, possibly due to the flexible 
nature of the His tag. The 3D experiments recorded following removal of the His tag did not 
have any gaps in the data. ~94% of possible backbone residues and 96% of side chain atoms 
were successfully assigned (Benjamin et al, 2015).   
 Structure calculation was performed through ARIA/CNS by providing the chemical 
shifts of the atoms, the NOESY peaklists and dihedral angle restraints. 2319 NOE peaks were 
provided for the structure calculation, out of which, 924 were intra-residual NOE peaks and 
1395 were inter-residual NOE peaks. ARIA produced an ensemble of 10 NMR structures 
with a resolution equivalent to a 0.55 Å crystal structure. The Ramachandran plot showed that 
H89 was an outlier in the PfIMP2 structure. This residue is present in a loop region between 
the fifth beta strand and the fourth alpha helix. Loop regions in proteins are highly dynamic 
and this dynamic nature could be the reason for the H89 atoms to have unusual chemical 
shifts and to be classified as an outlier.  
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 Further analysis of the structure of PfIMP2 showed that the protein has a long alpha 
helix surrounded by a semi-beta barrel. PfIMP2 is predicted to have two phosphorylation sites 
– S92 and S93. These residues are present on the fourth alpha helix in the structure. It is 
evident that protein folding is not compromised by lack of phosphorylation as overexpression 
of soluble protein was achieved in bacteria.  
The single cysteine residue in the PfIMP2 sequence, C71 is present in the third alpha 
helix in the structure. Although this residue was reduced when performing structural studies, 
it is present on the surface such that it can form inter-molecular disulphide bridges. 
Depending on the localisation of this protein, PfIMP2 can potentially form dimers. 
Mutagenesis studies have shown that when C71 was mutated to S71, no soluble 
overexpression was observed. This shows that this C71 residue is necessary for proper 
folding of the protein. Bioinformatic analysis shows that the C71 residue is conserved across 
other Class II IMP homologues. The structure also reveals that the protein has a hydrophobic 
groove formed by the first three beta sheets in the structure. This groove could play a role in 
protein-protein interaction.  
7.5 Comparison of Class I and Class II IMP structures 
The structures of the IMP domains of the TgIMP1 and EtIMP1 homologues were modelled 
based on the structure of PfIMP2 using Phyre. Sequence alignment of the three proteins 
reveals that the Class I homologues contain a few insertions in the IMP domain which are 
missing in the Class II homologue. When these insertions were mapped on the structure, it 
was found that the localisation of these insertions is conserved between the two Class I 
homologues. This suggests that these insertions may have a functional role. It is also likely 
that the insertions may be responsible for the species-specific antigenicity of IMP1 
homologues. 
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 Bioinformatic analysis has revealed that the hydrophobic groove found in PfIMP2 is 
conserved among other Class II IMP homologues. Analysis of the modelled structures of the 
IMP domains of TgIMP1 and EtIMP1 shows that although the hydrophobic residues are 
conserved in the first four beta strands of the protein, the groove is exposed in the TgIMP1 
homologue but not in the EtIMP1 homologue. This suggests that although the hydrophobic 
groove may be functionally significant in TgIMP1 and PfIMP2, it does not appear to be so in 
the EtIMP1 homologue. 
7.6 Localisation and Pull down studies 
PfIMP2, with C-terminal GFP and triple HA tags, was ectopically expressed in the P. 
falciparum 3D7 strain (Appendix II). The expression profile of PfIMP2 shows that the protein 
is expressed mainly during the schizont and early ring stages. This suggests that the protein 
might play a role in invasion. IFA was performed to study the localisation of the protein 
within the parasite. Since the expression profile revealed that the protein may be involved in 
the invasion mechanism, it was hypothesised that PfIMP2 might be an IMC protein. In order 
to confirm this hypothesis, GAP45 was used as a marker for IFA. However, the IFA results 
proved to be inconclusive. 
 The structure of PfIMP2 also revealed the presence of a hydrophobic groove which 
could potentially form protein-protein interactions. A pull down was performed to check for 
any binding partners of PfIMP2 within the parasite. The pull down results did not reveal any 
differences between the control sample and the PfIMP2 strain. A western blot was performed 
to check for the presence of the HA-tagged PfIMP2 protein in the pull down sample, which 
revealed that PfIMP2 was expressed in very low amounts in the parasite. Therefore, the 
results obtained for the pull down assay were not conclusive due to the low concentration of 
PfIMP2 expressed in the parasite. 
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 Due to time limitations and problems with ectopic overexpression of the PfIMP2 
protein, these experiments could not be pursued further. 
7.7 Challenges and further work 
Although we now possess knowledge about the structure of PfIMP2, because the structure is 
a novel fold, it does not provide any insight about the functional role of this protein within the 
parasite. Identifying the localisation of this protein within the parasite might allow us to draw 
closer to the role played by this protein within the parasite. Class I TgIMP1 has been found to 
be localised to the inner leaflet of the plasma membrane. It is likely that the Class II 
homologues are also localised in the same way. However, due to the lack of the localisation 
signal in Class II homologues, the mechanism of localisation is not the same and is yet to be 
identified.  
Various studies have shown that numerous apicomplexan proteins function as 
complexes such that one of the proteins in the complex anchors the complex to the parasite 
plasma membrane whereas the other proteins serve as a signalling molecule or an 
182dhesion. Since Class I IMP homologues are localised to the plasma membrane, Class II 
IMP homologues can be localised to the plasma membrane by a chaperone protein. However, 
the localisation of Class II IMP proteins and potential binding partners are yet to the 
identified.  
 Endogenous expression of tagged PfIMP2 might allow us to identify the localisation 
of the protein by IFA and identify any binding partners or chaperones that the protein may 
interact with. Since the localisation of the Class I TgIMP1 homologue is now known, a 
plasma membrane marker can be used instead of GAP45 in order to confirm if PfIMP2 is also 
localised to the plasma membrane. 
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 Although IMP1 has been found to be localised to the inner leaflet of the plasma 
membrane, various studies have shown that vaccination of hosts with IMP1 raises immunity 
against the parasite in a species-specific manner. This suggests that at some stage of the 
parasite life cycle, IMP1 might be presented on the parasite surface such that it is recognised 
by the host immune system. Although there is no evidence for this so far, it is worth studying 
the localisation of the protein in parasites at various stages in order to analyse whether the 
localisation of the protein remains the same or if it changes.  
 Recent studies by Jia et al (Appendix 1.4) have shown that the acylation of specific N-
terminal residue in TgIMP1 are necessary for plasma membrane localisation of this protein. 
PfIMP2 is also predicted to be phosphorylated at one of two possible residues – S92 and S93, 
at different stages of the parasite life cycle (Florens et al, 2004). It will be interesting to 
generate mutants which lack these phosphorylation sites to study if lack of phosphorylation 
affects localisation of the protein.  
 PfIMP2 also contains a single cysteine residue, C71, which appears to be necessary 
for protein folding. This residue is also capable of forming inter-molecular disulphide bridges 
leading to dimer formation. However, the functional relevance of these dimers is unknown. 
The cysteine residues were reduced for structural studies and this did not affect the structure. 
Depending on the localisation of the protein, if the protein is oxidised, the protein can form 
dimers due to the exposed nature of this residue in the structure. Endogenous overexpression 
of tagged PfIMP2 coupled with pull down assays will allow us to check for the presence or 
absence of dimers in the parasite. 
Bioinformatic analysis shows that most apicomplexan parasites contain homologues 
of both Class I and Class II IMP proteins. This shows that this protein is highly redundant 
within the parasite which further highlights the importance of this protein. Generating 
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knockouts of this protein would not give us a clear indication regarding protein function as 
the function would be complemented by one of the other homologues within the parasite. 
Thus, the redundancy of the protein within the parasite makes function determination even 
more challenging. 
Recent studies by Yin et al (2014) and Nolan et al (2015) have shown that the IMP 
domain of EtIMP1 is the immune dominant domain in the protein. Now that the structure of 
the IMP domain is known, it is possible to perform NMR titrations to identify which residues 
and structural regions in the protein interact with antibodies. Once these residues are 
identified, mutagenesis studies can be performed to further confirm the core residues which 
are involved in raising immunity against the parasite.    
The NMR structure of PfIMP2 and the modelled structure of the IMP domains of 
TgIMP1 and EtIMP1 show that although there are variations in the amino acid sequences of 
the proteins, they are structurally very similar. This suggests that the minor variations in the 
structure of these proteins and the insertions they possess or lack may be the reason for the 
species-specific immune response raised by these proteins. 
Even though performing structural studies of IMP1 proteins was challenging, solving 
the structure of PfIMP2 was only a small step towards identifying a potential vaccine 
candidate. Understanding the function of this protein within the parasite and the mechanism 
by which it raises immunity against the parasite will give us insight about the viability of 
developing this protein into a potential vaccine candidate.  
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Appendix I 
Protein Primer names Sequence 
Tm 
(°C) 
PCR 
(°C) 
TgIMP1 
clone 1 (full 
length) 
pET46Ek/LIC 
forward 
GAC GAC GAC 
AAGATGGGAACCGTTTGCACG
AAG 
67 
63 
pET46Ek/LIC 
reverse 
GA GGA GAA GCC CGG TTA 
CTACGCATTTGCTCTGTCCACC
AT 
68 
TgIMP1 
clone 2 (1 
to 350) 
pET46Ek/LIC 
forward 
GAC GAC GAC 
AAGATGGGAACCGTTTGCACG
AAG 
67 
64 
pET46Ek/LIC 
reverse 
GA GGA GAA GCC CGG TTA 
GCCTGCTGCCACTGCTAAGT 
69 
TgIMP1 
clone 3 (91 
to 350) 
pET46Ek/LIC 
forward 
GAC GAC GAC AAG ATG 
GAACCGGCTGCGGTAATTCG 
67 
64 
pET46Ek/LIC 
reverse 
GA GGA GAA GCC CGG TTA 
GCCTGCTGCCACTGCTAAGT 
69 
TgIMP1 
clone 4 (91 
to 400) 
pET46Ek/LIC 
forward 
GAC GAC GAC AAG ATG 
GAACCGGCTGCGGTAATTCG 
67 
63 pET46Ek/LIC 
reverse 
GA GGA GAA GCC CGG TTA 
CTACGCATTTGCTCTGTCCACC
AT 
68 
TgIMP1 
clone 5 (138 
to 350) 
pET46Ek/LIC 
forward 
GAC GAC GAC AAG ATG 
GCTGAGGACCTGGAACTGCTTC
G 
67 
64 
pET46Ek/LIC 
reverse 
GA GGA GAA GCC CGG TTA 
GCCTGCTGCCACTGCTAAGT 
69 
TgIMP1 
clone 6 (138 
to 400) 
pET46Ek/LIC 
forward 
GAC GAC GAC AAG ATG 
GCTGAGGACCTGGAACTGCTTC
G 
67 
63 
pET46Ek/LIC 
reverse 
GA GGA GAA GCC CGG TTA 
CTACGCATTTGCTCTGTCCACC
AT 
68 
TgIMP1 
clone 7 (176 
to 400) 
pET46Ek/LIC 
forward 
GAC GAC GAC 
AAGATGAGTGCGTCGGCTTAC
GG 
66 
63 
pET46Ek/LIC 
reverse 
GA GGA GAA GCC CGG TTA 
CTACGCATTTGCTCTGTCCACC
AT 
68 
EtIMP1 
clone 2 (152 
to 367) 
pET30Xa/LIC 
forward 
GGTATTGAGGGTCGCATG 
AGCAACGCGAACCTGC 
64 
59 pET30Xa/LIC 
reverse 
AGA GGA GAG TTA GAG CCT 
TTAATCCAAAGTAATTCCATTT
CCTTGTTGAATTTC 
64 
PfIMP2 
(codon 
optimised) 
Xa/LIC forward GGT ATT GAG GGT CGC 
ATGAGCGAAGAAAAAGGT 
56 
59 
Xa/LIC reverse AGA GGA GAG TTA GAG CCT 59 
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TTATTTCGATTACGAACGTGG 
PfIMP2 
(codon 
optimised) 
pNIC-ZB 
forward 
TACTTCCAATCCATGAGCGAAG
AAAAAGGT 
68 
63 
pNIC-ZB 
reverse 
TATCCACCTTTACTGTCAAAAG
CTAATGCT 
66 
PfIMP2 
(full length) 
pRM2_DD-
3HA-GFP 
forward 
ATATATCTCGAGATGTCAGAA
GAAAAG 
60 
63 
pRM2_DD-
3HA-GFP 
reverse 
ATTATTGGTACCAAAGGATATA
CTAGC 
60 
 
Vector Resistance Tags Homologue 
pET46 Ek/LIC Carbenicillin N-terminal His tag TgIMP1 
pET32 Xa/LIC Kanamycin N-terminal His, S and thioredoxin tags PfIMP2 
pET30 Xa/LIC Kanamycin N-terminal His and S tags 
EtIMP1 & 
PfIMP2 
pNIC-ZB Kanamycin N-terminal His tag PfIMP2 
pRM2_DD-
3HA-GFP WR99210 C-terminal triple HA and GFP tags PfIMP2 
 
 
 
Appendix 1.3: Paper describing the backbone assignment of PfIMP2 (referred to as PfIMP1 
throughout the manuscript). Reference: Benjamin, S., Williams, F., Kerry, L. & Matthews, S. 
(2015) NMR assignment of the immune mapped protein 1 (IMP1) homologue from 
Plasmodium falciparum. Biomol NMR Assign, 9(2), 393-5. 
 
Appendix Table 1.1: Table showing the primer sequences for various constructs designed 
during the course of the project, the vector that the gene was cloned into, the Tm of the primers 
and the annealing temperature used for PCR amplification (PCR).  
 
Appendix Table 1.2: Table showing the resistance gene and tags present in the various vectors 
used in the project and the gene sequences that were cloned into them. 
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Appendix 1.4: Unpublished manuscript of the paper describing the structure of PfIMP2 and 
various functional studies performed for TgIMP1. (Yonggen et al, 2016) 
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Appendix II 
In vitro studies of PfIMP2 isolated from Plasmodium falciparum 3D7 strain 
A2.1 Culturing of parasites 
The structure of PfIMP2 reveals a variety of interesting features about the protein which were 
previously not known. However, none of this gives us a definite indication regarding the 
function or the localisation of the protein in the parasite. In vivo studies were performed in Dr 
Jake Baum’s lab. Parasites were only studied in the erythrocytic stages in this study. 
A2.1.1 Transfection of parasites 
The PfIMP2 gene sequence was cloned into pRM-2 vector for ectopic expression of PfIMP2 
in P. falciparum 3D7 strain. The vector contains a C-terminal GFP and triple HA tag which 
are necessary for localisation and pull down assays. Transfection of 3D7 strain with this 
vector was performed by Dr. Chwen Ling Tay from the Baum lab (Imperial College London). 
The vector also contains a resistance gene to the WR99210 drug.  
WR99210 is a drug that inhibits the activity of dihydrofolate reductase in the parasite. 
Dihydrofolate reductase is an enzyme which reduces dihydrofolate into tetrahydrofolate in a 
NADPH dependent manner. This step acts as a methyl group shuttle which plays a major role 
in de novo synthesis of certain amino acids, purines and thymidylic acid (Cody et al, 2004). 
Therefore, disruption in the activity of this enzyme would affect the survival of the parasite. 
Due to the pivotal role of this protein in the parasite, it is a drug target for antimalarial drugs. 
Resistance to these drugs is on the rise as this protein undergoes mutations which evade the 
drug without affecting enzyme activity. The structure of the P. falciparum dihydrofolate 
reductase/thymidylate synthase enzyme has been solved bound to WR99210 (Figure A2.1.1) 
(Cody et al, 2004).  
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Figure A2.1.1: Figure showing a cartoon representation of the structure of the dihydrofolate 
reductase domain (pink) of P. falciparum dihydrofolate reductase-thymidylate synthase protein 
bound to WR99210. Secondary structure elements have been labelled. WR99210 is represented as 
sticks and carbon atoms are coloured cyan, nitrogen atoms coloured blue, chlorine atoms coloured 
green and oxygen atoms coloured red. (Cody et al, 2004)  
Increase in the concentration of WR99210 in the media would lead to increased 
expression of the PfIMP2 protein. The optimal drug concentration for successful ectopic 
expression of PfIMP2 was found to be 20 nM by Dr. Chwen Ling Tay. Following successful 
transfection of the parasite, the transgenic line had to be maintained and synchronised 
regularly in order to achieve the desired parasitemia for the respective experiments. 
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A2.1.2 Sorbitol synchronisation 
Maintaining the parasites is an important aspect of parasite culturing which involves changing 
the media regularly and diluting the culture to prevent them from crashing. Another important 
step in maintaining the parasites is keeping them synchronised. In order to study the parasites, 
all of the parasites in the culture need to be in the same stage in the erythrocytic cycle. In 
order to synchronise the parasites, the culture is regularly treated with 5% sorbitol when 
parasitemia of the ring stage parasites is high. Sorbitol synchronisation results in the survival 
of only ring stage parasites in the culture (Lambros & Vanderberg, 1979). 
A2.1.3 Immunofluorescence Assay (IFA) 
IFA is a commonly used technique that allows us to selectively visualise an antigen within the 
host organism. In this project, the antigens that were targeted for IFA were the GFP and triple 
HA tags present at the C-terminus of the PfIMP2 protein. Visualising the location of these 
tags will allow us to deduce the localisation of PfIMP2. There are two methods of IFA – 
direct and indirect (Figure A2.1.2). Direct IFA refers to the technique where an antibody with 
a bound chromophore is used to bind to the target antigen. Indirect IFA refers to the technique 
where a primary antibody is used to bind to the target antigen and a secondary antibody with 
a bound chromophore is used to bind to the primary antibody (Hoff, 2015). In this project, 
indirect IFA was used to deduce the localisation of PfIMP2 within the parasite. 
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Figure A2.1.2: Figure showing a schematic depicting the direct (left) and indirect (right) IFA 
techniques. The various parts of the figure are labelled in a colour-coded manner. 
 
 
 
 
 
 
 
 
A2.1.4 Confocal Microscopy 
Once the IFA samples were prepared, they were visualised using a confocal microscope with 
a photon-multiplier tube. Confocal microscopy allows us to obtain higher resolution images 
than those obtained when using light microscopes. A laser is used to generate the light source 
in confocal microscopy which allows the generation of more than one wavelength of light, 
within the range of visible light, simultaneously. This allows the excitation of more than one 
chromophore in the sample simultaneously which reduces the exposure time of the sample 
(Hoff, 2015). However, the laser cannot produce UV radiation which is required to excite 
DAPI, which is a stain used to stain nuclei. DAPI excitation is usually done as a second step.  
In light microscopy, the sample is flooded with light to illuminate the sample and all 
of the emitted light is detected. The disadvantage of this method is that the detector receives 
signal from the sample and from the background. The background signal drastically reduces 
image resolution.  
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Confocal microscopy relies on sample excitation at single points by the incident light. The 
emitted light from the sample then reaches the photon multiplier through an aperture. This 
aperture is positioned in such a way that only the emitted light originating from the focal 
plane of the sample reaches the photon multiplier and appears in the final image. This is 
referred to as in-focus emission light ray. The light emitted from the background does not 
pass through the aperture and does not appear in the final image. This is referred to as out-of-
focus emission light ray (Figure A2.1.3). The elimination of background noise in confocal 
microscopy improves the resolution of the images. A photon multiplier tube is usually used as 
a detector to magnify the intensity of the signal, which in turn improves image resolution 
further (Hoff, 2015). 
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A2.1.5 Pull down Assay 
Pull down assay is a technique used to identify binding partners for a particular protein. In 
this technique, the protein of interest is tagged such that it can bind a column containing an 
affinity tag specific to that tag. In this project, anti-HA magnetic beads were used to bind the 
triple HA tag in the PfIMP2 construct. Following this, a protein source containing the ligand 
protein is passed through the column containing the bound tagged protein. The protein of 
interest is then eluted and any bound complex analysed. In this project, the P. falciparum 3D7 
strain expressing PfIMP2 ectopically was lysed and the lysate was incubated with the anti-HA 
Figure A2.1.3: Figure showing a schematic representation of the principle behind confocal 
microscopy. The various components in the figure are labelled in a colour-coded manner. 
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Figure A2.1.4: Figure showing a schematic representation of the steps involved in a pull down assay 
magnetic beads to allow PfIMP2 to bind the beads. Following this, the protein was eluted and 
analysed on a SDS-PAGE gel. A schematic depicting the technique is shown in Figure 
A2.1.4. 
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Figure A2.2.1: Figure showing the expression of PfIMP2 in P. falciparum 3D7 at various time 
points following erythrocytic invasion (Bozdech et al, 2003; Llinás et al, 2006) 
A2.2 Localisation and pull down studies 
A2.2.1 PfIMP2 expression profile 
Previous work on PfIMP2 by the Derisi lab has shown that the expression of PfIMP2 is high 
around 8 hours and 42 hours post-erythrocytic invasion (Figure A2.2.1). This data suggests 
that PfIMP2 is expressed mainly in the schizont stage of the parasite life cycle (Bozdech et al, 
2003; Llinás et al, 2006). This further suggests that PfIMP2 might play a role in erythrocyte 
invasion. Further insight about the localisation of the protein in the parasite and possible 
binding partners would allow us to identify the role of this protein in this parasite. 
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Figure A2.2.2: Figure showing (left to right) the bright field view, DAPI stain, anti-HA antibody, 
anti-GAP45 antibody and a merge of the anti-HA and anti-GAP45 fluorescence for three RBCs. A 
scale (5µm) is also shown on the anti-HA and merge windows. Data was recorded on a confocal 
microscope.  Data and figure provided by Dr. Chwen Ling Tay (Baum lab). 
α-HA α-GAP45 Merge DAPI Bright field 
A2.2.2 Localisation studies of PfIMP2 
It was initially hypothesised that PfIMP2 might be localised to the IMC. In order to validate 
this hypothesis, IFA was used to study the localisation of PfIMP2 within P. falciparum. 
Indirect IFA was performed against the GFP and the triple HA tags in the ectopically 
expressed protein, using both fixed and suspended samples. The samples were also treated 
with anti-GAP45 antibody as GAP45 is known to localise to the IMC. However, fluorescence 
was not observed for PfIMP2 in the samples treated with the anti-GFP antibody. Both fixed 
and suspended samples treated with anti-HA antibodies showed fluorescence for PfIMP2 
(Figure A2.2.2). The results obtained from this study were inconclusive on their own and 
further experiments are required to conclusively report the exact localisation of the protein. 
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A2.2.3 Identification of PfIMP2 binding partners 
The structure of PfIMP2 reveals the presence of a hydrophobic groove which could 
potentially be involved in protein-protein interactions. A pull down assay was performed in 
order to identify potential binding partners of PfIMP2. A small scale pull down was 
performed, on a wild type P. falciparum 3D7 strain (control) and the strain expressing 
PfIMP2 ectopically, using anti-HA magnetic beads. SDS PAGE of the pull down samples 
was performed and the gel was silver stained (Figure A2.2.3). However, no notable difference 
is observed between the wild type and the strain expressing PfIMP2 ectopically. A band is 
expected around 48 kDa in the PfIMP2 strain, which would correspond to the ectopically 
over-expressed PfIMP2 protein. This band is not observed on the gel.  
Western blot of the gel was also performed, against the triple HA tag, to further 
confirm the presence or absence of the HA tagged-PfIMP2 protein. Although the silver 
stained gel does not show any difference between the two samples, the western blot shows 
two faint bands around 50 kDa (shown by the black box) which are more intense in the 
PfIMP2 sample. These bands could correspond to overexpressed PfIMP2. However, the 
concentration of the overexpressed protein appears to be very low. It is also worth noting that 
the wild type contains additional bands which are absent in the PfIMP2 sample. 
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Figure A2.2.3: Figure showing the silver stained SDS-PAGE gel (left) and Western blot (right) of 
the pull down samples from the WT and PfIMP2 strains. No difference is observed between the 
WT and PfIMP2 strains in the silver stained gel. The Western blot shows two faint bands around 
50 kDa which could correspond to the tagged PfIMP2 protein (shown by the black box). The lane 
labelled M corresponds to the protein molecular weight marker. The lane containing the wild type 
sample contains additional bands which are absent in the PfIMP2 sample. 
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A2.3 Summary 
PfIMP2 was ectopically expressed as a fusion protein with triple HA and GFP tags at the C-
terminus. Protein expression was controlled by altering the concentration of the WR99210 
drug. The optimal concentration of WR99210 for successful overexpression of PfIMP2 was 
found to be 20 nM. 
Parasites were grown to a high concentration and the parasitemia of the culture was 
monitored. Once the culture reached the desired parasitemia, samples were taken for IFA. 
IFA of PfIMP2 has given inconclusive results as the fluorescence obtained from PfIMP2 does 
not match the fluorescence from GAP45. Although this data is inconclusive, different 
markers can be used to identify the exact localisation of the protein in the parasite.  
The structure of PfIMP2 revealed that the protein has a hydrophobic groove which 
could potentially act as a binding pocket for ligand binding. In order to test this hypothesis, a 
pull down assay was performed using a wild type P. falciparum 3D7 strain as a control. The 
wild type strain and the strain expressing PfIMP2 ectopically were grown simultaneously and 
once the required parasitemia was achieved, samples were taken for pull down assays from 
both cultures. However, the pull down assay also proved to be inconclusive. There is no 
difference between the result observed for the wild type and for the PfIMP2 strain. It is also 
worth noting that the PfIMP2 lane does not have any prominent band corresponding to the 
molecular weight of the ectopically overexpressed PfIMP2 construct (~48 kDa).  
In order to check for the presence of the HA-tagged PfIMP2 protein, a western blot of 
the pull down samples was also performed. The western blot revealed a faint band in the 
PfIMP2 sample around 50 kDa which could correspond to the PfIMP2 protein. Although 
PfIMP2 is overexpressed, the concentration of the PfIMP2 protein appears to be much lower 
than expected. Due to the low concentration of the protein, it is not possible to observe any 
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further bands that might correspond to binding partners of this protein. Additional bands can 
be observed in the wild type sample which are absent in the PfIMP2 sample. The identities of 
these bands were not tested. Mass spectrometry would reveal the identities of these proteins 
and it is likely that they contain the HA amino acid sequence, which would have allowed 
them to bind the affinity column. 
Western blot has revealed that the concentration of the overexpressed PfIMP2 protein 
was much lower than expected. The IFA results further confirm that the protein is expressed 
in the parasite. WR99210 was used at 20 nM concentration to drive protein overexpression. 
This concentration is high and elevating it further would affect the viability of the parasite.  
Further IFA studies of PfIMP2 with different markers that localise in different 
compartments of the cell would allow us to conclusively determine PfIMP2 localisation 
within the parasite. Pull down of PfIMP2 could be repeated with a new transgenic line of P. 
falciparum 3D7 parasites with the tagged sequence of PfIMP2 present endogenously. This 
would also allow us to track the expression profile and localisation of the protein within the 
parasite by IFA. 
The expression profile of PfIMP2 shows that the protein is expressed in the schizont 
stage. This suggests that PfIMP2 may be involved in invasion of red blood cells, in which 
case it is likely that the protein forms interactions with the host proteins. However, there is 
not enough evidence to support this hypothesis and further studies are necessary to confirm or 
disprove the same. 
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Appendix III 
Table A3: Table showing recipes for buffers used throughout the project 
Buffer Name Ingredients Company 
TAE buffer 40 mM Tris pH7.6 Sigma-Aldrich, UK 
20 mM Acetic acid 
1 mM EDTA 
1% Agarose gel 1% w/v Agarose power Sigma-Aldrich, UK 
TAE buffer 
Phosphate Lysis buffer 50 mM NaH2PO4 pH 8  Sigma-Aldrich, UK 
300 mM NaCl 
10 mM Imidazole 
1 µg/ml PMSF 
Phosphate wash buffer 50 mM NaH2PO4 pH 8 Sigma-Aldrich, UK 
300 mM NaCl 
20 mM Imidazole 
Phosphate elution buffer 50 mM NaH2PO4 pH 8 Sigma-Aldrich, UK 
300 mM NaCl 
250 mM Imidazole 
Phosphate GF buffer 50 mM NaH2PO4 pH 8 Sigma-Aldrich, UK 
200 mM NaCl 
Phosphate NMR buffer 50 mM NaH2PO4 pH 8  
150 mM NaCl  
Crystallisation buffer 50 mM Tris pH 8 Sigma-Aldrich, UK 
150 mM NaCl 
Chymotrypsin digestion buffer 100 mM Tris-HCl pH 8  Sigma-Aldrich, UK 
10 mM CaCl2 
PVDF stain 0.1% Coomassie Blue R Sigma-Aldrich, UK 
50% Methanol 
1% acetic acid 
M9 Minimal media (per litre) 6 g Na2HPO4 Sigma-Aldrich, UK 
3 g KH2PO4 
0.5 g NaCl 
0.7 g 
15
NH4Cl 
pH adjusted to 7-7.4 and autoclaved  
2 ml 1M MgSO4 Sigma-Aldrich, UK 
10 µl 1M CaCl2 
2 g D-Glucose-
13
C6 
1 ml Vitamins solution  
1 ml micronutrients  
Micronutrients (1000x) 3 x 10
-6
M Ammonium Molybdate Sigma-Aldrich, UK 
4 x 10
-4
M H3BO3 
3 x 10
-5
M CoCl2 
1 x 10
-5
M CuSO4 
8 x 10
-5
M MnCl2 
1 x 10
-5
M ZnSO4 
Vitamins (1000x) 1 g riboflavin Sigma-Aldrich, UK 
1g niacinamide 
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1 g pyridoxine monohydrate 
1 g thiamine 
Hepes lysis buffer 50 mM Hepes pH 8 Sigma-Aldrich, UK 
300 mM NaCl 
10 mM Imidazole 
Hepes wash buffer 50 mM Hepes pH 8 Sigma-Aldrich, UK 
300 mM NaCl 
20 mM Imidazole 
Hepes elution buffer 50 mM Hepes pH 8 Sigma-Aldrich, UK 
300 mM NaCl 
250 mM Imidazole 
Hepes GF buffer 50 mM Hepes pH 7.5 Sigma-Aldrich, UK 
150 mM NaCl 
TEV buffer 50 mM Tris pH 8 Sigma-Aldrich, UK 
250 mM NaCl  
10 mM DTT 
Complete media 5% Albumax Sigma-Aldrich, UK 
7.5 % sodium bicarbonate 
Incomplete media  
Incomplete media RPMI Sigma-Aldrich, UK 
30 mM Hepes pH 7.2 
50 mg Hypoxanthine per litre 
25 mg Gentamicin per litre 
2 g Glucose per litre 
Parasite lysis buffer 1 mM EGTA Sigma-Aldrich, UK 
0.2 M NaCl 
20 mM Tris pH 7.5 
5 mM MgCl2 
5% glycerol 
2 mM DTT 
Parasite elution buffer 1 mM EGTA Sigma-Aldrich, UK 
0.2 M NaCl 
20 mM Tris pH 7.5 
5 mM MgCl2 
5% glycerol 
2 mM DTT 
2 mg/ml Influenza Hemagglutinin 
peptide 
 
